151
|
Guo BY, Wang Y, Li J, Li CF, Feng XQ, Zheng MC, Liu SX, Yang LH, Jiang H, Xu HG, He XL, Wen H. [Clinical features and prognosis of core binding factor acute myeloid leukemia children in South China: a multicenter study]. ZHONGHUA ER KE ZA ZHI = CHINESE JOURNAL OF PEDIATRICS 2023; 61:881-888. [PMID: 37803854 DOI: 10.3760/cma.j.cn112140-20230224-00126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 10/08/2023]
Abstract
Objective: To analyze the clinical features, efficacy and prognosis factors of core binding factor (CBF) acute myeloid leukemia (AML) children in South China. Methods: This was a retrospective cohort study. Clinical data of 584 AML patients from 9 hospitals between January 2015 to December 2020 was collected. According to fusion gene results, all patients were divided into two groups: CBF-AML group (189 cases) and non-CBF-AML group (395 cases). CBF-AML group were divided into AML1-ETO subgroup (154 cases) and CBFβ-MYH11 subgroup (35 cases). Patients in CBF-AML group chosen different induction scheme were divided into group A (fludarabine, cytarabine, granulocyte colony stimulating factor and idarubicin (FLAG-IDA) scheme, 134 cases) and group B (daunorubicin, cytarabine and etoposide (DAE) scheme, 55 cases). Age, gender, response rate, recurrence rate, mortality, molecular genetic characteristics and other clinical data were compared between groups. Kaplan-Meier method was used for survival analysis and survival curve was drawn. Cox regression model was used to analyze prognostic factors. Results: A total of 584 AML children were diagnosed, including 346 males and 238 females. And a total of 189 children with CBF-AML were included, including 117 males and 72 females. The age of diagnosis was 7.3 (4.5,10.0)years, and the white blood cell count at initial diagnosis was 21.4 (9.7, 47.7)×109/L.The complete remission rate of the first course (CR1) of induction therapy, relapse rate, and mortality of children with CBF-AML were significantly different from those in the non-CBF-AML group (91.0% (172/189) vs. 78.0% (308/395); 10.1% (19/189) vs. 18.7% (74/395); 13.2% (25/189) vs. 25.6% (101/395), all P<0.05). In children with CBF-AML, the CBFβ-MYH11 subgroup had higher initial white blood cells and lower proportion of extramedullary invasion than the AML1-ETO subgroup, with statistical significance (65.7% (23/35) vs. 14.9% (23/154), 2.9% (1/35) vs. 16.9% (26/154), both P<0.05). AML1-ETO subgroup had more additional chromosome abnormalities (75/154), especially sex chromosome loss (53/154). Compared with group B, group A had more additional chromosome abnormalities and a higher proportion of tumor reduction regimen, with statistical significance (50.0% (67/134) vs. 29.1% (16/55), 34.3% (46/134) vs. 18.2% (10/55), both P<0.05). Significant differences were found in 5-years event free survival (EFS) rate and 5-year overall survival (OS) rate between CBF-AML group and non-CBF-AML group ((77.0±6.4)%vs. (61.9±6.7)%,(83.7±9.0)%vs. (67.3±7.2)%, both P<0.05).EFS and OS rates of AML1-ETO subgroup and CBFβ-MYH11 subgroup in children with CBF-AML were not significantly different (both P>0.05). Multivariate analysis showed in the AML1-ETO subgroup, CR1 rate and high white blood cell count (≥50×109/L) were independent risk factors for EFS (HR=0.24, 95%CI 0.07-0.85,HR=1.01, 95%CI 1.00-1.02, both P<0.05) and OS (HR=0.24, 95%CI 0.06-0.87; HR=1.01, 95%CI 1.00-1.02; both P<0.05). Conclusions: In CBF-AML, AML1-ETO is more common which has a higher extramedullary involvement and additional chromosome abnormalities, especially sex chromosome loss. The prognosis of AML1-ETO was similar to that of CBFβ-MYH11. The selection of induction regimen group FLAG-IDA for high white blood cell count and additional chromosome abnormality can improve the prognosis.
Collapse
|
152
|
Yang F, Liu M, Wang X, Wu J, Tang B, Li J, Kang S. Influence of Contrast Materials on Dose Accuracy of MR-Linac in Patients with SBRT Liver Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e352-e353. [PMID: 37785220 DOI: 10.1016/j.ijrobp.2023.06.2429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Objective: Intravenous injection of contrast agent during CT scanning can improve the accuracy of target area contouring, however the contrast agent will cause dose bias due to the high relative electron density. This study aims to explore the influence of contrast agent on the accuracy of dose calculation of the planning system during SBRT based on MRI-Linac for liver cancer treatment. MATERIALS/METHODS Methods: In this study, 20 patients undergoing stereotactic body radiation therapy (SBRT) for liver cancer were selected, and their complete unenhanced CT, contrast-enhanced CT, and corresponding structures were imported into Monaco V.5.4. The target and organs at risk (OARs) in the unenhanced CT and contrast-enhanced CT were additionally contoured according to the target contouring guidelines and OARs were ranked. The average relative electron densities of OARs (lung, spinal cord, heart, rib, etc.) were calculated with Monaco TPS. The reference plan is based on unenhanced CT for plan calculation (plan1). To compare the dosimetry errors caused by the synthetic CT, the average relative electron density of all structures in unenhanced CT was forced and the plans were recalculated (plan2). To investigate dosimetric differences caused by the changes of relative electron density due to the contrast agent, the average relative electron density of all structures in contrast-enhanced CT was forced and the plans were recalculated(plan3). The dosimetric differences in groups A (plan 1 and plan2), B (plan 1 and plan3), and C (plan2 and plan3) were compared, respectively. RESULTS There were not significant difference between three groups in the affected lung, heart, liver, blood, all within 3%. However, differences were significantly different in the group B. The maximum deviation of spinal cord Dmax reached 4.78%. In addition, the deviation of the dose parameters in the target area was small, except that the maximum deviation of the CI value in group B was 3.23%. CONCLUSION For SBRT planning of liver cancer based on magnetic resonance accelerator, synthetic CT has little influence on the calculation of planned dose. The dose difference caused by contrast materials is also relatively small, although the deviation of the CI value of the target area exceeds 3%, which is also within the clinical acceptance range. However, the deviation of the maximum value of the spinal cord is relatively large, exceeding the clinically acceptable range. Therefore, when optimizing the SBRT plan for liver cancer, attention should be paid to important organs such as the spinal cord, and should be avoided as far as possible when setting the fields.
Collapse
|
153
|
Liu M, Li J, Zhang D, Yuan K, Wu F, Yang F, Peng G, Tang B, Orlandini LC. Challenges of Treating Lung Cancer Patients at MR-Linac Using MR-Based Synthetic CT Calculation in the Adaptive Workflow. Int J Radiat Oncol Biol Phys 2023; 117:e684. [PMID: 37786013 DOI: 10.1016/j.ijrobp.2023.06.2149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Magnetic Resonance guided adaptive radiotherapy (MRgART) allows plan adaptation according to the new patient anatomy; the contours of the structures are adjusted based on the patient's daily MRI, and in the adapt to shape (ATS) workflow, the adapted plan is recalculated on the MRI-based synthetic CT (sCT) generated by bulk density assignment. For sites where there is a high electronic density (ED) gradient between the target and surrounding tissues, such as in lung cancer treatments, the assignment of an average ED may not be able to reproduce an accurate dose calculation. This study evaluates the accuracy of the sCT adapted plan calculation for lung cancer patients and assesses whether the assignment of an optimized ED can reduce dosimetric differences should they arise MATERIALS/METHODS: Nine lung cancer patients treated at Unity 1.5 MR-Linac were selected for this retrospective study. The patient's target and organs at risk (OARs) were contoured, and a CT reference plan containing the ED bulk assignment information i.e., the contours to use in the ATS workflow, and their corresponding average ED was generated. To assess the accuracy of the dosimetry of the adapted plan calculated on the sCT, the plan was recalculated on an ideal sCT (sCTref) obtained from the reference CT by forcing the drawn contours to the average ED as defined on the CT reference plan. Targets and OARs dose-volume histogram (DVH) of the CT and sCTref plans and the dose distributions using gamma (γ) analysis with 2%-2mm criteria were compared. In the case of a discrepancy between the DVHs, the average Eds used for the recalculation on the sCTref were adjusted by several attempts to obtain a sCT optimized (sCTopt) for which a superposition of DVHs on CT and sCTopt was achieved. RESULTS For 7 of the 9 patients CT and sCTref target DVHs were not comparable, with a mean dosimetric difference of 5.55% (range 2.35%-7.46%) in the target volume receiving the prescription dose (VDpre), while OARs DVH dose differences remained below 1% for the nine patients. The adjustment of the ED of the homolateral lung in the sCTopt, reduced the mean target VDpre dosimetric difference between CT and sCTopt to 0.66% (range 0.17%-1.64%). In addition, the results of the gamma analysis increased from values ranging between 39.5%-70.3% to 88.5%-93.2%, as shown in the Table. CONCLUSION Dosimetric errors in the use of the sCT calculation for targets in high ED gradient areas may arise; the use of optimized ED for sCT calculation may be a promising strand to investigate in order to proceed with MR-based sCT plan adaptation for lung cancer treatment.
Collapse
|
154
|
Lin C, Ni X, Xiao N, Yang F, Guo B, Liao D, Li J. Prognostic Value of Tumor Volume Reduction during Radiotherapy in Patients with Locally Advanced Cervical Cancer in Different Risk Groups. Int J Radiat Oncol Biol Phys 2023; 117:e527. [PMID: 37785639 DOI: 10.1016/j.ijrobp.2023.06.1803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To evaluate the risk factors of patients with locally advanced cervical cancer (LACC) undergoing radical radiotherapy (with or without concurrent chemotherapy) and to assess the prognostic value of tumor volume regression (TVR) based on magnetic resonance imaging (MRI) in different risk groups. MATERIALS/METHODS A retrospective analysis was performed on 176 individuals diagnosed with stage IIA-IVA cervical cancer (CC) who underwent radical intensity-modulated radiotherapy in our center between January 2012 and December 2020. The tumor volume before radiotherapy (TVp) and before brachytherapy (TVmid) were evaluated based on three-dimensional MRI images, TVR = (TVp -TVmid)/TVp × 100%. Kaplan-Meier curves were used to assess patient's overall survival (OS) and progression-free survival (PFS). Prognostic factors were identified using Cox proportional hazards models. RESULTS For the entire cohort, patients with TVR ≥ 94% had better 5-year OS (82.7% vs 49.8%, p<0.001) and 5-year PFS (82.5% vs 51.1%, p<0.001) compared to TVR < 94%. Patients with TVR ≥ 94% were more likely to receive concurrent chemoradiotherapy (CCRT) than those with TVR < 94% (70.1% vs 40.5%, p<0.05). Among patients undergoing CCRT, those with a TVR ≥ 94% had a better prognosis than those with a TVR < 94%. However, among patients who received RT alone, those with TVR ≥ 94% had better PFS but no statistically significant difference in OS. Likewise, among patients with CYFRA21-1 < 7.7 ng/ml, patients with TVR ≥ 94% had a better prognosis. However, TVR was not a prognostic factor in patients with CYFRA21-1 ≥ 7.7 ng/ml. Both CYFRA21-1 (OS, PFS interaction, p<0.001) and FIGO stage (PFS interaction, p = 0.035) were found to significantly impact predictive effects of TVR. CONCLUSION In LACC patients with CRYFA21-1 < 7.7 ng/ml who received CCRT, TVR was an important prognostic factor. However, in patients with CRYFA21-1 ≥ 7.7 ng/ml who received RT alone, the prognostic value of TVR needs to be further explored.
Collapse
|
155
|
Hu J, Schild SE, Liu W, Li J, Fatyga M. Improving Dose Volume Histogram (DVH) Based Analysis of Clinical Outcomes Using Modern Statistical Techniques: A Systematic Answer to Multiple Comparisons Concerns. Int J Radiat Oncol Biol Phys 2023; 117:S20. [PMID: 37784451 DOI: 10.1016/j.ijrobp.2023.06.242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) DVH constraints are essential in the clinical practice of radiation therapy. Historically, DVH constraints were found through sparse sampling of all possible DVH indices to find one that appeared to be most predictive for clinical toxicity. This approach can lead to inconsistent results among studies and to multiple comparison concerns. We aim to solve both problems by examining a full array of DVH indices using statistical methods that account for strong correlations among DVH indices and incorporate radiobiological knowledge constraints. MATERIALS/METHODS We extracted a dense array of V%_D indices from a treatment planning system using ESAPI interface, with V%_D corresponding to the volume fraction irradiated to dose D, or higher. We used Fused Lasso as the base model to compensate for correlations among DVH indices because it applies a penalty on the difference between DVH variables with adjacent dose. The base model was augmented with additional constraints based on radiobiological considerations: the positivity constraint (beta_i > 0) which assumes that any tissue irradiation cannot reduce the risk of toxicity, and monotonicity constraint (beta_i+1 > = beta_i) which assumes that higher dose to a fixed volume fraction cannot be associated with a lower risk of toxicity. We called the hybrid model KC-Lasso (Knowledge Constrained Lasso) and applied it to two clinical examples: grade 2 acute rectal toxicity in conventionally fractionated RT for 79 prostate cancer patients (77.4 Gy + MR based boost to 81-83 Gy) and cardiac toxicity in conventionally fractionated RT for 119 locally advanced Non-small Cell Lung Cancer (NSCLC) patients (Median prescribed dose 62 Gy). We further examined alternative data driven models to determine the importance of knowledge constraints. RESULTS KC-Lasso detected two distinct dose thresholds for grade 2 rectal toxicity, at 35 Gy and 78 Gy. A threshold of 51 Gy was detected for reduced overall survival due to cardiac irradiation in NSCLC patients. An examination of KC-Lasso models at varying step size suggested that a single mid-range index can be used as a treatment planning constraint while full model can be used for confirmatory, final plan evaluation. Alternative models which lack knowledge constraints show patterns of negative and isolated coefficients which are difficult to interpret and are not likely to be generalizable. CONCLUSION A more systematic approach to the analysis of correlations between DVH constraints and clinical toxicity can lead to greater consistency of results among different studies, better understanding of true dose thresholds and results which are more generalizable.
Collapse
|
156
|
Matsui JK, Allen PK, Perlow HK, Johnson JM, Paulino AC, McAleer MF, Fouladi M, Grosshans DR, Ghia AJ, Li J, Zaky W, Chintagumpala M, Palmer JD, McGovern SL. Prognostic Factors for Pediatric, Adolescent, and Young Adult Patients with Non-DIPG Grade 4 Gliomas: A Contemporary Pooled Institutional Experience. Int J Radiat Oncol Biol Phys 2023; 117:e532. [PMID: 37785650 DOI: 10.1016/j.ijrobp.2023.06.1815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) WHO grade 4 gliomas are rare tumors in the pediatric and AYA (adolescent and young adult) population. In this study, we evaluate prognostic factors, toxicities, and outcomes in the pediatric versus AYA population. MATERIALS/METHODS This retrospective pooled institutional study included patients < 30 years old with grade 4 gliomas. Overall survival (OS) and progression free survival (PFS) were characterized using Kaplan-Meier and Cox regression analysis. RESULTS Ninety-seven patients (n = 20 < 15y, n = 77 ≥ 15y) were identified with a median age 23.9y at diagnosis. Most had biopsy-proven glioblastoma (91%) and the remainder had diffuse midline glioma, H3K27M-altered (9%). All patients received surgery and adjuvant radiotherapy. Median PFS and OS were 20.9 months and 79.4 months, respectively. Gross total resection was associated with better PFS in multivariate analysis [HR 2.00 (1.01-3.62), p = 0.023]. Age ≥15y was also associated with improved OS [HR 0.36 (0.16-0.81), p = 0.014] while female gender [HR 2.12 (1.08-4.16), p = 0.03] and K27M altered histology [HR 2.79 (1.11-7.02), p = 0.029] were associated with worse OS. Only 7% of patients experienced grade 2 toxicity during radiation. Sixty-two percent of patients experienced tumor progression, 28% local and 34% distant. Analysis of salvage treatment found reirradiation was not associated with improved OS, but second surgery and systemic therapy significantly improved survival from the time of tumor progression. CONCLUSION Age is a significant prognostic factor in WHO grade 4 glioma, which may reflect age-related molecular alterations in the tumor. Diffuse midline glioma was associated with worse OS compared to hemispheric glioblastoma; this may be related to lack of effective targeted therapies. Surgery and systemic therapy were effective salvage options that significantly improved outcome. Better understanding of prognostic factors may guide future treatment within this understudied patient population, and prospective studies are warranted.
Collapse
|
157
|
Damron EP, Florez M, De B, Huntoon K, Beckham T, Wang C, Li J, Amini B, Briere TM, Tom MC, Tatsui C, Rhines LD, Ghia AJ. Stratifying Response to Stereotactic Radiosurgery for Spinal Metastases by Primary Site Genomic Mutations. Int J Radiat Oncol Biol Phys 2023; 117:e97. [PMID: 37786225 DOI: 10.1016/j.ijrobp.2023.06.862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Spine stereotactic radiosurgery (SSRS) is effective in achieving durable local control (LC) and palliation of pain in patients with spinal metastases. Per institutional standards, SSRS prescription dose is tailored by primary site histology, with radioresistant disease receiving escalated doses. While the association between tumor histology and radioresistance is well studied, the association between specific genotypic mutations and radioresistance to SSRS is not well known. We sought to determine if a relationship exists between primary tumor mutations and clinical outcomes following SSRS. MATERIALS/METHODS We performed a retrospective analysis of 201 patients with available primary site mutation profiles who underwent SSRS to 327 spinal metastases from 2007-2022 at a single institution. Associations with overall survival (OS) and LC were identified using univariate and multivariable Cox proportional hazards modeling adjusted for clinicopathologic and treatment-related factors. RESULTS The median age was 59 years (range: 11-85) at the time of SSRS. One hundred and five patients were male (52%). The median SSRS dose to the gross tumor volume was 24 Gy (range: 12-50) given in a median of 1 fraction (range: 1-5), corresponding to a biologically effective dose (BED10) of 81.6 Gy. The most common primary tumor sites were head and neck (20%), lung (19%), and genitourinary (15%). The most common spine subsites were thoracic (57%) and lumbar (27%). Twenty-four mutated genes were identified in primary tumors with the most common being TP53 (28%), KIT (15%), PIK3CA (15%), and KRAS (10%). Prior to receipt of SSRS, 19% of patients underwent surgical resection and 23% received conventional radiation therapy (RT) to their treated sites. The median follow-up time and OS following SSRS was 97 months (95% confidence interval [CI] 86-128) and 41 months (95% CI 20-31), respectively. The median LC at 1 and 2 years following SSRS was 88% (95% CI 84-92) and 75% (95% CI 70-82), respectively. On multivariable analysis, receipt of prior RT (hazard ratio [HR] 1.86; 95% CI 1.29-2.67; P = 0.0008) and TP53 mutation (HR 1.68; 95% CI 1.20-2.35; P = 0.0024) were associated with shorter OS, whereas STK11 mutation (HR 2.14; 95% CI 0.47-4.70; P = 0.0589) trended towards shorter OS. LC was more durable with increasing BED10 (HR 0.98; 95% CI 0.96-1.00; P = 0.0166) and less durable with mutations in ATM (HR 2.40; 95% CI 1.06-5.44; P = 0.0362), STK11 (HR 4.89; 95% CI 1.40-15.01; P = 0.0119), and CTNNB1 (HR 4.49; 95% CI 1.90-10.62; P = 0.0006). CONCLUSION While favorable outcomes among all patients receiving SSRS were seen, increasing BED10 was associated with more durable LC. Primary site ATM, STK11, and CTNNB1 mutations may be associated with poorer LC following SSRS. Further investigation into the prognostic value of individual mutations and combinations thereof is warranted.
Collapse
|
158
|
Chen Y, Liang C, Li J, Ma L, Wang B, Yuan Z, Yang S, Nong X. Effect of artesunate on cardiovascular complications in periodontitis in a type I diabetes rat model and related mechanisms. J Endocrinol Invest 2023; 46:2031-2053. [PMID: 36892740 DOI: 10.1007/s40618-023-02052-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Accepted: 02/24/2023] [Indexed: 03/10/2023]
Abstract
PURPOSE Both cardiovascular disease and periodontitis are complications of diabetes that have a great impact on human life and health. Our previous research found that artesunate can effectively improve cardiovascular disease in diabetes and has an inhibitory effect on periodontal disease. Therefore, the present study aimed to explore the potential therapeutic possibility of artesunate in the protection against cardiovascular complications in periodontitis with type I diabetes rats and to elucidate the possible underlying mechanisms. METHODS Sprague‒Dawley rats were randomly divided into the healthy, diabetic, periodontitis, diabetic with periodontitis, and artesunate treatment groups (10, 30, and 60 mg/kg, i.g.). After artesunate treatment, oral swabs were collected and used to determine changes in the oral flora. Micro-CT was performed to observe changes in alveolar bone. Blood samples were processed to measure various parameters, while cardiovascular tissues were evaluated by haematoxylin-eosin, Masson, Sirius red, and TUNEL staining to observe fibrosis and apoptosis. The protein and mRNA expression levels in the alveolar bone and cardiovascular tissues were detected using immunohistochemistry and RT‒PCR. RESULTS Diabetic rats with periodontitis and cardiovascular complications maintained heart and body weight but exhibited reduced blood glucose levels, and they were able to regulate blood lipid indicators at normal levels after artesunate treatment. The staining assays suggested that treatment with 60 mg/kg artesunate has a significant therapeutic effect on myocardial apoptotic fibrosis. The high expression of NF-κB, TLR4, VEGF, ICAM-1, p38 MAPK, TGF-β, Smad2, and MMP9 in the alveolar bone and cardiovascular tissue in the type I diabetes and type I diabetes with periodontitis rat models was reduced after treatment with artesunate in a concentration-dependent manner. Micro-CT showed that treatment with 60 mg/kg artesunate effectively alleviated alveolar bone resorption and density reduction. The sequencing results suggested that each model group of rats had vascular and oral flora dysbiosis, but artesunate treatment could correct the dysbacteriosis. CONCLUSIONS Periodontitis-related pathogenic bacteria cause dysbiosis of the oral and intravascular flora in type I diabetes and aggravate cardiovascular complications. The mechanism by which periodontitis aggravates cardiovascular complications involves the NF-κB pathway, which induces myocardial apoptosis, fibrosis, and vascular inflammation.
Collapse
|
159
|
Grippin A, De B, Florez M, Tom MC, Beckham T, Wang C, Bishop AJ, Shanker MD, Li J, Amini B, Briere TM, Tatsui C, Rhines LD, McGovern SL, McAleer MF, Ghia AJ. Spine Stereotactic Radiosurgery for Primary and Metastatic Osteosarcoma. Int J Radiat Oncol Biol Phys 2023; 117:e299. [PMID: 37785092 DOI: 10.1016/j.ijrobp.2023.06.2312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Osteosarcoma is difficult to control due to its high propensity for metastasis and resistance to local and systemic therapies. High doses of radiation therapy (RT) may confer local control (LC) in some settings but for lesions involving the vertebral bodies, proximity to the spinal cord may limit the ability to deliver an adequate dose. In this analysis, we investigate the role of spine stereotactic radiosurgery (SSRS) to overcome this barrier and enable efficacious treatment of primary or metastatic osteosarcoma of the spine. MATERIALS/METHODS We retrospectively reviewed all patients treated with SSRS for osteosarcoma of the vertebrae between 2006 and 2022 at a single large tertiary cancer center. We utilized the Kaplan-Meier method to estimate overall survival (OS) and LC. RESULTS We identified 18 patients treated with SSRS for 25 lesions of spinal osteosarcoma. Median follow-up was 17.2 months. Two patients and three separate lesions were treated with SSRS for primary osteosarcoma of the vertebrae. The remaining 16 patients and 22 lesions received SSRS to the spine for metastatic disease. Lesions were treated to a dose of 24Gy in one fraction (n = 20) 27Gy in 3 fractions (n = 4) or 50Gy in 5 fractions (n = 1). Treatment sites included the cervical spine alone (n = 4), thoracic spine alone (n = 12), lumbar spine alone (n = 4), sacrum alone (n = 3), or both the thoracic and lumbar spine (n = 2). At latest follow up, local failure was observed in 9/25 (36%) treated lesions and median LC was 22.5 months (95% CI 6-43 months). Per-lesion LC at 1 year was 64% (95% CI 35-83%). Per-patient median OS was 14 months (95% CI 7-68 months) and OS estimates at 1 and 2 years were 60% (95% CI 32-80%) and 35% (11-60%), respectively. Among 15 patients who received 24 Gy in one fraction, at 1 year per-lesion LC was 72% (95% CI 41-88%) and per-patient OS was 60% (95% CI 28-81%). The most common acute treatment related toxicity was pain flare (12%). Four patients (16%) developed compression fractures in the treated vertebrae after radiation, with incidence between 57 and 578 days after radiation. Two of these fractures required intervention and two were incidental findings on imaging. No patients developed CTCAE Grade 3 or higher adverse events including neurological toxicities. CONCLUSION SSRS appears to be safe and effective in the treatment of metastatic or primary osteosarcoma involving spinal bone. Future work should include further investigation of this technique with pooled multi-institutional studies and randomized trials.
Collapse
|
160
|
Wang W, Xu R, Li J. CBCT Guided Interfraction Absolute Displacement and Setup Error Assessment during Breast Prone Radiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e735. [PMID: 37786136 DOI: 10.1016/j.ijrobp.2023.06.2260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To calculate interfraction absolute displacement/shift and setup error using cone beam computed tomography (CBCT) during breast prone radiotherapy. MATERIALS/METHODS Fifty-nine patients undergoing prone whole breast-irradiation after breast-conserving surgery (BCS) were studied as part of an institutional review board- approved prospective trial. Setup precision was monitored using a daily online CBCT. Translational shifts in 3 axes (AP: anterior posterior; LR: left right; and SI: superior inferior) and 3 rotations (pitch, roll, and rtn) after CBCT were analyzed for 1062 treatment fractions. The random and systematic setup errors (SE) were calculated and were analyzed for time trends during the course of radiotherapy. RESULTS For absolute inter-fractional shifts, the numbers of fractions exceeding 10 mm in the AP, LR, and SI directions were 6.5%, 17.42% and 8.92%, respectively; 0%, 0% and 1.31% fractions exceeded 3°for pitch, roll, and Rtn, respectively. The population systematic errors were 1.89/2.91/1.98 mm in AP/SI/LR directions, while the random error were 2.72/3.99/3.31 mm. In pitch, roll, rtn rotations, the population systematic error were 0.64°/0.49°/0.46°, and 0.89°/0.90°/0.93° for the random error. Without correction these would correspond to a clinical to planning target volume margin of 6.64/10.08/7.26 mm in AP/SI/LR directions and 2.22°/1.79°/1.8° in pitch, roll, rtn rotations. The magnitude of inter-fraction motion was not correlated with patient treatment time accept in AP direction (P = 0.000). CONCLUSION SE was larger in prone position in breast cancer patients, attributable mostly to random errors, which emphasize the need for on-line imaging guidance in breast prone radiotherapy. 10mm margins would adequately cover the target volume and account for setup errors in the absence of IGRT.
Collapse
|
161
|
Hu L, Fenghu L, Li J, Du Y, Mei F, Tian X, Qin Y, Lu B, Shan L. Efficacy and Safety of Local Radiotherapy Combined with Chemotherapy ± Bevacizumab in the Treatment of Patients with Advanced and Recurrent Metastatic Cervical Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e512-e513. [PMID: 37785603 DOI: 10.1016/j.ijrobp.2023.06.1771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To observe the efficacy and safety of local radiotherapy combined with chemotherapy ± bevacizumab in the treatment of patients with advanced or recurrent metastatic cervical cancer. MATERIALS/METHODS A total of 53 patients with advanced and recurrent metastatic cervical cancer who had received local radiotherapy combined with chemotherapy ± bevacizumab in Affiliated Cancer Hospital of Guizhou Medical University from July 2018 to October 2021 were collected. The recurrence types included 21 patients of pelvic recurrence, 7 patients of distant metastasis, 14 patients of complex pelvic recurrence and distant metastasis, and 11 patients of advanced stage (initial diagnosis stage IVB). The primary endpoints were objective response rate (ORR) and disease control rate (DCR). The secondary endpoints were progression-free survival (PFS), overall survival (OS) and incidence of adverse reactions. RESULTS (1) Complete response (CR) was achieved in 4 patients (7.5%), partial response (PR) in 34 patients (64.2%), stable disease (SD) in 12 patients (22.6%), and disease progression (PD) in 3 patients (5.7%), ORR was 71.7%, DCR was 94.3%. (2) The follow-up time was 5.3 to 45.7 months, the median OS was 29.3 months, the median PFS was 15.7 months, the one-year and two-year OS were 83.0% and 59.2%, and the 1-year and two-year PFS were 62.2% and 34.4%. (3) Recurrence type, tumor size at the time of recurrence, and efficacy after radiotherapy were significant factors for PFS and OS rates in multivariate analysis. (4) The main adverse reactions were myelosuppression, gastrointestinal reaction and urinary reaction. Grade IV leukopenia occurred at 13.2%, grade IV neutropenia at 11.3%, grade IV thrombocytopenia at 15.1%, and grade IV anemia at 5.7%, all of which were tolerable. The gastrointestinal and urinary reactions were mainly grade I-II, and the incidence of vesical or rectovaginal fistulas was about 7.5% (2 patients had rectovaginal fistulas and 2 patients had vesto-vaginal fistulas). CONCLUSION Local radiotherapy combined with chemotherapy ± bevacizumab can improve the efficacy and survival of patients with advanced and recurrent metastatic cervical cancer. Adverse reactions are tolerable and may provide survival benefits in these patients.
Collapse
|
162
|
Marqueen KE, Strom EA, Ning MS, Smith BD, Tereffe W, Hoffman KE, Stauder MC, Perkins GH, Buchholz TA, Li J, McAleer MF, Reddy J, Woodward WA. Phase II Trial of Definitive Therapy for Osseous Oligometastases in Breast Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e136. [PMID: 37784702 DOI: 10.1016/j.ijrobp.2023.06.941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Phase II data for consolidative local therapy for oligometastatic disease demonstrated improved outcomes for various malignancies. However, a randomized phase II study of oligometastatic breast cancer patients testing predominantly ablative dose radiotherapy (RT) did not demonstrate progression-free survival (PFS) benefit. We conducted a single-arm phase II trial evaluating local therapy as part of the multidisciplinary management of breast cancer patients with limited bone metastases. MATERIALS/METHODS Patients with synchronous (n = 15) and metachronous (n = 15) oligometastatic breast cancer involving ≤3 osseous sites were enrolled from July 2009 to April 2016 and treated to a total of 44 bone metastases. The trial closed early due to slow accrual. Following ≤9 months of systemic therapy, local therapy entailed surgery (n = 3) or RT delivered via conventional fractionation (≥60 Gy, n = 36) or stereotactic technique (27 Gy/3 fractions for spine mets, n = 6). When indicated, RT to the primary was delivered concurrently (n = 15). The primary endpoint was to determine PFS. Secondary endpoints were overall survival (OS), local control (LC) and toxicity. Outcomes were evaluated with Kaplan-Meier and univariate Cox proportional hazards analyses. RESULTS Of the 30 patients included in the trial, 23 (77%) had ER+ or PR+/HER2- disease, 4 (13%) had Her2+ disease, and 3 (10%) were triple negative. Median age was 53, and 20 patients (67%) presented with 1 distant metastasis. A total of 21 patients (70%) experienced disease progression at a median 20.5 months (IQR: 8.2-41.2), including 5 local failures among 44 treated bone metastases (11%). At a median follow-up of 76.7 mon (IQR: 45.4-108.8), the median PFS was 37.8 mon, with 2- and 5-year rates (95% CI) of 60% (45-80%) and 32% (19-55%), respectively. The 2- and 5-year OS rates were 93% (85-100%) and 64% (48-85%), respectively, and the 2- and 5-year LC rates were 91% (80-100%) and 71% (51-98%). For patients who achieved LC, median PFS was 47.7 months (IQR 12.2-73.0). Twenty-one patients (70%) received cytotoxic chemotherapy with or without endocrine therapy for newly diagnosed oligometastatic disease. Nine patients (30%) were still alive with no evidence of disease (NED) at a median 96.9 mon (range: 47.7-158.6). PFS was worse among triple negative patients (p = 0.03), with no difference based on synchronous vs non-synchronous presentation (p = 0.10), receipt of cytotoxic chemotherapy prior to definitive therapy (p = 0.08) or Her2+ status (p = 0.21). There were no Grade ≥3 adverse events. CONCLUSION Definitive, predominantly conventionally fractionated local therapy was associated with long-term NED status for 30% of patients with oligometastatic breast cancer involving osseous sites, with minimal treatment-associated toxicity. Developing randomized trials for breast cancer subsets may warrant consideration of standard fractionation regimen data and the need for strategies to identify patients who may benefit from definitive local therapy.
Collapse
|
163
|
Li J, Ji Z. Comment to: "Onlay mesh repair for treatment of small umbilical hernias ≤ 2 cm in adults: a single-centre investigation". Hernia 2023; 27:1329-1330. [PMID: 37036540 DOI: 10.1007/s10029-023-02791-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 04/02/2023] [Indexed: 04/11/2023]
|
164
|
Li J, Zhang Y, Bai KX, Qi XJ, Zhao Y, Bu H. Bioinformatics screening of gene expression profile and diagnostic application of meningeal carcinoma. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2023; 27:9601-9613. [PMID: 37916326 DOI: 10.26355/eurrev_202310_34132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/03/2023]
Abstract
OBJECTIVE The aim of this study was to research gene expression profiles and diagnostic applications of meningeal carcinoma based on bioinformatics. MATERIALS AND METHODS We used the Gene Expression Omnibus (GEO) database to obtain the GSE43290 dataset based on the expression data of normal meninges and meningiomas consisting of 51 samples divided into two groups (47 samples of meningioma tumors and four samples of normal meninges). We used the GEO2R tool to identify differentially expressed genes (DEGs) by setting the log2 fold change as greater than two and an adjusted p-value lower than 0.05. We used the database for annotation, visualization and integrated discovery (DAVID) to perform gene ontology, biological pathways and functional annotation of the DEGs. A search Tool for the Retrieval of Interacting Gene database (STRING) was used to obtain Protein-Protein Interaction (PPI) and modular networks based on the Markov clustering algorithm. RESULTS Our study identified 358 significant DEGs, of which 343 were downregulated genes while 15 were upregulated. Five significant hub genes (CXCL8, AGT, CXCR4, CXCL12 and CXCL2) were associated with various biological pathways, molecular functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The DEGs were enriched in biological pathways of chemokine-mediated signaling, positive regulation of leukocyte chemotaxis, second messenger-mediated signaling, induction of positive chemotaxis, CXCR chemokine receptor binding and activities of cytokines. CONCLUSIONS These hub genes and pathways could be targeted in clinical research to discover new treatments for meningeal carcinoma.
Collapse
|
165
|
Feng M, Tang Y, Fan M, Li L, Wang S, Yin Q, Ai H, Zhao S, Yin Y, Liu D, Ren Y, Li J, Li F, Lang J. Low-Dose Fractionated Radiotherapy Combined with Neoadjuvant Chemotherapy for T3-4 Nasopharyngeal Carcinoma Patients: The Preliminary Results of a Phase II Randomized Controlled Trial. Int J Radiat Oncol Biol Phys 2023; 117:e580-e581. [PMID: 37785764 DOI: 10.1016/j.ijrobp.2023.06.1921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Over 70% of NPC patients were local advanced NPC (LANPC). The 5-year local recurrence-free survival rate is only 70% in T3-4 patients. Neoadjuvant chemotherapy (NACT) followed with concurrent chemoradiotherapy (CCRT) was recommended for LANPC patients. Low-dose fractionated radiotherapy (LDFRT), which is <100cGy, induces enhanced cell killing by the hyper-radiation sensitivity phenomenon and potentiates effects of chemotherapy. The synergy of LDFRT and NACT has not been used in the clinical practice and few studies focused on it. A single arm study found the ORR of primary site was improved to 90% for head and neck squamous carcinoma patients treated with LDFRT and NACT. Our previous study found the ORR of lymph nodes was higher in LDFRT group for high-risk LANPC patients. However, another study showed there was no significant difference between LDFRT and control group for LANPC patients. So, we aimed to investigate the potential efficacy of this novel neoadjuvant therapy for T3-4 NPC patients. MATERIALS/METHODS A total of 60 pathological confirmed T3-4 (UICC/AJCC8th) NPC patients were prospectively enrolled in our study. They were randomly assigned to two groups. For the LDFRT group, the patients received 3 cycles of NACT (docetaxel 75mg/m2 D1, cisplatin 80mg/m2 D1) with LDFRT, and followed with CCRT. LDFRT was delivered as 50cGy per fraction twice a day to primary site on D1,2 for each cycle of NACT. The patients in the control group only received NACT and followed with CCRT. All the patients underwent IGRT. RECIST criteria and CTCAE 5.0 was used to evaluate the ORR and toxicity at post-NACT and the completion of CCRT. RESULTS From February 2022 to December 2022, 60 T3-4 NPC patients were included, and 30 patients for each group. For the primary site, the median volume reduction rate and the ORR after NACT was significantly improved in LDFRT group (69.27% vs 40.10%, p<0.001;93.33% vs 73.33%, p = 0.038). For the median volume reduction rate of primary site and lymph node, it was also obviously improved in LDFRT group (86.59% vs 55.43%, p<0.001). Though there was a tendency of ORR improvement in LDFRT group, but no significant difference (96.67% vs 83.33%, p = 0.195). After the completion of CCRT, the median volume reduction rate of primary site had an increased tendency in LDFRT group (96.16% vs 88.3%, p = 0.065), but the ORR had no statistical significance (LDFRT group: CR 45.8%, PR 54.2%; control group: CR 37.5%, PR 62.5%). For the toxicity, the incidence of grade 3-4 adverse events had no difference between two groups (p = 0.786). No grade 5 adverse events occurred. CONCLUSION LDFRT combined with NACT could obviously improve the median volume reduction rate and ORR of primary tumor for T3-4 NPC patients, and the toxicity was similar and tolerable. This novel treatment could be a promising strategy to improve treatment response and needed to be confirmed further.
Collapse
|
166
|
Feng M, Zhao S, Fan M, Li L, Wang S, Ai H, Tang Y, Yin Y, Ren Y, Li J, Li F, Lang J. Long-Term Survival Outcome for Metastatic Nasopharyngeal Carcinoma Patients Receiving Radiation to Primary and Metastatic Sites with Palliative Chemotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e581. [PMID: 37785765 DOI: 10.1016/j.ijrobp.2023.06.1922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) A total of 6% - 8% of NPC patients were initial diagnosed as distant metastatic disease. The median overall survival (OS) is only 10-15 months with palliative chemotherapy for these patients. A phase III study showed that palliative chemotherapy combined with radical radiotherapy to primary site could be a newly effective treatment method for metastatic NPC. Another phase 2, RCT found that the patients who had the solid tumors with 1-5 metastases received standard palliative care plus stereotactic body radiation therapy (SABR), and the 5-year OS were improved to 42.3%. Nevertheless, there was few studies focus on the radiation to both primary site and metastatic lesions. Therefore, we aimed to investigate the potential clinical benefits for initial diagnosed metastatic NPC patients with radiation to both primary site and distant metastatic lesions plus palliative chemotherapy. MATERIALS/METHODS Metastatic NPC patients treated with radiation to both primary site and distant metastatic lesions plus palliative chemotherapy were retrospectively collected in our hospital from May 2008 to May 2022. For treatment group, all patients underwent IGRT according to ICRU reports 50 and 62. The prescribed dose for primary site: GTVT: ≥66Gy, GTVn: ≥66Gy, CTV1: 60-66Gy, CTV2 54-60Gy, CTVln 50-54Gy. And the prescribed dose for distant metastatic lesions was more than 30Gy. For the control group, the patients treated with palliative chemotherapy were selected by propensity score matching from our hospital. The regimen for palliative chemotherapy was cisplatin-based chemotherapy every three weeks (100mg/m2 D1) for both groups. Kaplan-Meier method was used to analyze the OS. Cox regression model was used for multivariate analysis. RESULTS A total of 54 metastatic NPC patients with radiation to both primary site and distant metastatic lesions were retrospectively included in the treatment group, and another 54 patients were selected as the control group. The median follow-up time was 52 months. In the treatment group, the median age was 52 years (37-82), male (68%), female (32%), the main metastatic sites were bone (36 cases, 66%), lung (18 cases, 33%) and liver (10 cases, 18%). There were 23 oligometastasis cases and 31 cases. 3-year and 5-year OS in the treatment group were both dramatically improved than control group (63.2% vs 50.6%, p<0.05; 49.6% vs 38.9%, p<0.05). Multivariate analysis showed that T stage, liver metastatic lesion and oligometastases were the independent prognostic factors for them. CONCLUSION Palliative chemotherapy combined with radiation to primary sites and distant metastatic lesions might improve the OS for initial diagnosed distant metastatic NPC patients. More prospective clinical trials were needed to confirm it further.
Collapse
|
167
|
Vick LV, Yoon D, Perks JR, Li JJ, Murphy WJ, Monjazeb AM. Tumor Resistance to Fractionated Radiotherapy in Obese Mice. Int J Radiat Oncol Biol Phys 2023; 117:S139. [PMID: 37784355 DOI: 10.1016/j.ijrobp.2023.06.546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Obesity has reached pandemic levels in the United States and will soon surpass smoking as the number one cause of preventable cancer. Clinical data demonstrate that obese cancer patients are more resistant to radiotherapy and have higher rates of recurrence. Although a growing number of cancer patients are obese, and obesity is linked to poor outcomes with radiotherapy, little is understood about how obesity impacts the efficacy of radiotherapy. Understanding if and how obesity induces radio-resistance and how to best treat obese cancer patients is a critical unmet need. In this study we test the hypothesis that tumors in obese mice have increased resistance to fractionated radiotherapy. MATERIALS/METHODS Control and diet induce obese (DIO) mice were generated by feeding 4-6-week-old, genetically identical, inbred C57BL/6 mice with a high-fat diet consisting of 60% kcal from fat (DIO) or a control diet consisting of 10% fat (control) until 6 months of age. Mice were then implanted with syngeneic B16F0 tumors in the hind leg. When tumors reached 5mm in diameter mice were treated with fractionated radiotherapy (12 Gy delivered in daily 4 Gy fractions X 3 days) using a 2cm electron cutout to treat the tumor + margin only. RESULTS DIO mice had significantly increased body weight (control 30-40 g; DIO 50-65 g), significantly increased visceral and subcutaneous fat deposits, and elevated leptin levels. Blood glucose levels and HgbA1c in DIO mice, although slighter higher than controls, were within normal limits and did not indicate insulin resistance. Mice were divided into four groups of 8 mice (control, control + RT, DIO, DIO + RT). Fractionated radiotherapy (4 Gy x 3) significantly reduced the growth of B16F0 tumors by about three-fold in control mice compared to untreated controls. Radiotherapy failed to significantly reduce tumor size in DIO mice (compared to unirradiated DIO), although the treated tumors trended towards being modestly smaller. Additionally, tumors in the DIO + RT group were significantly larger than the tumors in the control + RT group. Initial mechanistic studies suggest increased tumor proliferation and immune dysfunction in DIO mice may induce the observed radio-resistance. CONCLUSION Using genetically identical mice with genetically identical tumors we demonstrate, for the first time, that diet and obesity can drastically alter the anti-tumor effects of radiotherapy. Mechanistic studies and studies in other tumor models are underway. Understanding how obesity impacts radiotherapy response and developing strategies to address these issues will improve outcomes in obese patients. Thus, these studies can have a major clinical impact and represent a step towards personalized medicine by tailoring radiotherapy treatment strategies to a patient's metabolic parameters.
Collapse
|
168
|
Li Y, Chen L, Li J, Zhao B, Jing T, Wang R. Computational explorations of the interaction between laccase and bisphenol A: influence of surfactant and different organic solvents. SAR AND QSAR IN ENVIRONMENTAL RESEARCH 2023; 34:963-981. [PMID: 38009185 DOI: 10.1080/1062936x.2023.2280584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Accepted: 10/30/2023] [Indexed: 11/28/2023]
Abstract
Bisphenol A (BPA), as an environmental endocrine disruptor can cause damage to the reproductive, nervous and immune systems. Laccase can be used to degrade BPA. However, laccase is easily deactivated, especially in organic solvents, but the specific details are not clear. Molecular dynamics simulations were used to investigate the reasons for changes in laccase activity in acetonitrile (ACN) and dimethyl formamide (DMF) solutions. In addition, the effects of ACN and DMF on the activity of laccase and surfactant rhamnolipid (RL) on the degradation of BPA by laccase were investigated. Results showed that addition of ACN changed the structure of the laccase, not only decreasing the van der Waals interaction that promoted the binding of laccase with BPA, but also increasing the polar solvation free energy that hindered the binding of laccase with BPA, so it weakened the laccase activity. DMF greatly enhanced the van der Waals interaction between laccase and BPA, and played a positive role in their binding. The addition of surfactant RL alleviated the effect of organic solvent on the activity of laccase by changing the polar solvation energy. The mechanism of surfactant RL affecting laccase activity in ACN and DMF is described, providing support for understanding the effect of organic solvents on laccase.
Collapse
|
169
|
Li J, Ji Z. Comment to: Safety and efficacy of absorbable and non-absorbable fixation systems for intraperitoneal mesh fixation: an experimental study in swine. Hernia 2023; 27:1327-1328. [PMID: 36637607 DOI: 10.1007/s10029-023-02738-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2022] [Accepted: 12/29/2022] [Indexed: 01/14/2023]
|
170
|
Yao X, Liu M, Liao X, Yuan K, Li J, Wang X, Orlandini LC. Study on the Clinical Use of a Respiratory Navigator Combined with Breath-Hold for MRI- Guided Liver SBRT. Int J Radiat Oncol Biol Phys 2023; 117:e740-e741. [PMID: 37786151 DOI: 10.1016/j.ijrobp.2023.06.2274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Respiratory movement strongly affects the accuracy of stereotactic body radiation therapy (SBRT) of liver malignancies treated without the use of a respiratory gating system. This study investigates the feasibility and advantages of using a respiratory navigator-guided combined with patient breath-hold for liver SBRT in an adaptive magnetic-resonance guided workflow. MATERIALS/METHODS Clinical datasets of 10 liver cancer patients treated with 1.5T MR-Linac with respiratory navigator-guided SBRT combined with patient breath-hold were retrospectively analyzed. All patients underwent simulation CT with and without contrast, and 4D-CT and 3D-T2w MRI without contrast. Patients received a prescription dose ranging from 36 to 50 Gy in 5 to 8 fractions and followed the adapt to shape (ATS) workflow including contours adjustment and a subsequent MR-based synthetic CT (sCT) calculation on the online MRI acquired. The reference treatment plan was optimized on the expiratory phase of the 4D-CT, and during the online session the contours and the adapted plans were performed using the 3D-T2w navigator MRI of the patient's end-expiratory signal; 2D-T2w real-time monitoring MRI was also used as support for the contour's definition. The radiation therapist instructed the patients to hold their breath at the end of the breathing cycle for the time of the beam on. A total of 59 fractions were analyzed. For each fraction the dosimetric parameters of the target and normal liver of the adaptive and reference plans were compared; particularly the volume, the conformity index (CI) and gradient index (GI) for the target, and V5, V10 and Dmean for the normal liver. T-student statistical analysis was performed; a p-value less than 0.05 was considered statistically significant. RESULTS In the free breathing state, the 3D-T2w navigator MRI images enable a clear visualization of the tumor and its boundaries. The average target CI of the adaptive and reference plans is not significantly different (p = 0.448), while the GI is significantly higher (p = 0.043). Normal liver V10 and Dmean are lower and V5 is slightly increased, but without statistical differences. The mean values and standard deviation of the dosimetric parameters of the reference and adapted plans are shown in the Table below. CONCLUSION The use of a respiratory navigator combined with the breath-hold for MRI- guided liver SBRT allows clear visualization of the tumor, ensures the accuracy of the delivered dose and may be considered an alternative when the respiratory gating system is not available during MRgART sessions.
Collapse
|
171
|
Nasr LF, Li J, Swanson TA, Ghia AJ, Wang C, Yeboa DN, Grosshans DR, McAleer MF, Beckham T, McGovern SL. Early Outcomes from Proton Craniospinal Irradiation (pCSI) for Leptomeningeal Disease from Solid Tumors. Int J Radiat Oncol Biol Phys 2023; 117:e139-e140. [PMID: 37784708 DOI: 10.1016/j.ijrobp.2023.06.948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Prospective data suggest that proton craniospinal irradiation (pCSI) improves overall survival (OS) in patients with leptomeningeal disease (LMD) from solid tumors, compared to the historical standard of involved field radiation. To evaluate outcomes of this novel approach in a real-world setting, our institutional experience with treating adults with pCSI for LMD from solid malignancies was evaluated. MATERIALS/METHODS On an IRB-approved protocol, medical records of adults with LMD from solid tumors treated with pCSI were retrospectively reviewed for patient, disease and treatment characteristics and outcomes. CNS-PFS and OS were calculated from the last day of pCSI, and survival was modeled using Kaplan-Meier analysis. RESULTS From December 2021 to November 2022, 17 patients with median age 51y (range 22-71y) were treated with pCSI for LMD from solid tumors. Thirteen patients (76%) were female. Ten had ECOG PS of 0-1, and seven had PS 2-3. Nine patients (53%) had breast cancer, 3 (18%) had non-small cell lung cancer (NSCLC), 2 (12%) had melanoma, 1 (6%) had colorectal adenocarcinoma, 1 (6%) had endocervical adenocarcinoma, and 1 (6%) had two synchronous primaries (adenocarcinoma of the gastro-esophageal junction and neuroendocrine carcinoma of the lung). All patients had prior radiation; ten had prior radiation to the brain, one had prior radiation to the spine, and six had other sites previously radiated. Fourteen patients (82%) were treated to 30 Gy in 10 fractions and 3 (18%) were treated to 25 Gy in 10 fractions due to overlap with prior radiation fields. Median follow-up was 4 months (range, 1-13 months). Among 15 evaluable patients, median CNS-PFS and median OS were 3.6 months and 4.7 months, respectively. For patients with breast cancer or NSCLC, 62% were alive at 6 months; median OS has not been reached. Treatment was well tolerated with no grade 3-4 non-hematologic adverse events. CONCLUSION pCSI is a novel method for treatment of LMD from solid tumors that has been rapidly adopted. Based on our preliminary review, it is safe and well-tolerated; patient selection is critical. As these patients are often heavily pretreated, prior radiation fields must be considered in pCSI planning.
Collapse
|
172
|
Yu N, Li J, Chen X, Wang Z, Kang X, Zhang R, Qin J, Zheng Q, Feng G, Deng L, Zhang T, Wang W, Liu W, Wang J, Feng Q, Lv J, Chen D, Zhou Z, Xiao Z, Li Y, Bi N, Li Y, Wang X. Chemoradiotherapy Combined with Nab-Paclitaxel plus Cisplatin in Patients with Locally Advanced Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma: A Phase I/II Study. Int J Radiat Oncol Biol Phys 2023; 117:e354. [PMID: 37785224 DOI: 10.1016/j.ijrobp.2023.06.2433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-PTX) plus cisplatin as the regimen of conversional chemoradiotherapy (cCRT) in locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma (ESCC). MATERIALS/METHODS Patients with locally advanced ESCC (cT3-4, Nany, M0-1, M1 was limited to lymph node metastasis in the supraclavicular area) were enrolled. All the patients received the cCRT of nab-PTX plus cisplatin. After the cCRT, those resectable patients received esophagectomy; those unresectable patients continued to receive the definitive chemoradiotherapy (dCRT). The locoregional control (LRC), overall survival (OS), progression-free survival (PFS), distant metastasis free survival (DMFS), pathological complete response (pCR), R0 resection rate and adverse events (AEs) were calculated. RESULTS A total of 45 patients with ESCC treated from October 2019 to May 2021 were finally included. The median follow-up time was 30.3 months. The LRC, OS, EFS, DMFS at 1and 2 years were 81.5%, 86.6%, 64.3%, 73.2% and 72.4%, 68.8%, 44.8%, 52.7% respectively. 21 patients (46.7%) received conversional chemoradiotherapy plus surgery (cCRT+S). The pCR rate and R0 resection rate were 47.6% and 84.0%. The LRC rate at 1 and 2 years were 95.0%, 87.1% in cCRT+S patients and 69.3%, 58.7% in dCRT patients respectively (HR, 5.14; 95% CI, 1.10-23.94; P = 0.021). The OS rate at 1 and 2 years were 95.2% and 84.2% in resectable patients compared to 78.8% and 54.4% in unresectable patients (HR, 3.41; 95% CI, 1.10-10.61; P = 0.024). The toxicities during chemoradiotherapy were tolerated, the most common grade 3-4 toxicities were radiation esophagitis (15.6%). CONCLUSION Nab-PTX plus cisplatin were effective and safe as the regimen of conversional chemoradiotherapy of ESCC. The patients receiving conversional chemoradiotherapy plus surgery (cCRT+S) were prone to have a better survival.
Collapse
|
173
|
Garg AK, Hernandez M, Schlembach PJ, McAleer MF, Brown PD, Gopal RS, Wiederhold L, Swanson TA, Shah SJ, Li J, Ferguson S, Philip N, De Gracia B, Bloom E, Chun SG. Frameless Fractionated Linear Accelerator-Based Stereotactic Radiotherapy for Brain Metastases: Results of a Single-Arm Phase II Multi-Institutional Clinical Trial. Int J Radiat Oncol Biol Phys 2023; 117:e94-e95. [PMID: 37786219 DOI: 10.1016/j.ijrobp.2023.06.857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Stereotactic radiotherapy (SRT) yields high rates of local control for brain metastases while minimizing neurocognitive side effects. While advanced SRT platforms are widely available in urban centers, rural/suburban patients face geographic and socioeconomic barriers to access SRS. For this reason, we conducted a multi-institutional Phase 2 clinical trial to test the safety and efficacy of 3-5 fraction frameless fractionated stereotactic radiotherapy (FFSRT) for brain metastases in an integrated academic satellite network MATERIALS/METHODS: This IRB-approved Phase 2 trial was conducted for patients ≥18-years-old with 1-4 brain metastases. Brain metastases involving the optic pathway or brainstem were excluded. Gross tumor volume (GTV) was delineated with a volumetric brain MRI and planning target volume (PTV) was GTV + 2 mm margin. Radiation dose was based on GTV size: < 3.0 cm, 27 Gy in 3 fractions, and 3.0-3.9 cm, 30 Gy in 5 fractions. Toxicity was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 4. RESULTS Of 76 evaluable patients, the median age was 67 years, 56.6% were female, 82.9% were white/Caucasian and 89.6% had an Eastern Cooperative Oncology Group performance status ≤ 2. Most brain metastases were from lung cancer (51.3%) and breast cancer (15.7%). With median follow-up of 10 months, local control was 93%, median survival was 1.8 years (95% confidence interval (CI): 1.5-2.4 years), 1-year OS was 73.8% (95% CI: 0.59-0.84), and 2-year OS was 31% (95% CI: 0.12-0.52). There were no CTCAE Grade ≥ 3 protocol-related adverse events. CONCLUSION Outcomes of this trial compare favorably with contemporary SRT trials for brain metastases. FFSRT may provide opportunities to expand SRS access for underserved populations across the MDACC enterprise and in future clinical trials for brain metastases.
Collapse
|
174
|
Kennedy WR, Chang YW, Jiang J, Molloy J, Pennington-Krygier C, Harmon J, Hong A, Wanebo J, Braun K, Garcia MA, Barani IJ, Yoo W, Tovmasyan A, Tien AC, Li J, Mehta S, Sanai N. A Combined Phase 0/2 "Trigger" Trial Evaluating Pamiparib or Olaparib with Concurrent Radiotherapy in Patients with Newly-Diagnosed or Recurrent Glioblastoma. Int J Radiat Oncol Biol Phys 2023; 117:e115. [PMID: 37784657 DOI: 10.1016/j.ijrobp.2023.06.898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) This study evaluates the pharmacokinetic (PK) and pharmacodynamic (PD) profiles and clinical efficacy of PARP1/2 selective inhibitors, pamiparib and olaparib, in newly-diagnosed or recurrent glioblastoma (GBM) patients in combination with radiotherapy (RT). MATERIALS/METHODS In this combined phase 0/2 trial presumed newly-diagnosed (Arm A) or recurrent (Arm B) GBM patients received 4 days of pamiparib (60 mg BID) prior to resection either 2-4 or 8-12 hours following the final dose. Arm C enrolled patients with recurrent GBM to 4 days of olaparib (200 mg BID) prior to resection. Enhancing and nonenhancing tumor tissue, cerebrospinal fluid (CSF) and plasma were collected. Total and unbound drug concentrations were measured using validated LC-MS/MS methods. A PK 'trigger', defined as unbound drug and gt; 5-fold biochemical IC 50 in nonenhancing tumor, determined eligibility for the therapeutic expansion phase 2. PARP inhibition was assessed via ex vivo radiation and quantification of PAR levels compared to non-radiated control. Newly-diagnosed MGMT unmethylated GBMs and recurrent GBMs exceeding the PK threshold were eligible for an expansion phase of pamiparib (Arms A and B) or olaparib (Arm C) with concurrent RT followed by maintenance pamiparib or olaparib. RT was 60 Gy in 30 fractions in newly-diagnosed patients and 40 Gy in 15 fractions in recurrent patients, delivered using volumetric-modulated arc therapy (VMAT). RESULTS A total of 38 patients (Arm A, n = 16; Arm B, n = 16; Arm C, n = 6) were enrolled in the initial phase 0 study. The mean unbound concentrations of pamiparib in nonenhancing tumor region for Arm A and Arm B were 167.3 nM and 109.4 nM respectively, and in Arm C the mean unbound concentration of olaparib was 5.2 nM. All patients in the pamiparib arms (n = 32/32) but only 1 of 6 patients in the olaparib Arm C exceeded the PK threshold. Radiation-induced PAR expression was 2.44-fold in untreated control vs 1.16 in Arm A (p<0.05), 0.85 in Arm B (p<0.01) and 1.11 in Arm C patients, respectively. In Arm A, 11 patients had unmethylated tumors, and of those, 7 patients enrolled in phase 2. In Arm B, 9 of the 16 clinically eligible patients with positive PK results were enrolled in phase 2. At a median follow-up of 8.4 months [range: 1.3-15.7 months], the median progression-free survival (PFS) was 5.4, 6.0, and 3.8 months for Arms A (n = 7), B (n = 9), and C (n = 1), respectively. Grade 3+ toxicities related to pamiparib occurred in 4 patients, with 2 adverse events resulting in treatment discontinuation. No grade 3+ toxicities were documented in the olaparib arm. CONCLUSION Pamiparib achieved pharmacologically-relevant concentrations in nonenhancing GBM tissue and suppressed induction of PAR levels ex vivo post-radiation. The majority of patients with MGMT-unmethylated GBM advanced to the phase 2 portion of the trial, and pamiparib was generally well-tolerated in these patients.
Collapse
|
175
|
Li J, Iwai Y, Isaacs TJ, Ma SJ, Elmore SNC, Kamran S, Oladeru OT. Palliative Care among Incarcerated Populations: A National Survey of Radiation Oncologists' Perspectives and Experiences. Int J Radiat Oncol Biol Phys 2023; 117:e36. [PMID: 37785237 DOI: 10.1016/j.ijrobp.2023.06.726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Incarcerated individuals carry a high disease burden, including cancer which is now the leading cause of illness-related deaths. Disparities in access to screening, care coordination, timely treatment, and comorbidities have been identified as contributors to late-stage diagnosis and poor cancer-related outcomes. As the first of its kind, we assessed oncologists' knowledge, attitudes, and practices (KAP) in providing cancer care to incarcerated patients. MATERIALS/METHODS A KAP survey on incarcerated patients with cancer was developed and piloted with volunteer radiation oncologists. Following IRB approval, the KAP survey questionnaire included physicians' demographics and Likert scale questions on practice patterns and experiences caring for incarcerated patients. The survey was distributed to 150 medical and radiation oncologists randomly selected from national societies' membership directories (ASTRO and ASCO). Data collection took place from 7/2020-12/2021, and descriptive statistics were used for analysis. RESULTS Of the 75 surveyed radiation oncologists (RO), 34 responded with a response rate of 45% among the specialty cohort. Most RO (59%) incorrectly identified "heart disease" as the leading cause of death among incarcerated patients, followed by "substance use disorder" (19%); only 9% correctly reported "cancer" as the leading cause of death. Most RO reported caring for a patient who underwent cancer treatment while incarcerated (70%) or recently incarcerated (within 6 months of release; 63%). 38% (n = 10/26) indicated incarcerated patients presented with delayed diagnosis at consultation. 58% (n = 14/24) reported that ≥50% of their patients who were incarcerated presented with cancer-related pain, and 82% (n = 18/22) indicated that ≥50% of their patients had a history of opioid use disorder. Yet 38% (n = 9/24) reported their clinic adequately treated cancer-related pain for incarcerated patients, while 54% (n = 13/24) reported their clinic needed improvement. CONCLUSION Most radiation oncologists have experience providing cancer care for incarcerated patients and acknowledge disparities in later-stage disease presentation in this patient population. Interventions are needed to ensure cancer-related pain is appropriately managed among patients experiencing incarceration. Further studies are required to understand practice patterns and ensure equitable cancer treatment for carceral populations.
Collapse
|
176
|
Wu J, Tang B, Orlandini LC, Li J, Wu F. Evaluation of Flattening-Filter-Free and Flattening Filter Dosimetric and Radiobiological Criteria for Lung SBRT: A Volume-Based Analysis. Int J Radiat Oncol Biol Phys 2023; 117:e738. [PMID: 37786143 DOI: 10.1016/j.ijrobp.2023.06.2267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The use of volumetric modulated arc therapy (VMAT) with flattening-filter-free (FFF) beams is becoming more prevalent in lung cancer stereotactic body radiotherapy (SBRT). The aim in this study was to assess the impact of dosimetric and radiobiological differences between FFF and flattening filter (FF) beams for lung SBRT based on the target volume. MATERIALS/METHODS A total of 198 lung stereotactic body radiation therapy treatment plans with FFF beams and FF beams were retrospectively selected for this study. For all plans, the prescribed dose was 50 Gy/5 fractions, and the dose volume histogram (DVH) for the target and organs at risk (OAR) and the normal tissue complication probability (NTCP) of the lung were recorded and compared. Moreover, monitor units (MUs), the beam on-time and the treatment time were evaluated. The study was performed following the Radiation Therapy Oncology Group (RTOG) 0813 and 0915 protocols. RESULTS No significant differences in D90, coverage rate (CR) or conformity index (CI) of the target were observed between FFF beams and FF beams (p>0.05). The D2, R50% and gradient index (GI) for the target improved with FFF beams compared with FF beams (p<0.05). FFF beams also significantly reduced the dose for the lung, heart, spinal cord, esophagus and NTCP of the lung (p<0.05), compared with FF beams. However, there was no significant difference in sparing of the trachea (p>0.05). The mean MUs, beam on-time and treatment time were 1871±278 MUs, 3.2 ±0.2 min and 3.9 ±0.3 min for FFF beams, and 1890±260 MUs, 4.2±0.3 min and 4.8 ±0.4 min for FF beams, respectively. CONCLUSION The FFF beam technique for lung SBRT with VMAT results in a better dose fall-off, better dose-sparing of OAR, lower NTCP of the lung and a shorter beam on-time compared with the FF beam technique. Additionally, the improvement in target and OAR-sparing for FFF beams was increased with increasing target volume.
Collapse
|
177
|
Zhang J, Luo X, Zhou R, Dai Z, Guo C, Qu G, Li J, Zhang Z. The axial and sagittal CT values of the 7th thoracic vertebrae in screening for osteoporosis and osteopenia. Clin Radiol 2023; 78:763-771. [PMID: 37573241 DOI: 10.1016/j.crad.2023.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2023] [Revised: 07/06/2023] [Accepted: 07/11/2023] [Indexed: 08/14/2023]
Abstract
AIM To evaluate the difference in computed tomography (CT) attenuation value of different planes of the 7th thoracic vertebra and investigate the efficacy of axial and sagittal vertebral CT measurements in predicting osteoporosis. MATERIALS AND METHODS Patients who underwent routine chest CT and dual-energy X-ray absorptiometry (DXA) within 1 month were included in this retrospective study. The CT attenuation values of different planes were compared. Logistic regression and receiver operating characteristic (ROC) were used to analyse the difference of each plane in the diagnosis of osteoporosis. RESULTS The study included 1,338 patients (mean age of 61.9±11.9; 54% female). The CT attenuation values decreased successively in the normal group, osteopenia group, and osteoporosis group. The paired t-test results showed that the mid-axial measurements were greater than mid-sagittal measurements, with a mean difference of 9 HU, the difference was statistically significant (p<0.001, 95% confidence interval [CI] = 7.8-10.1). For each one-unit reduction in mid-sagittal CT attenuation value, the risk of osteopenia or osteoporosis increased by 3.6%. To distinguish osteoporosis from non-osteoporosis (osteopenia + normal), the sensitivity was 90% and the specificity was 52.4% at the mid-sagittal threshold of 113.7 HU. CONCLUSIONS The CT attenuation values of mid-sagittal plane have higher diagnostic efficacy than axial planes in predicting osteoporosis. For patients with a sagittal CT attenuation value of <113.7 HU in the T7, further DXA examination is warranted.
Collapse
|
178
|
Li XJ, Li J, Zhang QQ, Su LP, Guo Y, Gong XL, Yao JJ, Wang L, Zhang ZQ. The expression of annexin-A1 in esophageal squamous cell carcinoma and its association with the biological behavior of the primary human esophageal squamous carcinoma cell line. JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY : AN OFFICIAL JOURNAL OF THE POLISH PHYSIOLOGICAL SOCIETY 2023; 74. [PMID: 38085519 DOI: 10.26402/jpp.2023.5.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Accepted: 10/31/2023] [Indexed: 12/18/2023]
Abstract
This study aimed to observe the differential expression of Annexin-A1 in esophageal squamous cell carcinoma (ESCC) and explored the effect of small interfering ribonucleic acid (RNAi)-Annexin-A1 on the biological behavior of CE81T-0 cells. An immunohistochemical approach was used to detect the expression of Annexin-A1 in 86 pairs of ESCC samples. Quantitative reverse transcription polymerase chain reaction was used to detect the expression of Annexin-A1 in CE81T-0 and CE81T-4 cells, and the expression of Annexin-A1 in CE81T-0 cells was knocked out by RNAi. A methyl-thiazolyl-tetrazolium assay was used to observe the effect of Annexin-A1 on cell proliferation, and flow cytometry was conducted to analyze its effect on cell cycles and apoptosis. A scratch assay and a Transwell chamber were used to detect changes in cell migration and invasion. From the results, compared with the Annexin-A1 expression rate of 59.3% in para-carcinoma tissues, the expression of Annexin-A1 in cancer was reduced to only 32.6% in ESCC cells. Annexin-A1 was strongly expressed in highly differentiated ESCC cells without lymphatic metastasis and highly expressed in the CE81T-0 cell group with low metastasis. Annexin-A1 gene silencing promoted cell proliferation and inhibited apoptosis, blocked cells in the S-phase, and increased cell migration, leading to an increase in the number of invaded cells. Above all, Annexin-A1 could reflect the differentiation degree and lymph node metastasis of ESCC cells to some extent and was involved in the invasion, metastasis, proliferation, and other biological behaviors of ESCC cells, indicating an experimental basis for Annexin-A1 as a molecular marker in the early diagnosis of ESCC and the prediction of cell metastasis, invasion, and differentiation degree.
Collapse
|
179
|
Li J, Choi W, Anne PR. Deep-Learning Based Auto-Segmentation for Liver Yttrium-90 Selective Internal Radiation Therapy. Int J Radiat Oncol Biol Phys 2023; 117:e684-e685. [PMID: 37786012 DOI: 10.1016/j.ijrobp.2023.06.2150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) In resin Yttrium-90 (Y-90) selective internal radiation therapy (SIRT), liver volume sizes are needed for Y-90 activity calculations using the body-surface-area method, which are obtained from contours that are manually delineated in 3D images. The aim was to apply a deep-learning based auto-segmentation method for liver delineation for Y-90 SIRT. MATERIALS/METHODS A deep-learning-based liver segmentation method was applied using the U-Net3D architecture, which is a 3D convolutional neural network (CNN) extended from the original 2D U-Net architecture for 3D objects in medical imaging. The segmentation model was trained on the Liver Tumor Segmentation (LiTS) dataset. The training data set contained 130 CT scans, and the test data set contained 70 CT scans. The model was deployed in the clinic using DICOM communication. Auto-segmentation of liver in the CT images of 18 SIRT patients was studied. The CT images were exported from clinical database to the segmentation model's DICOM location, where a monitoring software detected the incoming data and automatically ran the liver segmentation. The results were then returned to the original DICOM location where the CT images were stored. Auto-segmented liver contours were compared with physician manually-delineated contours. Dice similarity coefficient (DSC), mean distance to agreement (MDA), ratio of volume (RV), and ratio of activity (RA, ratio of activity calculated using an auto-segmented liver contour to the accurate activity calculated using a manually-delineated contour), were assessed. RESULTS DSC, MDA, and RV are 0.942±0.014 (range: 0.908-0.959), 1.902±0.503 mm (range: 1.043-2.956 mm), and 0.988±0.039 (range: 0.901-1.045), respectively. RA is 1.001±0.003 (range: 0.993-1.007), which indicates that the activities calculated using the auto-segmented liver contours are close to the accurate activities. CONCLUSION The segmentation model was able to successfully identify and segment livers in the CT images, and provide accurate and reliable results. The proposed method is beneficial for clinical use as it can process large amounts of data quickly and efficiently, and can be easily deployed in a clinical environment using DICOM communication.
Collapse
|
180
|
Shanker MD, Cavazos A, Li J, Beckham T, Yeboa DN, Wang C, McAleer MF, Briere TM, Amini B, Tatsui C, North R, Alvarez-Breckenridge C, Cezayirli P, Rhines LD, Ghia AJ, Bishop AJ. Dosimetric Analysis of Local Failure Outcomes and Vertebral Compression Fracture Risk in Single-Fraction Spine Stereotactic Radiosurgery for Metastatic Sarcoma. Int J Radiat Oncol Biol Phys 2023; 117:e148-e149. [PMID: 37784729 DOI: 10.1016/j.ijrobp.2023.06.966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Sarcoma spinal metastases (SSM) are particularly difficult to manage given their poor response rates to chemotherapy and their inherent radioresistance. We sought to analyze dosimetric parameters impacting local failure and vertebral compression fracture outcomes in a homogenously treated cohort of patients with SSM treated with single-fraction spine stereotactic radiosurgery (SSRS). MATERIALS/METHODS A retrospective review was conducted on a cohort of patients with SSM treated with definitive SSRS at a single tertiary institution. 16-24 Gy was delivered to the GTV and 16 Gy uniformly to the CTV. Kaplan-Meier analysis was conducted to assess time to local failure (LF). The log-rank test was utilized to examine group differences. Patients were censored at time of last follow-up or death. Cox proportionate hazards modeling was used to determine hazard ratios (HR) and their respective 95% confidence intervals (CI). RESULTS A total of 66 patients with 96 lesions underwent SSRS for SSM. Median follow-up was 17 months (IQR 8-28). Median age was 55 years (IQR 41-63). The most common histological subtype was leiomyosarcoma (41%) followed by liposarcoma (9%). 81 lesions received 24 Gy to the GTV, 12 received 18 Gy and 3 received 16 Gy. Median GTV and CTV volume was 13.6cc (IQR 5-27) and 51.6cc (IQR 30-80) respectively. 27% of patients had Bilsky 1b or greater disease. 16 of 96 lesions demonstrated progression representing a crude local failure rate of 17% with median time to failure of 8 months (IQR 5-18). The 1-year actuarial progression free survival (PFS) was 89% with a median PFS of 13 months (IQR 16-63). Median overall survival (OS) was 15 months (IQR 8-28) from SSRS. 8% of patients developed vertebral compression fractures at a median of 13 months post SSRS (IQR 7-25). Every 1 Gy increase in GTV minimum dose (DMin) across the range (5.8-25cc) was associated with a reduced risk of local failure (HR = 0.875 [95% CI 0.787-0.974], p = 0.01). Stratifying thresholds for GTV DMin, a local control benefit was seen as low as 12 Gy and higher (HR = 0.329 [95% CI 0.11-0.97, p = 0.044) with a significantly greater magnitude benefit seen at 14 Gy (HR = 0.267 [95% CI 0.09-0.77, p = 0.014) and above 15 Gy (HR = 0.091 [95% CI 0.03-0.41], p = 0.0018). There were no other queried variables besides GTV Dmin associated with local control including: GTV: volume, mean, Dmax, D90, CTV: volume, Dmin, Dmean, Dmax, or D90. There was an increased risk of VCF with increasing CTV DMean (HR = 2.4 [95% CI 1.4-4.1], p = 0.002) and CTV D90 (HR = 2.2 [95% CI 1.2-4.0], p = 0.01); however, no association with GTV parameters. CONCLUSION This study represents one of the most homogenously treated and the largest cohorts of patients with sarcoma spinal metastases treated with single-fraction SSRS. Despite inherent radioresistance, SSRS confers durable and high rates of local control in SSM without unexpected long-term toxicity rates. Increasing GTV minimum dose is significantly associated with superior local control with no corresponding increased risk of VCF.
Collapse
|
181
|
Wang T, Li J, Ji S. A Bidirectional Mendelian Randomization Analysis of Circulating Inflammatory Cytokines with Colon and Rectum Cancers. Int J Radiat Oncol Biol Phys 2023; 117:e239. [PMID: 37784945 DOI: 10.1016/j.ijrobp.2023.06.1164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Chronic inflammation has been proposed to be associated with tumor development and progression. Dynamic changes in serum cytokines induced by feedback mechanisms from tumors make differentiation of cause and effect difficult. MATERIALS/METHODS In this study, a bidirectional summary-level Mendelian randomization (MR) analysis was performed to elucidate the causal correlation between inflammatory regulators with colon (CC) and rectum (RC) carcinomas. Summary-level data on inflammation-related genetic variations were extracted from a genome-wide association meta-analysis. Corresponding data for CC and RC were obtained from the FinnGen (CC: 1396 cases vs. 174,006 controls; RC: 1,078 cases vs. 174,006 controls) and UK Biobank (CC: 2,226 cases vs. 358,968 controls; RC: 1,170 cases vs. 360,024 controls) consortiums. Inverse-variance weighted MR was used as the primary method, and sensitivity analysis was performed to assess the MR assumptions. RESULTS After P value correction and meta-analysis, there was evidence of direct associations between macrophage migration inhibitory factor (MIF) and CC (95% confidence interval (CI):1.001-1.003; P = 8.77×10-4) and inverse correlations between Interleukin-17 (IL-17) and RC (95% CI: 0.997-0.999; P = 1.15×10-3). Conversely, interleukin-1 receptor antagonist (IL1ra) was downregulated in patients at a higher risk of RC (P = 0.006), and no reliable results revealed a causal association between other cytokines and CC and RC. CONCLUSION Thus, this MR study suggests that downregulated serum MIF and elevated serum IL-17 concentrations may reduce the risk of CC and RC, respectively. Therefore, MIF and IL-17 may serve as potential therapeutic targets, and further exploration of their underlying mechanisms is warranted.
Collapse
|
182
|
Wang T, Li J, Ji S. Prognostic Value of Naples Prognostic Score on Survival in Unresectable Small Cell Lung Cancer Patients Undergoing Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e28. [PMID: 37785047 DOI: 10.1016/j.ijrobp.2023.06.710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Chemoradiotherapy is a major modality for treatment of small cell lung cancer (SCLC). Naples prognosis score (NPS) is a novel prognostic biomarker-based immune and nutritional status and that can be used to evaluate prognosis. Our study aimed to investigate the prognostic role of NPS in unresectable SCLC patients. MATERIALS/METHODS Patients treated with chemoradiotherapy were retrospectively analyzed between June 2012 and August 2017. We divided patients into three groups depending on the NPS: group 0, n = 31; group 1, n = 100; and group 2, n = 48, and associations between clinical characteristics and NPS group were analyzed. Spearman correlation analyses were used to estimate the correlations among NPS parameters. The univariable and multivariable Cox analyses were used to evaluate the prognostic value of clinicopathological characteristics and laboratory indicators for overall survival (OS) and progression-free survival (PFS). RESULTS Data from 179 patients were analyzed. Treatment modality (P < 0.001) and serum CEA (P = 0.03) were significantly different among the NPS groups. The age, sex, smoking status, KPS, Karnofsky performance score (KPS), disease extent, and number of metastatic sites were not correlated with NPS (all P > 0.05). Spearman correlation analyses showed that neutrophil-to-lymphocyte ratio (NLR) had a significant correlation with lymphocyte-to-monocyte ratio (LMR) (r = -0.495, P < 0.001). KPS, disease extent, prophylactic cranial irradiation, treatment response and NPS Group were associated with OS. In addition, KPS, disease extent, prophylactic cranial irradiation, treatment response and NPS Group were associated with PFS. Multivariate analysis results showed that NPS was identified as an independent prognostic factor for OS (Group 1: hazard ratio [HR] = 2.704, 95% confidence interval [CI] = 1.403-5.210; P = 0.003; Group 2: HR = 5.154, 95% CI = 2.614-10.166; P < 0.001) and PFS (Group 1: HR = 2.018, 95% CI = 1.014-4.014; P = 0.045; Group 2: HR = 3.339, 95% CI = 1.650-6.756; P = 0.001). CONCLUSION NPS is related to clinical outcomes in patients with unresectable SCLC. NPS as an innovative scoring system, can improves prediction of survival in unresectable SCLC patients.
Collapse
|
183
|
Florez M, De B, Kowalchuk RO, Tang C, Bishop AJ, Kouzy R, Amini B, Briere TM, Beckham T, Wang C, Li J, Tatsui C, Rhines LD, Merrell KW, Ghia AJ. Validation of the Prognostic Index for Spine Metastasis (PRISM) Score for Stratifying Survival in Patients Treated with Spinal Stereotactic Radiosurgery. Int J Radiat Oncol Biol Phys 2023; 117:e103-e104. [PMID: 37784632 DOI: 10.1016/j.ijrobp.2023.06.875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Stereotactic spinal radiosurgery (SSRS) has been increasingly utilized as a first-line treatment for the management of spine metastases due to its ability to prolong survival and improve symptom control. Studies have shown that SSRS is helpful for select patients; however, there is no universal scoring system utilized to predict patient response to treatment. The Prognostic Index for Spinal Metastases (PRISM) score was shown to predict the likelihood of patients benefiting from SSRS. We sought to further demonstrate its generalizability by performing validation with a large dataset from a second high-volume institution. MATERIALS/METHODS We performed a retrospective review from 2017-2019 of 424 patients treated with SSRS at a single institution. Patients were stratified on the previously described PRISM criteria: Female sex (+2), solitary bone disease (+3), performance status (0 through +3.5), prior surgery at the SSRS site (+1), number of other metastatic sites (-N), prior radiation at the SSRS site (-1), and latency to treatment ≥ 5 months (+3). Patients were grouped based on PRISM scores: >7, Group 1; 4-7, Group 2; 1-3, Group 3; <1 Group 4. There were 89, 188, 88, and 59 patients in Groups 1, 2, 3, and 4, respectively. Most patients were male (70%) with a performance status of 0 (53%). The most common tumor histologies were prostate (34%), renal (18%), and lung (11%). The median biological effective dose (BED10) was 60 Gy (interquartile range [IQR], 60-82). We performed Cox proportional hazards analysis on overall survival (OS) based on PRISM score and patient and tumor characteristics. Concordance indices created from PRISM criteria and the multivariate Cox proportional analysis were compared. RESULTS The median follow-up time was 50.5 months (95% confidence interval [CI], 45.8-54.7) with a median overall survival of 30.3 months (95% CI, 27.3-38.4). The median overall survivals for PRISM Groups 1, 2, 3, and 4 were 57.1, 37, 23.7, and 8.8 months, respectively. There were significant differences in overall survival among PRISM groups with hazard ratios of 0.49 (95% CI, 0.35-0.69; P<0.001) for Group 1, 0.71 (95% CI, 0.55-0.91); P<0.007) for Group 2, 1,45 (95% CI, 1.08-1.94); P = 0.010) for Group 3, and 3.47 (95% CI, 2.56-4.70; P<0.001) for Group 4. Multivariable Cox analysis for patient and tumor characteristics revealed only the number of organs involved and performance status as significant clinicopathologic prognostic attributes. However, the C-index using the PRISM criteria was 0.76, which was superior to the C-index when using the significant clinicopathologic attributes by themselves (0.71). CONCLUSION These data demonstrate robust validation of the PRISM score to stratify OS in patients treated with SSRS and may help guide optimal treatment selection in prospective trials and clinical settings.
Collapse
|
184
|
Jin Y, Wang W, Li J. Target Volumes Comparison between Postoperative Simulation MRI and Preoperative Diagnostic MRI for Prone Breast Radiotherapy after Breast-Conserving Surgery. Int J Radiat Oncol Biol Phys 2023; 117:e182. [PMID: 37784805 DOI: 10.1016/j.ijrobp.2023.06.1035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To investigate the correlation and difference between target volumes determined by postoperative prone positioning magnetic resonance imaging (MRI) and preoperative prone diagnostic MRI for breast radiotherapy after breast-conserving surgery (BCS) based on deformable image registration (DIR). MATERIALS/METHODS A total of 17 patients undergoing prone whole breast-irradiation after BCS were enrolled, all these patients were undergoing preoperative and postoperative prone MRI scans. The gross tumor volume (GTV) was delineated on the preoperative MRI images, then expanding 10 mm to simulate the preoperative lumpectomy cavity (LC). The LC were expended to clinical target volume (CTV), and planning target volume (PTV) on preoperative and postoperative MRI sequences, respectively. Preoperative and postoperative MRI was registered based on DIR by a commercially available software system. The target volume, the distance between the centers of mass (dCOM), conformity index (CI), degree of inclusion (DI) were compared to explore the target volume variation for pre- and post-surgery delineation. And evaluated the relationship between CILC/CIPTV and clinical factors. RESULTS The volume of GTVpre was 3.05cm3(range, 1-23.63cm3). The median volume of LCpre were 26.84 cm3 (range, 11.75-102.28 cm3). 0.85cm3 smaller than the LCpre, the LCpost were 25.99 cm3 (range, 5.98-41.95) (P = 0.04). The dCOM, CI, and DI between LCpre and LCpost were 1.371cm (range, 0.533-5.447), 0.221 (range, 0.041-0.516), and 0.472 (range, 0.108-0.804). There was no significant statistically difference between PTVpre and PTVpost (120.73cm3 vs 131.67cm3, p = 0.723). Compared with LC, the CI and DI between PTVpre and PTVpost were increased to 0.446 (range, 0.233-0.700), 0.636 (range, 0.362-0.834), respectively. Meanwhile, the dCOM was reduced to 1.239cm (range, 0.413-3.642). There was no obvious linear correlation between the CI with the GTV volume, the ratio of the primary tumor volume to the breast volume, the distance from the primary tumor to the nipple and chest wall, and the Body Mass Index (BMI), respectively. CONCLUSION For prone breast irradiation, even based on DIR, the spatial correspondence of the target volumes between preoperative and postoperative MRI images were still poor. Therefore, it is not reasonable to delineate postoperative LC refer to preoperative diagnostic MRI based on DIR. Preoperative MRI also cannot provide individualized guidance for LC delineation according to tailored patient.
Collapse
|
185
|
Liu H, Tang Q, Yan X, Wang L, Wang J, Yang Q, Wei B, Li J, Qi J, Hu J, Hu B, Han C, Wang J, Li L. Mass spectrometry-based metabolic profiling for identification of biomarkers related to footpad dermatitis in ducks. Br Poult Sci 2023; 64:577-585. [PMID: 37254666 DOI: 10.1080/00071668.2023.2214884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Revised: 03/02/2023] [Accepted: 04/04/2023] [Indexed: 06/01/2023]
Abstract
1. A new assessment method for duck footpad dermatitis (FPD) evaluation was developed, combining visual and histological characters using the images and sections of 400 ducks' feet at 340 d of age. All ducks were graded as G0 (healthy), G1 (mild), G2 (moderate) and G3 (severe) according to the degree of FPD.2. To reveal the potential biomarkers in serum related to duck FPD, non-targeted metabolomics and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were used to explore differential metabolites in each group.3. There were 57, 91 and 210 annotated differential metabolites in groups G1, G2 and G3 compared with G0, which meant that the severity of FPD increased in line with the number of metabolites. Four metabolites, L-phenylalanine, L-arginine, L-leucine and L-lysine, were considered potential biomarkers related to FPD.4. KEGG enrichment analysis showed that the FPD was mainly involved in glycolysis, the tricarboxylic acid (TCA) cycle, the pentose phosphate pathway and amino acid metabolism. These are related to production metabolism and can affect the physiological activities of ducks, which might explain the decrease in production performance.
Collapse
|
186
|
Wang JZ, Wang Y, Shao Q, Li J. Study on the Dynamic Changes of Myocardial Injury Markers in Radiotherapy for Esophageal Carcinoma and Its Correlation with Cardiac Dosimetry. Int J Radiat Oncol Biol Phys 2023; 117:e266. [PMID: 37785011 DOI: 10.1016/j.ijrobp.2023.06.1226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) It was hypothesized that radiotherapy for esophageal cancer could cause radiation-induced heart damage. To investigate the dynamic changes of myocardial enzyme, high-sensitive troponin T (hs-TnT), N-terminal pro-brain natriuretic peptide precursors (PRO-BNP) and left ventricular ejection fraction (LVEF) during radiotherapy and six months after radiotherapy for middle and lower thoracic squamous cell carcinoma, and to analyze the correlation between these indicators and dose-volume histogram (DVH) parameters of the heart. MATERIALS/METHODS A total of 35 patients with thoracic esophageal squamous cell carcinoma who underwent radical concurrent chemoradiotherapy were enrolled in the study. Radiation therapy was performed for up to 6 weeks. All patients received Intensity modulated radiation therapy (IMRT). Total radiation dose was from 50.4Gy to 60 Gy in each patient with a dose of 1.8-2.0 Gy per fraction. Blood samples to determine creatine kinase (CK), creatine kinase isoenzyme MB (CK-MB), lactic dehydrogenase (LDH), alpha-hydroxybutyric dehydrogenase (α-HBDH), hs-TnT, PRO-BNP and LVEF were measured before radiotherapy, during (10th -20th fraction), at the end of radiotherapy, 1, 3, 6 months after radiotherapy. The dynamic changes of the above indexes were analyzed. The correlation between the above indexes and the mean heart dose (Dmean), V5-V60 (dose-volume histograms data were recorded in discrete 5Gy dose levels) of the heart in the course of radiotherapy was also analyzed. RESULTS The Serum hs-TNT and LVEF show an upward trend during radiotherapy, at the end of radiotherapy and 6 months after radiotherapy for esophageal cancer. The hs-TnT of patients before, during, at the end of radiotherapy and 1, 3, and 6 months after radiotherapy were 7.2pg/ml, 9.1pg/ml, 9.1pg/ml, 9.0pg/ml, 9.4pg/ml, and 8.1pg/ml, respectively (p<0.05). The LVEF were 63.7%, 62.4%, 62.0%, 62.5%, 62.2%, 61.9% respectively (p<0.05). The pro-BNP showed an upward trend during radiotherapy and gradually returned to normal after radiotherapy. The CK and CK-MB showed a downward trend during radiotherapy and 1 month after radiotherapy, and gradually returned to normal 3 months after radiotherapy. Compared with the low dose group (the average dose of heart < 2000cGy), the high dose group (≥2000cGy) had a greater increase in hs-TNT, pro-BNP and LVEF, and a slower recovery time. There was no correlation between the changes of myocardial enzyme, hs-TnT, PRO-BNP, LVEF and the heart mean dose, V5-V60 during radiotherapy (p>0.05). CONCLUSION Cardiac injury induced by concurrent chemoradiotherapy for middle and lower thoracic esophageal cancer can lead to the increase of serum hs-TNT and pro-BNP and the increase of LVEF in the early stage of treatment, and this phenomenon is more obvious in the high-dose group. The hs-TnT and PRO-BNP are sensitive parameters to reflect the heart damage in esophageal cancer radiotherapy, which may provide reference for the heart protection during radiotherapy.
Collapse
|
187
|
Li J, Mu J, Li F, Ran L, Du Y, Mei F, Hu L, Tian X, Hong W, Mao W, Qin Y, Li M, Lu B. Silva Classification System for HPV-Related EAC of Stage I ∼ IIIc1p Cervical Adenocarcinoma and Its Effect on Prognosis and Survival. Int J Radiat Oncol Biol Phys 2023; 117:e526. [PMID: 37785635 DOI: 10.1016/j.ijrobp.2023.06.1801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The proportion of adenocarcinoma in cervical cancer gradually increased and presented a younger trend. The previous pathological classification of cervical adenocarcinoma is difficult to provide reference for clinical treatment. In recent years, Silva classification, a new pathologic system for cervical adenocarcinoma, has been confirmed to be suitable for HPV-associated adenocarcinoma (HPVA), and has shown certain clinical application value in subsequent studies. Therefore, this study will retrospectively analyze the distribution of Silva typing system in patients with HPVA under standard treatment mode and its relationship with prognosis and survival. MATERIALS/METHODS From January 2010 to September 2021, 124 cervical adenocarcinoma patients with HPVA were retrospectively included, who underwent radical resection of cervical cancer. The HE staining sections of the patients were divided into SilvaA, SilvaB, and SilvaC types according to the Silva typing system. Kaplan-Meier calculation was used for single-factor analysis, and COX stepwise regression model was used for multi-factor analysis. RESULTS Of the 124 patients with HPVA who could be graded according to the Silva system, 16 (12.9%, 16/124) were SilvaA, 27 (21.7%, 27/124) SilvaB, and 81 (65.4%, 81/124) SilvaC. In Silva classification, FIGO staging of Silva A and B was stage I. And FIGO staging of Silva C was more significantly later than the staging of Silva A and B. All lymph node metastases and paruterine infiltrates were found only in Silva C. In addition, the patients with Silva C large mass accounted for a higher proportion (41.7%). SilvaA type cervical adenocarcinoma patients were in a survival state by the end of follow-up. Among Silva B, 3 patients died due to tumor, and the 5-year OS rate were 91.3%. Among SilvaC, 15 patients died due to tumor, and the 5-year OS rate were 76.5%. FIGO stage and lymph node invasion were the influencing factors for survival and prognosis of Silva classification (P <0.05). FIGO stage, tumor size, lymph node invasion, and paralegal invasion were the influencing factors for survival and prognosis of SilvaC patients (P <0.05). CONCLUSION Silva model classification system combined with clinicopathological features has certain clinical value for the prognostic guidance of HPVA patients. Among Silva classification, SilvaC had the worst prognosis. Late FIGO stage, lymph node metastasis, and paralegal infiltration are the influencing factors for survival and prognosis of SilvaC type.
Collapse
|
188
|
Yeboa DN, Woodhouse K, Prabhu S, Li J, Beckham T, Weinberg JS, Wang C, McCutcheon IE, Swanson TA, Kim BYS, McGovern SL, North R, McAleer MF, Alvarez-Breckenridge C, Jiang W, Ene C, Ejezie CL, Lang F, Rao G, Ferguson S. MD Anderson Phase III Randomized Preoperative Stereotactic Radiosurgery (SRS) vs. Postoperative SRS for Brain Metastases Trial. Int J Radiat Oncol Biol Phys 2023; 117:e160-e161. [PMID: 37784756 DOI: 10.1016/j.ijrobp.2023.06.990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Postoperative stereotactic radiation therapy/radiosurgery (SRT/SRS) is being evaluated in comparison to Preoperative SRT for brain metastases (mets) in a limited number of prospective clinical trials. Our objective is to address the significant knowledge gap concerning the logistics of preoperative SRT in comparison to postoperative SRT in a randomized controlled study. MATERIALS/METHODS Patients with brain mets with at least 1 surgically operable met were randomized (1:1) to Preop vs Postop SRT. In this abstract, we present non-primary endpoint data on the trial concept and logistics of treatment for this data safety monitoring board reviewed study. Patients enrolled had 1-2 lesions resected and <15 lesions treated at time of SRT to best reflect the standard population that receive SRT and surgery at our institution. RESULTS From 12/2018 to 12/2022, 99 patients with 1-2 operable brain mets were enrolled and randomized to Preop (n = 49) or Postop (n = 50) SRT. Males represented 56% of the cohort compared to females, and <25% were age 18-49 years, while 27%, 29, and 19% respectively were 50-59, 60-69, and > = 70. The most frequent histologies enrolled were lung (29%), renal cell (15%), melanoma (14%), and breast (11%) cancers. The majority of patients (83%) had 1-4 brain mets on their baseline MRI and 91% subsequently had a single lesion resected. Seventy-nine patients completed both SRT and surgery, while 9% received no therapy due to drop out before study therapy initiation. Among patients receiving both therapies in the combined cohort, 68% received a non-invasive stereotactic radiosurgery instrument to the randomized cavity lesion compared to 32% receiving LINAC based SRT. Treatment of the lesion or cavity with single fraction SRT was 51% in the Preop arm vs 31% in the Postop arm. Multi-fraction (3-5 SRT) was 67% in the Postop cohort in contrast to 47% in the Preop cohort. Time from randomization to RT was 5.6 days and 33.7 days in the Preop and Postop cohorts respectively, and for surgery was 10.2 days vs 12.9 days in the Postop vs Preop cohorts. The average time from RT to surgery was 7.3 days in the Preop arm and 23.5 days in the Postop arm (to allow for incisional healing time). CONCLUSION In one of the early initiated randomized prospective cohorts of Preop vs Postop SRT, we demonstrated logistical feasibility with an efficient clinical trial workflow for study treatment. Differences in Preop vs Postop logistics reflect clinical practice differences in time-to-treatment. Therapy with various modalities reflected real-world practice and possibly provider preferences in technique when addressing the nature of delineating cavities and changes in cavity volume with regard to fractionation. Independent of the primary outcomes, our data provides insights in the practical management of patients receiving these two modalities of therapy, and further data at the completion of trial will address relevant primary outcomes.
Collapse
|
189
|
Gao J, Zeng H, Xie Y, Xu B, Yang Y, Li X, Li J, Chen Y. The Robotic System for the Treatment of Locally Advanced Cervical Cancer with Stereotactic Body Radiotherapy Boost: Results of a Phantom-Based and Preliminary Study. Int J Radiat Oncol Biol Phys 2023; 117:e653-e654. [PMID: 37785941 DOI: 10.1016/j.ijrobp.2023.06.2081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To fix uterocervical position, compensate uterocervical intrafraction motion, and thus improve the accuracy of dose delivery based on the robotic system for the treatment of locally advanced cervical cancer with stereotactic body radiotherapy boost. MATERIALS/METHODS CT images were acquired after robot arm implanted a fixator with fiducial markers into the cervix of pelvic phantom. The treatment plans were designed by contoured a simulated tumor lesion site. The fiducial markers position was obtained by real-time image guidance system and was registered with digitally reconstructed radiographs to calculate correlation error of six directions. The correlation error was delivered to the robotic arm to precisely adjust the position and posture of the fixator, and thus compensated uterocervical intrafraction movement through the interactive interface of the robotic system. The pressure sensor at the head of the fixator provided real-time feedback on the pressure value at the contact surface between the fixer and the cervix. The correlation error of six directions and the pressure value were extracted and analyzed from the log file. RESULTS The data from the log file indicated that the three translational direction correlation error of x, y and z were 0.19mm, 0.20mm and 0.10mm, respectively. The three rotational direction correlation error of roll, pitch and yaw were 0.25°, 0.21° and 0.23°, respectively. With the increase of the relative distance between cervix and pressure sensor, the mean value of pressure variation decreases gradually. When the relative distance is 0.5mm and 3mm, the mean value of pressure variation is approximately 76% and 32%, respectively. CONCLUSION The correlation accuracy of the robotic system meets the clinical requirements. The robot arm can fix and monitor the cervical motion in real time during radiotherapy. The robot system adjusts the position of the fixator to correct the uterocervical intrafraction motion error, which is feasible and has good clinical application prospect.
Collapse
|
190
|
Shi Y, Abidan A, Li D, Zibigu R, Wang M, Zheng X, Kang X, Wang H, Li J, Zhang C. [Effect of Echinococcus multilocularis infection on Tim3 expression in spleen natural killer cells of mice]. ZHONGGUO XUE XI CHONG BING FANG ZHI ZA ZHI = CHINESE JOURNAL OF SCHISTOSOMIASIS CONTROL 2023; 35:366-373. [PMID: 37926471 DOI: 10.16250/j.32.1374.2023064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/07/2023]
Abstract
OBJECTIVE To investigate the effect of Echinococcus multilocularis infection on Tim3 expression and its co-expression with immune checkpoint molecules 2B4 and LAG3 in spleen natural killer (NK) cells of mice. METHODS C57BL/6 mice, each weighing (20 ± 2) g, were randomly divided into a high-dose infection group (15 mice), a low-dose infection group (13 mice), and a control group (11 mice). Mice in the high- and low-dose infection groups were inoculated with 2 000 and 50 Echinococcus multilocularis protoscolices via the hepatic portal vein, while animals in the control group was injected with an equivalent amount of physiological saline via the hepatic portal vein. Mouse spleen cells were harvested 12 and 24 weeks post-infection, and Tim3 expression and its co-expression with 2B4 and LAG3 in NK cells were detected using flow cytometry. RESULTS There were significant differences in the proportions of Tim3 expression (F = 13.559, P < 0.001) and Tim3 and 2B4 co-expression (F = 12.465, P < 0.001) in mouse spleen NK cells among groups 12 weeks post-infection with E. multilocularis, and the proportion of Tim3 expression was significantly higher in mouse spleen NK cells in the low-dose infection group [(23.84 ± 2.28)%] than in the high-dose infection group [(15.72 ± 3.67)%] and the control group [(16.14 ± 3.83)%] (both P values < 0.01), while the proportion of Tim3 and 2B4 co-expression was significantly higher in mouse spleen NK cells in the low-dose infection group [(22.20 ± 2.13)%] than in the high-dose infection group [(14.17 ± 3.81)%] and the control group [(15.20 ± 3.77)%] (both P values < 0.01). There were significant differences in the proportions of Tim3 expression (F = 5.243, P < 0.05) and Tim3 and 2B4 co-expression (F = 4.659, P < 0.05) in mouse spleen NK cells among groups 24 weeks post-infection with E. multilocularis infection, and the proportions of Tim3 expression and Tim3 and 2B4 co-expression were significantly lower in mouse spleen NK cells in the high-dose infection group [(20.55 ± 7.04)% and (20.98 ± 7.12)%] than in the control group [(31.38 ± 3.19)% and (31.25 ± 3.06)%] (both P values < 0.05), and there were no significantly difference between the proportions of Tim3 expression and Tim3 and 2B4 co-expression in splenic NK cells in the low-dose infection group [(26.80 ± 6.47)% and (26.48 ± 6.48)%] and the control group (both P > 0.05). There were no significant differences in the proportions of Tim3 and LAG3 co-expression in mouse spleen NK cells among groups 12 (F = 2.283, P > 0.05) and 24 weeks post-infection (F = 0.375, P > 0.05). In the low-dose infection group, there were no significant differences in the proportions of Tim3 expression or Tim3 and 2B4 co-expression in mouse spleen NK cells 12 (t = -1.137, P > 0.05) or 24 weeks post-infection (t = -1.658, P > 0.05), and the proportion of Tim3 and LAG3 co-expression increased in mouse spleen NK cells 24 weeks post-infection relative to 12 weeks post-infection (t = -5.261, P < 0.01). In the highdose infection group, there was no significant difference in the proportion of Tim3 expression in mouse spleen NK cells 12 and 24 weeks post-infection (t = -1.546, P > 0.05); however, the proportions of Tim3 co-expression with 2B4 and LAG3 increased in mouse splenic NK cells 24 weeks post-infection relative to 12 weeks post-infection (t = -2.425 and -4.745, both P values < 0.05). CONCLUSIONS The Tim3 expression and Tim3 co-expression with LAG3 and 2B4 on spleen NK cells is affected by doses of E. multilocularis infection and disease stages, and present different phenotypes during the course of alveolar echinococcosis. NK cells tend to form an immunosuppressive phenotype with the progression of E. multilocularis infection, which facilitates immune escape and chronic parasitism of E. multilocularis.
Collapse
|
191
|
Li J, Sun JH, Li XJ, Liu Y, Yu MY, Li DM, Ma YX, Luo HY, Yang YJ. [Impact of COVID-19 on primary percutaneous coronary intervention in patients with acute ST segment elevation myocardial infarction in Beijing]. ZHONGHUA XIN XUE GUAN BING ZA ZHI 2023; 51:977-983. [PMID: 37709715 DOI: 10.3760/cma.j.cn112148-20230104-00007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/16/2023]
Abstract
Objective: To investigate the impact of COVID-19 on treatment of patients with acute ST segment elevation myocardial infarction(STEMI) undergoing primary percutaneous coronary intervention(PPCI). Methods: This was a multicenter retrospective study. STEMI patients undergoing PPCI from January 1, 2019 to December 31, 2021 were selected, based on the data of Xinnaolvsetongdao App. Clinical data and treatment time indicators, including symptom to first medical contact (S-FMC), symptom to door (StoD), first medical contact to ECG (FMC-ECG), first medical contact to guide wire (FMC-W), door to balloon (DtoB) and total ischemic time in 2019, 2020 and 2021 were compared. STEMI patients aged<60 years were sub-grouped as the young and middle-aged group, and STEMI patients aged≥60 years were sub-grouped as the elderly group. Results: A total of 7 435 (3 305 in 2019, 1 796 in 2020 and 2 334 in 2021) STEMI patients aged (59.6±12.6) years undergoing PPCI were included in this analysis. There were 5 990 males. For STEMI patients with PPCI in 2019, 2020 and 2021, FMC-ECG was 3 (1, 5) min, 3(1, 7) min and 4 (1, 7) min. FMC-W was 73 (56, 87) min, 78 (62, 95) min and 77 (62, 87) min. DtoB was 73 (56, 85) min, 78 (62, 95) min and 77 (62, 86) min. Total ischemic time was 189 (130, 273) min, 196 (138, 295) min and 209 (143, 276) min. FMC-ECG, FMC-W, DtoB and total ischemic time were longer in 2020 and 2021 than in 2019 (all P<0.05). The proportions of patients with FMC-ECG≤10 min (88.4% (1 588/1 796) vs. 92.7% (3 064/3 305), P<0.05), FMC-W≤120 min (87.9% (1 579/1796) vs. 91.7% (3 030/3 305), P<0.05) and DtoB≤90 min (72.3% (1 298/1 796) vs. 80.8% (2 672/3 305), P<0.05) were lower in 2020 than in 2019, whereas no differences were observed in the proportions of patients with FMC-ECG≤10 min (91.3% (2 131/2 334) vs. 92.7% (3 064/3 305), P=0.054), FMC-W≤120 min (92.0% (2 148/2 334) vs. 91.7% (3 030/3 305), P=0.635) and DtoB≤90 min (80.0% (1 867/2 334) vs. 80.8% (2 672/3 305), P=0.424) in 2021 compared with 2019. In the subgroup analysis, the proportions of patients with FMC-ECG≤10 min, FMC-W≤120 min and DtoB≤90 min were lower in the elderly group than in young and middle-aged group in 2019 (all P<0.05). The proportions of patients with FMC-W≤120 min and DtoB≤90 min were lower in the elderly group than in young and middle-aged group in 2021(all P<0.05). No differences were observed in the proportions of patients with FMC-ECG≤10 min, FMC-W≤120 min and DtoB≤90 min between the two group in 2020 (all P>0.05). Conclusions: Affected by the COVID-19, there is a reduction in the number of PPCI cases and treatment delays in STEMI patients, especially in the elderly. After adjusting the treatment strategy and widely applying the Xinnaolvsetongdao APP, the above indicators are significantly improved in 2021 as compared with 2020.
Collapse
|
192
|
Tumasyan A, Adam W, Andrejkovic JW, Bergauer T, Chatterjee S, Damanakis K, Dragicevic M, Escalante Del Valle A, Hussain PS, Jeitler M, Krammer N, Lechner L, Liko D, Mikulec I, Paulitsch P, Schieck J, Schöfbeck R, Schwarz D, Sonawane M, Templ S, Waltenberger W, Wulz CE, Darwish MR, Janssen T, Kello T, Rejeb Sfar H, Van Mechelen P, Bols ES, D'Hondt J, De Moor A, Delcourt M, El Faham H, Lowette S, Morton A, Müller D, Sahasransu AR, Tavernier S, Van Doninck W, Van Putte S, Vannerom D, Clerbaux B, De Lentdecker G, Favart L, Hohov D, Jaramillo J, Lee K, Mahdavikhorrami M, Makarenko I, Malara A, Paredes S, Pétré L, Postiau N, Thomas L, Vanden Bemden M, Vander Velde C, Vanlaer P, Dobur D, Knolle J, Lambrecht L, Mestdach G, Rendón C, Samalan A, Skovpen K, Tytgat M, Van Den Bossche N, Vermassen B, Wezenbeek L, Benecke A, Bruno G, Bury F, Caputo C, David P, Delaere C, Donertas IS, Giammanco A, Jaffel K, Jain S, Lemaitre V, Mondal K, Taliercio A, Tran TT, Vischia P, Wertz S, Alves GA, Coelho E, Hensel C, Moraes A, Rebello Teles P, Aldá Júnior WL, Alves Gallo Pereira M, Barroso Ferreira Filho M, Brandao Malbouisson H, Carvalho W, Chinellato J, Da Costa EM, Da Silveira GG, De Jesus Damiao D, Dos Santos Sousa V, Fonseca De Souza S, Martins J, Mora Herrera C, Mota Amarilo K, Mundim L, Nogima H, Santoro A, Silva Do Amaral SM, Sznajder A, Thiel M, Vilela Pereira A, Bernardes CA, Calligaris L, Tomei TRFP, Gregores EM, Mercadante PG, Novaes SF, Padula SS, Aleksandrov A, Antchev G, Hadjiiska R, Iaydjiev P, Misheva M, Rodozov M, Shopova M, Sultanov G, Dimitrov A, Ivanov T, Litov L, Pavlov B, Petkov P, Petrov A, Shumka E, Thakur S, Cheng T, Javaid T, Mittal M, Yuan L, Ahmad M, Bauer G, Hu Z, Lezki S, Yi K, Chen GM, Chen HS, Chen M, Iemmi F, Jiang CH, Kapoor A, Liao H, Liu ZA, Milosevic V, Monti F, Sharma R, Tao J, Thomas-Wilsker J, Wang J, Zhang H, Zhao J, Agapitos A, An Y, Ban Y, Levin A, Li C, Li Q, Lyu X, Mao Y, Qian SJ, Sun X, Wang D, Xiao J, Yang H, Lu M, You Z, Lu N, Gao X, Leggat D, Okawa H, Zhang Y, Lin Z, Lu C, Xiao M, Avila C, Barbosa Trujillo DA, Cabrera A, Florez C, Fraga J, Mejia Guisao J, Ramirez F, Rodriguez M, Ruiz Alvarez JD, Giljanovic D, Godinovic N, Lelas D, Puljak I, Antunovic Z, Kovac M, Sculac T, Brigljevic V, Chitroda BK, Ferencek D, Mishra S, Roguljic M, Starodumov A, Susa T, Attikis A, Christoforou K, Konstantinou S, Mousa J, Nicolaou C, Ptochos F, Razis PA, Rykaczewski H, Saka H, Stepennov A, Finger M, Finger M, Kveton A, Ayala E, Carrera Jarrin E, Abdelalim AA, Salama E, Abdullah Al-Mashad M, Mahmoud MA, Bhowmik S, Dewanjee RK, Ehataht K, Kadastik M, Lange T, Nandan S, Nielsen C, Pata J, Raidal M, Tani L, Veelken C, Eerola P, Kirschenmann H, Osterberg K, Voutilainen M, Bharthuar S, Brücken E, Garcia F, Havukainen J, Kim MS, Kinnunen R, Lampén T, Lassila-Perini K, Lehti S, Lindén T, Lotti M, Martikainen L, Myllymäki M, Rantanen MM, Siikonen H, Tuominen E, Tuominiemi J, Luukka P, Petrow H, Tuuva T, Amendola C, Besancon M, Couderc F, Dejardin M, Denegri D, Faure JL, Ferri F, Ganjour S, Gras P, Hamel de Monchenault G, Lohezic V, Malcles J, Rander J, Rosowsky A, Sahin MÖ, Savoy-Navarro A, Simkina P, Titov M, Baldenegro Barrera C, Beaudette F, Buchot Perraguin A, Busson P, Cappati A, Charlot C, Damas F, Davignon O, Diab B, Falmagne G, Fontana Santos Alves BA, Ghosh S, Granier de Cassagnac R, Hakimi A, Harikrishnan B, Liu G, Motta J, Nguyen M, Ochando C, Portales L, Salerno R, Sarkar U, Sauvan JB, Sirois Y, Tarabini A, Vernazza E, Zabi A, Zghiche A, Agram JL, Andrea J, Apparu D, Bloch D, Bourgatte G, Brom JM, Chabert EC, Collard C, Darej D, Goerlach U, Grimault C, Le Bihan AC, Van Hove P, Beauceron S, Blancon B, Boudoul G, Carle A, Chanon N, Choi J, Contardo D, Depasse P, Dozen C, El Mamouni H, Fay J, Gascon S, Gouzevitch M, Grenier G, Ille B, Laktineh IB, Lethuillier M, Mirabito L, Perries S, Torterotot L, Vander Donckt M, Verdier P, Viret S, Lomidze I, Toriashvili T, Tsamalaidze Z, Botta V, Feld L, Klein K, Lipinski M, Meuser D, Pauls A, Röwert N, Teroerde M, Diekmann S, Dodonova A, Eich N, Eliseev D, Erdmann M, Fackeldey P, Fasanella D, Fischer B, Hebbeker T, Hoepfner K, Ivone F, Lee MY, Mastrolorenzo L, Merschmeyer M, Meyer A, Mondal S, Mukherjee S, Noll D, Novak A, Nowotny F, Pozdnyakov A, Rath Y, Redjeb W, Rehm F, Reithler H, Schmidt A, Schuler SC, Sharma A, Stein A, Torres Da Silva De Araujo F, Vigilante L, Wiedenbeck S, Zaleski S, Dziwok C, Flügge G, Haj Ahmad W, Hlushchenko O, Kress T, Nowack A, Pooth O, Stahl A, Ziemons T, Zotz A, Aarup Petersen H, Aldaya Martin M, Alimena J, Asmuss P, Baxter S, Bayatmakou M, Becerril Gonzalez H, Behnke O, Bhattacharya S, Blekman F, Borras K, Brunner D, Campbell A, Cardini A, Cheng C, Colombina F, Consuegra Rodríguez S, Correia Silva G, De Silva M, Eckerlin G, Eckstein D, Estevez Banos LI, Filatov O, Gallo E, Geiser A, Giraldi A, Greau G, Grohsjean A, Guglielmi V, Guthoff M, Jafari A, Jomhari NZ, Kaech B, Kasemann M, Kaveh H, Kleinwort C, Kogler R, Komm M, Krücker D, Lange W, Leyva Pernia D, Lipka K, Lohmann W, Mankel R, Melzer-Pellmann IA, Mendizabal Morentin M, Metwally J, Meyer AB, Milella G, Mormile M, Mussgiller A, Nürnberg A, Otarid Y, Pérez Adán D, Ranken E, Raspereza A, Ribeiro Lopes B, Rübenach J, Saggio A, Savitskyi M, Scham M, Scheurer V, Schnake S, Schütze P, Schwanenberger C, Shchedrolosiev M, Sosa Ricardo RE, Stafford D, Tonon N, Van De Klundert M, Vazzoler F, Ventura Barroso A, Walsh R, Walter D, Wang Q, Wen Y, Wichmann K, Wiens L, Wissing C, Wuchterl S, Yang Y, Zimermmane Castro Santos A, Albrecht A, Albrecht S, Antonello M, Bein S, Benato L, Bonanomi M, Connor P, De Leo K, Eich M, El Morabit K, Feindt F, Fröhlich A, Garbers C, Garutti E, Hajheidari M, Haller J, Hinzmann A, Jabusch HR, Kasieczka G, Keicher P, Klanner R, Korcari W, Kramer T, Kutzner V, Labe F, Lange J, Lobanov A, Matthies C, Mehta A, Moureaux L, Mrowietz M, Nigamova A, Nissan Y, Paasch A, Pena Rodriguez KJ, Quadfasel T, Rieger M, Rieger O, Savoiu D, Schindler J, Schleper P, Schröder M, Schwandt J, Sommerhalder M, Stadie H, Steinbrück G, Tews A, Wolf M, Brommer S, Burkart M, Butz E, Chwalek T, Dierlamm A, Droll A, Faltermann N, Giffels M, Gosewisch JO, Gottmann A, Hartmann F, Horzela M, Husemann U, Klute M, Koppenhöfer R, Link M, Lintuluoto A, Maier S, Mitra S, Müller T, Neukum M, Oh M, Quast G, Rabbertz K, Rauser J, Shvetsov I, Simonis HJ, Trevisani N, Ulrich R, van der Linden J, Von Cube RF, Wassmer M, Wieland S, Wolf R, Wozniewski S, Wunsch S, Zuo X, Anagnostou G, Assiouras P, Daskalakis G, Kyriakis A, Stakia A, Diamantopoulou M, Karasavvas D, Kontaxakis P, Manousakis-Katsikakis A, Panagiotou A, Papavergou I, Saoulidou N, Theofilatos K, Tziaferi E, Vellidis K, Zisopoulos I, Bakas G, Chatzistavrou T, Karapostoli G, Kousouris K, Papakrivopoulos I, Tsipolitis G, Zacharopoulou A, Adamidis K, Bestintzanos I, Evangelou I, Foudas C, Gianneios P, Kamtsikis C, Katsoulis P, Kokkas P, Kosmoglou Kioseoglou PG, Manthos N, Papadopoulos I, Strologas J, Csanád M, Farkas K, Gadallah MMA, Lökös S, Major P, Mandal K, Pásztor G, Rádl AJ, Surányi O, Veres GI, Bartók M, Bencze G, Hajdu C, Horvath D, Sikler F, Veszpremi V, Beni N, Czellar S, Karancsi J, Molnar J, Szillasi Z, Teyssier D, Raics P, Ujvari B, Zilizi G, Csorgo T, Nemes F, Novak T, Babbar J, Bansal S, Beri SB, Bhatnagar V, Chaudhary G, Chauhan S, Dhingra N, Gupta R, Kaur A, Kaur A, Kaur H, Kaur M, Kumar S, Kumari P, Meena M, Sandeep K, Sheokand T, Singh JB, Singla A, Ahmed A, Bhardwaj A, Chhetri A, Choudhary BC, Kumar A, Naimuddin M, Ranjan K, Saumya S, Baradia S, Barman S, Bhattacharya S, Bhowmik D, Dutta S, Dutta S, Gomber B, Maity M, Palit P, Saha G, Sahu B, Sarkar S, Behera PK, Behera SC, Chatterjee S, Kalbhor P, Komaragiri JR, Kumar D, Muhammad A, Panwar L, Pradhan R, Pujahari PR, Saha NR, Sharma A, Sikdar AK, Verma S, Naskar K, Aziz T, Das I, Dugad S, Kumar M, Mohanty GB, Suryadevara P, Banerjee S, Guchait M, Karmakar S, Kumar S, Majumder G, Mazumdar K, Mukherjee S, Thachayath A, Bahinipati S, Das AK, Kar C, Mal P, Mishra T, Muraleedharan Nair Bindhu VK, Nayak A, Saha P, Swain SK, Vats D, Alpana A, Dube S, Kansal B, Laha A, Pandey S, Rastogi A, Sharma S, Bakhshiansohi H, Khazaie E, Zeinali M, Chenarani S, Etesami SM, Khakzad M, Mohammadi Najafabadi M, Grunewald M, Abbrescia M, Aly R, Aruta C, Colaleo A, Creanza D, Cristella L, De Filippis N, De Palma M, Di Florio A, Elmetenawee W, Errico F, Fiore L, Iaselli G, Maggi G, Maggi M, Margjeka I, Mastrapasqua V, My S, Nuzzo S, Pellecchia A, Pompili A, Pugliese G, Radogna R, Ramos D, Ranieri A, Selvaggi G, Silvestris L, Simone FM, Sözbilir Ü, Stamerra A, Venditti R, Verwilligen P, Abbiendi G, Battilana C, Bonacorsi D, Borgonovi L, Brigliadori L, Campanini R, Capiluppi P, Castro A, Cavallo FR, Cuffiani M, Dallavalle GM, Diotalevi T, Fabbri F, Fanfani A, Giacomelli P, Giommi L, Grandi C, Guiducci L, Lo Meo S, Lunerti L, Marcellini S, Masetti G, Navarria FL, Perrotta A, Primavera F, Rossi AM, Rovelli T, Siroli GP, Costa S, Di Mattia A, Potenza R, Tricomi A, Tuve C, Barbagli G, Bardelli G, Camaiani B, Cassese A, Ceccarelli R, Ciulli V, Civinini C, D'Alessandro R, Focardi E, Latino G, Lenzi P, Lizzo M, Meschini M, Paoletti S, Sguazzoni G, Viliani L, Benussi L, Bianco S, Meola S, Piccolo D, Bozzo M, Chatagnon P, Ferro F, Robutti E, Tosi S, Benaglia A, Boldrini G, Brivio F, Cetorelli F, De Guio F, Dinardo ME, Dini P, Gennai S, Ghezzi A, Govoni P, Guzzi L, Lucchini MT, Malberti M, Malvezzi S, Massironi A, Menasce D, Moroni L, Paganoni M, Pedrini D, Pinolini BS, Ragazzi S, Redaelli N, Tabarelli de Fatis T, Zuolo D, Buontempo S, Carnevali F, Cavallo N, De Iorio A, Fabozzi F, Iorio AOM, Lista L, Paolucci P, Rossi B, Sciacca C, Azzi P, Bacchetta N, Bisello D, Bortignon P, Bragagnolo A, Carlin R, Checchia P, Dorigo T, Gasparini F, Gasparini U, Grosso G, Gulmini M, Layer L, Lusiani E, Margoni M, Meneguzzo AT, Pazzini J, Ronchese P, Rossin R, Simonetto F, Strong G, Tosi M, Yarar H, Zanetti M, Zotto P, Zucchetta A, Abu Zeid S, Aimè C, Braghieri A, Calzaferri S, Fiorina D, Montagna P, Re V, Riccardi C, Salvini P, Vai I, Vitulo P, Asenov P, Bilei GM, Ciangottini D, Fanò L, Magherini M, Mantovani G, Mariani V, Menichelli M, Moscatelli F, Piccinelli A, Presilla M, Rossi A, Santocchia A, Spiga D, Tedeschi T, Azzurri P, Bagliesi G, Bertacchi V, Bhattacharya R, Bianchini L, Boccali T, Bossini E, Bruschini D, Castaldi R, Ciocci MA, D'Amante V, Dell'Orso R, Donato S, Giassi A, Ligabue F, Matos Figueiredo D, Messineo A, Musich M, Palla F, Parolia S, Ramirez-Sanchez G, Rizzi A, Rolandi G, Roy Chowdhury S, Sarkar T, Scribano A, Spagnolo P, Tenchini R, Tonelli G, Turini N, Venturi A, Verdini PG, Barria P, Campana M, Cavallari F, Del Re D, Di Marco E, Diemoz M, Longo E, Meridiani P, Organtini G, Pandolfi F, Paramatti R, Quaranta C, Rahatlou S, Rovelli C, Santanastasio F, Soffi L, Tramontano R, Amapane N, Arcidiacono R, Argiro S, Arneodo M, Bartosik N, Bellan R, Bellora A, Biino C, Cartiglia N, Costa M, Covarelli R, Demaria N, Grippo M, Kiani B, Legger F, Mariotti C, Maselli S, Mecca A, Migliore E, Monteno M, Mulargia R, Obertino MM, Ortona G, Pacher L, Pastrone N, Pelliccioni M, Ruspa M, Shchelina K, Siviero F, Sola V, Solano A, Soldi D, Staiano A, Tornago M, Trocino D, Umoret G, Vagnerini A, Vlasov E, Belforte S, Candelise V, Casarsa M, Cossutti F, Della Ricca G, Sorrentino G, Dogra S, Huh C, Kim B, Kim DH, Kim GN, Kim J, Lee J, Lee SW, Moon CS, Oh YD, Pak SI, Ryu MS, Sekmen S, Yang YC, Kim H, Moon DH, Asilar E, Kim TJ, Park J, Choi S, Han S, Hong B, Lee K, Lee KS, Lim J, Park J, Park SK, Yoo J, Goh J, Kim HS, Kim Y, Lee S, Almond J, Bhyun JH, Choi J, Jeon S, Kim J, Kim JS, Ko S, Kwon H, Lee H, Lee S, Oh BH, Oh SB, Seo H, Yang UK, Yoon I, Jang W, Kang DY, Kang Y, Kim D, Kim S, Ko B, Lee JSH, Lee Y, Merlin JA, Park IC, Roh Y, Song D, Watson IJ, Yang S, Ha S, Yoo HD, Choi M, Kim MR, Lee H, Lee Y, Yu I, Beyrouthy T, Maghrbi Y, Dreimanis K, Pikurs G, Potrebko A, Seidel M, Veckalns V, Ambrozas M, Carvalho Antunes De Oliveira A, Juodagalvis A, Rinkevicius A, Tamulaitis G, Bin Norjoharuddeen N, Hoh SY, Yusuff I, Zolkapli Z, Benitez JF, Castaneda Hernandez A, Encinas Acosta HA, Gallegos Maríñez LG, León Coello M, Murillo Quijada JA, Sehrawat A, Valencia Palomo L, Ayala G, Castilla-Valdez H, Heredia-De La Cruz I, Lopez-Fernandez R, Mondragon Herrera CA, Perez Navarro DA, Sánchez Hernández A, Oropeza Barrera C, Vazquez Valencia F, Pedraza I, Salazar Ibarguen HA, Uribe Estrada C, Bubanja I, Mijuskovic J, Raicevic N, Ahmad A, Asghar MI, Awais A, Awan MIM, Gul M, Hoorani HR, Khan WA, Avati V, Grzanka L, Malawski M, Bialkowska H, Bluj M, Boimska B, Górski M, Kazana M, Szleper M, Zalewski P, Bunkowski K, Doroba K, Kalinowski A, Konecki M, Krolikowski J, Araujo M, Bargassa P, Bastos D, Boletti A, Faccioli P, Gallinaro M, Hollar J, Leonardo N, Niknejad T, Pisano M, Seixas J, Varela J, Adzic P, Dordevic M, Milenovic P, Milosevic J, Aguilar-Benitez M, Alcaraz Maestre J, Barrio Luna M, Bedoya CF, Cepeda M, Cerrada M, Colino N, De La Cruz B, Delgado Peris A, Fernández Del Val D, Fernández Ramos JP, Flix J, Fouz MC, Gonzalez Lopez O, Goy Lopez S, Hernandez JM, Josa MI, León Holgado J, Moran D, Perez Dengra C, Pérez-Calero Yzquierdo A, Puerta Pelayo J, Redondo I, Redondo Ferrero DD, Romero L, Sánchez Navas S, Sastre J, Urda Gómez L, Vazquez Escobar J, Willmott C, de Trocóniz JF, Alvarez Gonzalez B, Cuevas J, Fernandez Menendez J, Folgueras S, Gonzalez Caballero I, González Fernández JR, Palencia Cortezon E, Ramón Álvarez C, Rodríguez Bouza V, Soto Rodríguez A, Trapote A, Vico Villalba C, Brochero Cifuentes JA, Cabrillo IJ, Calderon A, Duarte Campderros J, Fernandez M, Fernandez Madrazo C, García Alonso A, Gomez G, Lasaosa García C, Martinez Rivero C, Martinez Ruiz Del Arbol P, Matorras F, Matorras Cuevas P, Piedra Gomez J, Prieels C, Scodellaro L, Vila I, Vizan Garcia JM, Jayananda MK, Kailasapathy B, Sonnadara DUJ, Wickramarathna DDC, Dharmaratna WGD, Liyanage K, Perera N, Wickramage N, Abbaneo D, Auffray E, Auzinger G, Baechler J, Baillon P, Barney D, Bendavid J, Bermúdez Martínez A, Bianco M, Bilin B, Bin Anuar AA, Bocci A, Brondolin E, Caillol C, Camporesi T, Cerminara G, Chernyavskaya N, Chhibra SS, Choudhury S, Cipriani M, d'Enterria D, Dabrowski A, David A, De Roeck A, Defranchis MM, Deile M, Dobson M, Dünser M, Dupont N, Fallavollita F, Florent A, Forthomme L, Franzoni G, Funk W, Ghosh S, Giani S, Gigi D, Gill K, Glege F, Gouskos L, Govorkova E, Haranko M, Hegeman J, Innocente V, James T, Janot P, Kaspar J, Kieseler J, Kratochwil N, Laurila S, Lecoq P, Leutgeb E, Lourenço C, Maier B, Malgeri L, Mannelli M, Marini AC, Meijers F, Mersi S, Meschi E, Moortgat F, Mulders M, Orfanelli S, Orsini L, Pantaleo F, Perez E, Peruzzi M, Petrilli A, Petrucciani G, Pfeiffer A, Pierini M, Piparo D, Pitt M, Qu H, Quast T, Rabady D, Racz A, Reales Gutiérrez G, Rovere M, Sakulin H, Salfeld-Nebgen J, Scarfi S, Selvaggi M, Sharma A, Silva P, Sphicas P, Stahl Leiton AG, Summers S, Tatar K, Treille D, Tropea P, Tsirou A, Wanczyk J, Wozniak KA, Zeuner WD, Caminada L, Ebrahimi A, Erdmann W, Horisberger R, Ingram Q, Kaestli HC, Kotlinski D, Lange C, Missiroli M, Noehte L, Rohe T, Aarrestad TK, Androsov K, Backhaus M, Calandri A, Datta K, De Cosa A, Dissertori G, Dittmar M, Donegà M, Eble F, Galli M, Gedia K, Glessgen F, Gómez Espinosa TA, Grab C, Hits D, Lustermann W, Lyon AM, Manzoni RA, Marchese L, Martin Perez C, Mascellani A, Nessi-Tedaldi F, Niedziela J, Pauss F, Perovic V, Pigazzini S, Ratti MG, Reichmann M, Reissel C, Reitenspiess T, Ristic B, Riti F, Ruini D, Sanz Becerra DA, Seidita R, Steggemann J, Valsecchi D, Wallny R, Amsler C, Bärtschi P, Botta C, Brzhechko D, Canelli MF, Cormier K, De Wit A, Del Burgo R, Heikkilä JK, Huwiler M, Jin W, Jofrehei A, Kilminster B, Leontsinis S, Liechti SP, Macchiolo A, Meiring P, Mikuni VM, Molinatti U, Neutelings I, Reimers A, Robmann P, Sanchez Cruz S, Schweiger K, Senger M, Takahashi Y, Adloff C, Kuo CM, Lin W, Rout PK, Tiwari PC, Yu SS, Ceard L, Chao Y, Chen KF, Chen PS, Cheng H, Hou WS, Khurana R, Kole G, Li YY, Lu RS, Paganis E, Psallidas A, Steen A, Wu HY, Yazgan E, Asawatangtrakuldee C, Srimanobhas N, Wachirapusitanand V, Agyel D, Boran F, Demiroglu ZS, Dolek F, Dumanoglu I, Eskut E, Guler Y, Gurpinar Guler E, Isik C, Kara O, Kayis Topaksu A, Kiminsu U, Onengut G, Ozdemir K, Polatoz A, Simsek AE, Tali B, Tok UG, Turkcapar S, Uslan E, Zorbakir IS, Karapinar G, Ocalan K, Yalvac M, Akgun B, Atakisi IO, Gülmez E, Kaya M, Kaya O, Tekten S, Cakir A, Cankocak K, Komurcu Y, Sen S, Aydilek O, Cerci S, Hacisahinoglu B, Hos I, Isildak B, Kaynak B, Ozkorucuklu S, Simsek C, Sunar Cerci D, Grynyov B, Levchuk L, Anthony D, Brooke JJ, Bundock A, Clement E, Cussans D, Flacher H, Glowacki M, Goldstein J, Heath HF, Kreczko L, Krikler B, Paramesvaran S, Seif El Nasr-Storey S, Smith VJ, Stylianou N, Walkingshaw Pass K, White R, Ball AH, Bell KW, Belyaev A, Brew C, Brown RM, Cockerill DJA, Cooke C, Ellis KV, Harder K, Harper S, Holmberg ML, Jain S, Linacre J, Manolopoulos K, Newbold DM, Olaiya E, Petyt D, Reis T, Salvi G, Schuh T, Shepherd-Themistocleous CH, Tomalin IR, Williams T, Bainbridge R, Bloch P, Bonomally S, Borg J, Brown CE, Buchmuller O, Cacchio V, Carrillo Montoya CA, Cepaitis V, Chahal GS, Colling D, Dancu JS, Dauncey P, Davies G, Davies J, Della Negra M, Fayer S, Fedi G, Hall G, Hassanshahi MH, Howard A, Iles G, Langford J, Lyons L, Magnan AM, Malik S, Martelli A, Mieskolainen M, Monk DG, Nash J, Pesaresi M, Radburn-Smith BC, Raymond DM, Richards A, Rose A, Scott E, Seez C, Shukla R, Tapper A, Uchida K, Uttley GP, Vage LH, Virdee T, Vojinovic M, Wardle N, Webb SN, Winterbottom D, Coldham K, Cole JE, Khan A, Kyberd P, Reid ID, Abdullin S, Brinkerhoff A, Caraway B, Dittmann J, Hatakeyama K, Kanuganti AR, McMaster B, Saunders M, Sawant S, Sutantawibul C, Toms M, Wilson J, Bartek R, Dominguez A, Huerta Escamilla C, Uniyal R, Vargas Hernandez AM, Chudasama R, Cooper SI, Di Croce D, Gleyzer SV, Henderson C, Perez CU, Rumerio P, Usai E, West C, Akpinar A, Albert A, Arcaro D, Cosby C, Demiragli Z, Erice C, Fontanesi E, Gastler D, May S, Rohlf J, Salyer K, Sperka D, Spitzbart D, Suarez I, Tsatsos A, Yuan S, Benelli G, Coubez X, Cutts D, Hadley M, Heintz U, Hogan JM, Kwon T, Landsberg G, Lau KT, Li D, Luo J, Narain M, Pervan N, Sagir S, Simpson F, Wong WY, Yan X, Yu D, Zhang W, Abbott S, Bonilla J, Brainerd C, Breedon R, Calderon De La Barca Sanchez M, Chertok M, Conway J, Cox PT, Erbacher R, Haza G, Jensen F, Kukral O, Mocellin G, Mulhearn M, Pellett D, Regnery B, Yao Y, Zhang F, Bachtis M, Cousins R, Datta A, Hauser J, Ignatenko M, Iqbal MA, Lam T, Manca E, Nash WA, Saltzberg D, Stone B, Valuev V, Clare R, Gary JW, Gordon M, Hanson G, Long OR, Manganelli N, Si W, Wimpenny S, Branson JG, Cittolin S, Cooperstein S, Diaz D, Duarte J, Gerosa R, Giannini L, Guiang J, Kansal R, Krutelyov V, Lee R, Letts J, Masciovecchio M, Mokhtar F, Pieri M, Quinnan M, Sathia Narayanan BV, Sharma V, Tadel M, Vourliotis E, Würthwein F, Xiang Y, Yagil A, Amin N, Campagnari C, Citron M, Collura G, Dorsett A, Incandela J, Kilpatrick M, Kim J, Li AJ, Masterson P, Mei H, Oshiro M, Richman J, Sarica U, Schmitz R, Setti F, Sheplock J, Siddireddy P, Stuart D, Wang S, Bornheim A, Cerri O, Dutta I, Latorre A, Lawhorn JM, Mao J, Newman HB, Nguyen TQ, Spiropulu M, Vlimant JR, Wang C, Xie S, Zhu RY, Alison J, An S, Andrews MB, Bryant P, Dutta V, Ferguson T, Harilal A, Liu C, Mudholkar T, Murthy S, Paulini M, Roberts A, Sanchez A, Terrill W, Cumalat JP, Ford WT, Hassani A, Karathanasis G, MacDonald E, Marini F, Perloff A, Savard C, Schonbeck N, Stenson K, Ulmer KA, Wagner SR, Zipper N, Alexander J, Bright-Thonney S, Chen X, Cranshaw DJ, Fan J, Fan X, Gadkari D, Hogan S, Monroy J, Patterson JR, Reichert J, Reid M, Ryd A, Thom J, Wittich P, Zou R, Albrow M, Alyari M, Apollinari G, Apresyan A, Bauerdick LAT, Berry D, Berryhill J, Bhat PC, Burkett K, Butler JN, Canepa A, Cerati GB, Cheung HWK, Chlebana F, Di Petrillo KF, Dickinson J, Elvira VD, Feng Y, Freeman J, Gandrakota A, Gecse Z, Gray L, Green D, Grünendahl S, Guerrero D, Gutsche O, Harris RM, Heller R, Herwig TC, Hirschauer J, Horyn L, Jayatilaka B, Jindariani S, Johnson M, Joshi U, Klijnsma T, Klima B, Kwok KHM, Lammel S, Lincoln D, Lipton R, Liu T, Madrid C, Maeshima K, Mantilla C, Mason D, McBride P, Merkel P, Mrenna S, Nahn S, Ngadiuba J, Noonan D, Norberg S, Papadimitriou V, Pastika N, Pedro K, Pena C, Ravera F, Reinsvold Hall A, Ristori L, Sexton-Kennedy E, Smith N, Soha A, Spiegel L, Stoynev S, Strait J, Taylor L, Tkaczyk S, Tran NV, Uplegger L, Vaandering EW, Zoi I, Avery P, Bourilkov D, Cadamuro L, Chang P, Cherepanov V, Field RD, Koenig E, Kolosova M, Konigsberg J, Korytov A, Kuznetsova E, Lo KH, Matchev K, Menendez N, Mitselmakher G, Muthirakalayil Madhu A, Rawal N, Rosenzweig D, Rosenzweig S, Shi K, Wang J, Wu Z, Adams T, Askew A, Bower N, Habibullah R, Hagopian V, Kolberg T, Martinez G, Prosper H, Viazlo O, Wulansatiti M, Yohay R, Zhang J, Baarmand MM, Butalla S, Elkafrawy T, Hohlmann M, Kumar Verma R, Rahmani M, Yumiceva F, Adams MR, Cavanaugh R, Dittmer S, Evdokimov O, Gerber CE, Hofman DJ, Lemos DS, Merrit AH, Mills C, Oh G, Roy T, Rudrabhatla S, Tonjes MB, Varelas N, Wang X, Ye Z, Yoo J, Alhusseini M, Dilsiz K, Emediato L, Karaman G, Köseyan OK, Merlo JP, Mestvirishvili A, Nachtman J, Neogi O, Ogul H, Onel Y, Penzo A, Snyder C, Tiras E, Amram O, Blumenfeld B, Corcodilos L, Davis J, Gritsan AV, Kyriacou S, Maksimovic P, Roskes J, Sekhar S, Swartz M, Vámi TÁ, Abreu A, Alcerro Alcerro LF, Anguiano J, Baringer P, Bean A, Flowers Z, King J, Krintiras G, Lazarovits M, Le Mahieu C, Lindsey C, Marquez J, Minafra N, Murray M, Nickel M, Rogan C, Royon C, Salvatico R, Sanders S, Smith C, Wang Q, Wilson G, Allmond B, Duric S, Ivanov A, Kaadze K, Kalogeropoulos A, Kim D, Maravin Y, Mitchell T, Modak A, Nam K, Roy D, Rebassoo F, Wright D, Adams E, Baden A, Baron O, Belloni A, Bethani A, Eno SC, Hadley NJ, Jabeen S, Kellogg RG, Koeth T, Lai Y, Lascio S, Mignerey AC, Nabili S, Palmer C, Papageorgakis C, Wang L, Wong K, Busza W, Cali IA, Chen Y, D'Alfonso M, Eysermans J, Freer C, Gomez-Ceballos G, Goncharov M, Harris P, Hu M, Kovalskyi D, Krupa J, Lee YJ, Long K, Mironov C, Paus C, Rankin D, Roland C, Roland G, Shi Z, Stephans GSF, Wang J, Wang Z, Wyslouch B, Yang TJ, Chatterjee RM, Crossman B, Hiltbrand J, Joshi BM, Kapsiak C, Krohn M, Kubota Y, Mahon D, Mans J, Revering M, Rusack R, Saradhy R, Schroeder N, Strobbe N, Wadud MA, Cremaldi LM, Bloom K, Bryson M, Claes DR, Fangmeier C, Finco L, Golf F, Joo C, Kamalieddin R, Kravchenko I, Reed I, Siado JE, Snow GR, Tabb W, Wightman A, Yan F, Zecchinelli AG, Agarwal G, Bandyopadhyay H, Hay L, Iashvili I, Kharchilava A, McLean C, Morris M, Nguyen D, Pekkanen J, Rappoccio S, Williams A, Alverson G, Barberis E, Haddad Y, Han Y, Krishna A, Li J, Lidrych J, Madigan G, Marzocchi B, Morse DM, Nguyen V, Orimoto T, Parker A, Skinnari L, Tishelman-Charny A, Wamorkar T, Wang B, Wisecarver A, Wood D, Bhattacharya S, Bueghly J, Chen Z, Gilbert A, Hahn KA, Liu Y, Odell N, Schmitt MH, Velasco M, Band R, Bucci R, Cremonesi M, Das A, Goldouzian R, Hildreth M, Hurtado Anampa K, Jessop C, Lannon K, Lawrence J, Loukas N, Lutton L, Mariano J, Marinelli N, Mcalister I, McCauley T, Mcgrady C, Mohrman K, Moore C, Musienko Y, Ruchti R, Townsend A, Wayne M, Yockey H, Zarucki M, Zygala L, Bylsma B, Carrigan M, Durkin LS, Hill C, Joyce M, Lesauvage A, Nunez Ornelas M, Wei K, Winer BL, Yates BR, Addesa FM, Das P, Dezoort G, Elmer P, Frankenthal A, Greenberg B, Haubrich N, Higginbotham S, Kopp G, Kwan S, Lange D, Loeliger A, Marlow D, Ojalvo I, Olsen J, Stickland D, Tully C, Malik S, Bakshi AS, Barnes VE, Chawla R, Das S, Gutay L, Jones M, Jung AW, Kondratyev D, Koshy AM, Liu M, Negro G, Neumeister N, Paspalaki G, Piperov S, Purohit A, Schulte JF, Stojanovic M, Thieman J, Virdi AK, Wang F, Xiao R, Xie W, Dolen J, Parashar N, Acosta D, Baty A, Carnahan T, Dildick S, Ecklund KM, Fernández Manteca PJ, Freed S, Gardner P, Geurts FJM, Kumar A, Li W, Padley BP, Redjimi R, Rotter J, Yang S, Yigitbasi E, Zhang Y, Bodek A, de Barbaro P, Demina R, Dulemba JL, Fallon C, Garcia-Bellido A, Hindrichs O, Khukhunaishvili A, Parygin P, Popova E, Taus R, Van Onsem GP, Goulianos K, Chiarito B, Chou JP, Gershtein Y, Halkiadakis E, Hart A, Heindl M, Jaroslawski D, Karacheban O, Laflotte I, Lath A, Montalvo R, Nash K, Osherson M, Routray H, Salur S, Schnetzer S, Somalwar S, Stone R, Thayil SA, Thomas S, Wang H, Acharya H, Delannoy AG, Fiorendi S, Holmes T, Nibigira E, Spanier S, Bouhali O, Dalchenko M, Delgado A, Eusebi R, Gilmore J, Huang T, Kamon T, Kim H, Luo S, Malhotra S, Mueller R, Overton D, Rathjens D, Safonov A, Akchurin N, Damgov J, Hegde V, Lamichhane K, Lee SW, Mengke T, Muthumuni S, Peltola T, Volobouev I, Whitbeck A, Appelt E, Greene S, Gurrola A, Johns W, Melo A, Romeo F, Sheldon P, Tuo S, Velkovska J, Viinikainen J, Cardwell B, Cox B, Cummings G, Hakala J, Hirosky R, Ledovskoy A, Li A, Neu C, Perez Lara CE, Karchin PE, Aravind A, Banerjee S, Black K, Bose T, Dasu S, De Bruyn I, Everaerts P, Galloni C, He H, Herndon M, Herve A, Koraka CK, Lanaro A, Loveless R, Madhusudanan Sreekala J, Mallampalli A, Mohammadi A, Mondal S, Parida G, Pinna D, Savin A, Shang V, Sharma V, Smith WH, Teague D, Tsoi HF, Vetens W, Warden A, Afanasiev S, Andreev V, Andreev Y, Aushev T, Azarkin M, Babaev A, Belyaev A, Blinov V, Boos E, Borshch V, Budkouski D, Chekhovsky V, Chistov R, Danilov M, Dermenev A, Dimova T, Dremin I, Dubinin M, Dudko L, Epshteyn V, Ershov A, Gavrilov G, Gavrilov V, Gninenko S, Golovtcov V, Golubev N, Golutvin I, Gorbunov I, Gribushin A, Ivanov Y, Kachanov V, Kardapoltsev L, Karjavine V, Karneyeu A, Kim V, Kirakosyan M, Kirpichnikov D, Kirsanov M, Klyukhin V, Kodolova O, Konstantinov D, Korenkov V, Kozyrev A, Krasnikov N, Lanev A, Levchenko P, Litomin A, Lychkovskaya N, Makarenko V, Malakhov A, Matveev V, Murzin V, Nikitenko A, Obraztsov S, Ovtin I, Palichik V, Perelygin V, Petrushanko S, Polikarpov S, Popov V, Radchenko O, Savina M, Savrin V, Selivanova D, Shalaev V, Shmatov S, Shulha S, Skovpen Y, Slabospitskii S, Smirnov V, Snigirev A, Sosnov D, Sulimov V, Tcherniaev E, Terkulov A, Teryaev O, Tlisova I, Toropin A, Uvarov L, Uzunian A, Vorobyev A, Voytishin N, Yuldashev BS, Zarubin A, Zhizhin I, Zhokin A. Measurement of the Dependence of the Hadron Production Fraction Ratios f_{s}/f_{u} and f_{d}/f_{u} on B Meson Kinematic Variables in Proton-Proton Collisions at sqrt[s]=13 TeV. PHYSICAL REVIEW LETTERS 2023; 131:121901. [PMID: 37802954 DOI: 10.1103/physrevlett.131.121901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 03/27/2023] [Accepted: 06/20/2023] [Indexed: 10/08/2023]
Abstract
The dependence of the ratio between the B_{s}^{0} and B^{+} hadron production fractions, f_{s}/f_{u}, on the transverse momentum (p_{T}) and rapidity of the B mesons is studied using the decay channels B_{s}^{0}→J/ψϕ and B^{+}→J/ψK^{+}. The analysis uses a data sample of proton-proton collisions at a center-of-mass energy of 13 TeV, collected by the CMS experiment in 2018 and corresponding to an integrated luminosity of 61.6 fb^{-1}. The f_{s}/f_{u} ratio is observed to depend on the B p_{T} and to be consistent with becoming asymptotically constant at large p_{T}. No rapidity dependence is observed. The ratio of the B^{0} to B^{+} meson production fractions, f_{d}/f_{u}, is also measured, for the first time in proton-proton collisions, using the B^{0}→J/ψK^{*0} decay channel. The result is found to be within 1 standard deviation of unity and independent of p_{T} and rapidity, as expected from isospin invariance.
Collapse
|
193
|
Durand A, Clua-Provost T, Fabre F, Kumar P, Li J, Edgar JH, Udvarhelyi P, Gali A, Marie X, Robert C, Gérard JM, Gil B, Cassabois G, Jacques V. Optically Active Spin Defects in Few-Layer Thick Hexagonal Boron Nitride. PHYSICAL REVIEW LETTERS 2023; 131:116902. [PMID: 37774304 DOI: 10.1103/physrevlett.131.116902] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Accepted: 08/22/2023] [Indexed: 10/01/2023]
Abstract
Optically active spin defects in hexagonal boron nitride (hBN) are promising quantum systems for the design of two-dimensional quantum sensing units offering optimal proximity to the sample being probed. In this Letter, we first demonstrate that the electron spin resonance frequencies of boron vacancy centers (V_{B}^{-}) can be detected optically in the limit of few-atomic-layer thick hBN flakes despite the nanoscale proximity of the crystal surface that often leads to a degradation of the stability of solid-state spin defects. We then analyze the variations of the electronic spin properties of V_{B}^{-} centers with the hBN thickness with a focus on (i) the zero-field splitting parameters, (ii) the optically induced spin polarization rate and (iii) the longitudinal spin relaxation time. This Letter provides important insights into the properties of V_{B}^{-} centers embedded in ultrathin hBN flakes, which are valuable for future developments of foil-based quantum sensing technologies.
Collapse
|
194
|
Wang WF, Yang B, Liu HF, Ren LF, He D, Zhao XC, Li J. A multiline fitting method for measuring ethylene concentration based on WMS-2f/1f. Sci Rep 2023; 13:15302. [PMID: 37714900 PMCID: PMC10504384 DOI: 10.1038/s41598-023-42398-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2023] [Accepted: 09/09/2023] [Indexed: 09/17/2023] Open
Abstract
Coal spontaneous combustion risk assessment is a global technical challenge for the sustainable development of deep mining technology, and C2H4 is a key indicator for early warning of coal spontaneous combustion. Tunable diode laser absorption spectroscopy (TDLAS) has the advantages of high selectivity, high sensitivity, high accuracy and real-time on-line measurement, and it can detect multiple gases simultaneously, so it has significant advantages in the accurate detection of coal spontaneous combustion indicator gases. To address the problem of cross-interference between the near-infrared absorption lines of CH4 and C2H4, which are the indicator gases of spontaneous combustion in coal, a multi-line fitting method was proposed in this study to calibrate the concentration of C2H4. The high-precision Environics2000 automatic standard gas dispenser from the United States, which has a built-in CPU computer control and data control and processing system, was used. Its gas concentration accuracy: ± 1.0%, gas flow accuracy: ± 1.0%, gas repeatability accuracy: ± 1.0%, flow linearity accuracy: ± 0.5%, and inlet operating pressure: minimum 10 psig (0.67 bar) ~ 75 psig (5.04 bar). The measured and simulated WMS-2f/1f signals were multilinearly fitted using a multilinear fitting algorithm and wavelength modulation spectroscopy (WMS), and the measurement of C2H4 concentration was achieved based on the extracted spectral line information. The results show that the maximum relative error of C2H4 concentration measurement is 2.40%, which is 54% lower than that of the conventional 2f peak measurement method, thus demonstrating the effectiveness of the multilinear fitting algorithm in the inversion of C2H4 concentration under the interference of absorption lines. In addition, this study has far-reaching implications for the application of TDLAS technology in the accurate detection of coal spontaneous combustion indicator gases.
Collapse
|
195
|
Liu XX, Dong J, Li J, Liu QH, Zhang H. [Congenital neutropenia caused by ELANE gene mutation: a case report]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2023; 44:787. [PMID: 38049327 PMCID: PMC10630574 DOI: 10.3760/cma.j.issn.0253-2727.2023.09.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Indexed: 12/06/2023]
|
196
|
Meng XJ, Gu J, Jia TJ, Chen TZ, Li J, Yin HL. [Evaluation of effects of comprehensive intervention based on key persons on AIDS-related high-risk behaviors in male sex workers in entertainment venues]. ZHONGHUA LIU XING BING XUE ZA ZHI = ZHONGHUA LIUXINGBINGXUE ZAZHI 2023; 44:1434-1439. [PMID: 37743278 DOI: 10.3760/cma.j.cn112338-20230215-00080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/26/2023]
Abstract
Objective: To evaluate the effect of comprehensive intervention model based on key persons in entertainment venues on the incidence of AIDS-related high-risk behaviors in male sex workers (MSW). Data from this study thus can be used to provide compelling evidence for the wider implementation of the intervention model. Methods: In this randomized controlled trial, MSW were recruited and followed-up from May to December, 2021 in entertainment venues in Wuxi, Jiangsu Province, with an estimated sample size of 320. The MSW in the intervention group were provided with comprehensive interventions via key persons in entertainment venues compared with the control group receiving routine interventions. The effect of the intervention model was assessed by comparing the behavioral differences between these two groups and in the intervention group before and after intervention. Results: A total of 330 MSW were recruited at baseline survey, in which 168 were divided into intervention group and 162 into control group. There was no significant difference in socio-demographic characteristics between two groups (all P>0.05). After intervention for 6 months, the rate of consistent condom use in commercial homosexual activities in the intervention group was 79.5% (101/127), higher than 63.2% (74/117) in the control group, and in the intervention group, 90.1% (73/81) of MSW used condom consistently in heterosexual activities, higher than in the control group (59.6%, 59/99) . Compared with 30.8% (36/117) of MSW with drug abuse history in the control group, a lower proportion of 9.4% (12/127) was observed in the intervention group. Differences in all of aforementioned variables were significant (all P<0.05). After intervention, the incidence of group sex was 3.9% (5/127) in the intervention group and 9.4% (11/117) in the control group, the incidence of anal sex post-alcohol consumption was 40.2% (51/127) in the intervention group and 32.5% (38/117) in control group, the differences were not significant (all P>0.05). Conclusions: The intervention model based on key persons in entertainment venues could promote consistent condom use in MSW in both commercial homosexual and heterosexual activities and help them reduce drug abuse, but had no significant effect on decreasing group sex and anal sex after alcohol consumption. It is crucial to improve the intervention model according to the specific characteristics of MSW in order to enhance the effects of comprehensive intervention.
Collapse
|
197
|
Tumasyan A, Adam W, Andrejkovic JW, Bergauer T, Chatterjee S, Damanakis K, Dragicevic M, Escalante Del Valle A, Hussain PS, Jeitler M, Krammer N, Lechner L, Liko D, Mikulec I, Paulitsch P, Pitters FM, Schieck J, Schöfbeck R, Schwarz D, Templ S, Waltenberger W, Wulz CE, Darwish MR, Janssen T, Kello T, Rejeb Sfar H, Van Mechelen P, Bols ES, D'Hondt J, De Moor A, Delcourt M, El Faham H, Lowette S, Moortgat S, Morton A, Müller D, Sahasransu AR, Tavernier S, Van Doninck W, Vannerom D, Clerbaux B, De Lentdecker G, Favart L, Hohov D, Jaramillo J, Lee K, Mahdavikhorrami M, Makarenko I, Malara A, Paredes S, Pétré L, Postiau N, Starling E, Thomas L, Vanden Bemden M, Vander Velde C, Vanlaer P, Dobur D, Knolle J, Lambrecht L, Mestdach G, Niedziela M, Rendón C, Roskas C, Samalan A, Skovpen K, Tytgat M, Van Den Bossche N, Vermassen B, Wezenbeek L, Benecke A, Bruno G, Bury F, Caputo C, David P, Delaere C, Donertas IS, Giammanco A, Jaffel K, Jain S, Lemaitre V, Mondal K, Prisciandaro J, Taliercio A, Tran TT, Vischia P, Wertz S, Alves GA, Coelho E, Hensel C, Moraes A, Rebello Teles P, Aldá Júnior WL, Alves Gallo Pereira M, Barroso Ferreira Filho M, Brandao Malbouisson H, Carvalho W, Chinellato J, Da Costa EM, Da Silveira GG, De Jesus Damiao D, Dos Santos Sousa V, Fonseca De Souza S, Martins J, Mora Herrera C, Mota Amarilo K, Mundim L, Nogima H, Santoro A, Silva Do Amaral SM, Sznajder A, Thiel M, Torres Da Silva De Araujo F, Vilela Pereira A, Bernardes CA, Calligaris L, Tomei TRFP, Gregores EM, Mercadante PG, Novaes SF, Padula SS, Aleksandrov A, Antchev G, Hadjiiska R, Iaydjiev P, Misheva M, Rodozov M, Shopova M, Sultanov G, Dimitrov A, Ivanov T, Litov L, Pavlov B, Petkov P, Petrov A, Shumka E, Cheng T, Javaid T, Mittal M, Yuan L, Ahmad M, Bauer G, Hu Z, Lezki S, Yi K, Chen GM, Chen HS, Chen M, Iemmi F, Jiang CH, Kapoor A, Liao H, Liu ZA, Milosevic V, Monti F, Sharma R, Tao J, Thomas-Wilsker J, Wang J, Zhang H, Zhao J, Agapitos A, An Y, Ban Y, Chen C, Levin A, Li C, Li Q, Lyu X, Mao Y, Qian SJ, Sun X, Wang D, Xiao J, Yang H, Lu M, You Z, Gao X, Leggat D, Okawa H, Zhang Y, Lin Z, Lu C, Xiao M, Avila C, Barbosa Trujillo DA, Cabrera A, Florez C, Fraga J, Mejia Guisao J, Ramirez F, Rodriguez M, Ruiz Alvarez JD, Giljanovic D, Godinovic N, Lelas D, Puljak I, Antunovic Z, Kovac M, Sculac T, Brigljevic V, Chitroda BK, Ferencek D, Majumder D, Roguljic M, Starodumov A, Susa T, Attikis A, Christoforou K, Kole G, Kolosova M, Konstantinou S, Mousa J, Nicolaou C, Ptochos F, Razis PA, Rykaczewski H, Saka H, Finger M, Finger M, Kveton A, Ayala E, Carrera Jarrin E, Abdelalim AA, Salama E, Abdullah Al-Mashad M, Mahmoud MA, Bhowmik S, Dewanjee RK, Ehataht K, Kadastik M, Lange T, Nandan S, Nielsen C, Pata J, Raidal M, Tani L, Veelken C, Eerola P, Kirschenmann H, Osterberg K, Voutilainen M, Bharthuar S, Brücken E, Garcia F, Havukainen J, Kim MS, Kinnunen R, Lampén T, Lassila-Perini K, Lehti S, Lindén T, Lotti M, Martikainen L, Myllymäki M, Ott J, Rantanen MM, Siikonen H, Tuominen E, Tuominiemi J, Luukka P, Petrow H, Tuuva T, Amendola C, Besancon M, Couderc F, Dejardin M, Denegri D, Faure JL, Ferri F, Ganjour S, Gras P, Hamel de Monchenault G, Jarry P, Lohezic V, Malcles J, Rander J, Rosowsky A, Sahin MÖ, Savoy-Navarro A, Simkina P, Titov M, Baldenegro Barrera C, Beaudette F, Buchot Perraguin A, Busson P, Cappati A, Charlot C, Damas F, Davignon O, Diab B, Falmagne G, Fontana Santos Alves BA, Ghosh S, Granier de Cassagnac R, Hakimi A, Harikrishnan B, Liu G, Motta J, Nguyen M, Ochando C, Portales L, Salerno R, Sarkar U, Sauvan JB, Sirois Y, Tarabini A, Vernazza E, Zabi A, Zghiche A, Agram JL, Andrea J, Apparu D, Bloch D, Bourgatte G, Brom JM, Chabert EC, Collard C, Darej D, Goerlach U, Grimault C, Le Bihan AC, Van Hove P, Beauceron S, Bernet C, Blancon B, Boudoul G, Carle A, Chanon N, Choi J, Contardo D, Depasse P, Dozen C, El Mamouni H, Fay J, Gascon S, Gouzevitch M, Grenier G, Ille B, Laktineh IB, Lethuillier M, Mirabito L, Perries S, Torterotot L, Vander Donckt M, Verdier P, Viret S, Chokheli D, Lomidze I, Tsamalaidze Z, Botta V, Feld L, Klein K, Lipinski M, Meuser D, Pauls A, Röwert N, Teroerde M, Diekmann S, Dodonova A, Eich N, Eliseev D, Erdmann M, Fackeldey P, Fasanella D, Fischer B, Hebbeker T, Hoepfner K, Ivone F, Lee MY, Mastrolorenzo L, Merschmeyer M, Meyer A, Mondal S, Mukherjee S, Noll D, Novak A, Nowotny F, Pozdnyakov A, Rath Y, Redjeb W, Reithler H, Schmidt A, Schuler SC, Sharma A, Vigilante L, Wiedenbeck S, Zaleski S, Dziwok C, Flügge G, Haj Ahmad W, Hlushchenko O, Kress T, Nowack A, Pooth O, Stahl A, Ziemons T, Zotz A, Aarup Petersen H, Aldaya Martin M, Asmuss P, Baxter S, Bayatmakou M, Behnke O, Bermúdez Martínez A, Bhattacharya S, Bin Anuar AA, Blekman F, Borras K, Brunner D, Campbell A, Cardini A, Cheng C, Colombina F, Consuegra Rodríguez S, Correia Silva G, De Silva M, Didukh L, Eckerlin G, Eckstein D, Estevez Banos LI, Filatov O, Gallo E, Geiser A, Giraldi A, Greau G, Grohsjean A, Guglielmi V, Guthoff M, Jafari A, Jomhari NZ, Kaech B, Kasem A, Kasemann M, Kaveh H, Kleinwort C, Kogler R, Komm M, Krücker D, Lange W, Leyva Pernia D, Lipka K, Lohmann W, Mankel R, Melzer-Pellmann IA, Mendizabal Morentin M, Metwally J, Meyer AB, Milella G, Mormile M, Mussgiller A, Nürnberg A, Otarid Y, Pérez Adán D, Raspereza A, Ribeiro Lopes B, Rübenach J, Saggio A, Saibel A, Savitskyi M, Scham M, Scheurer V, Schnake S, Schütze P, Schwanenberger C, Shchedrolosiev M, Sosa Ricardo RE, Stafford D, Tonon N, Van De Klundert M, Vazzoler F, Ventura Barroso A, Walsh R, Walter D, Wang Q, Wen Y, Wichmann K, Wiens L, Wissing C, Wuchterl S, Yang Y, Zimermmane Castro Santos A, Albrecht A, Albrecht S, Antonello M, Bein S, Benato L, Bonanomi M, Connor P, De Leo K, Eich M, El Morabit K, Feindt F, Fröhlich A, Garbers C, Garutti E, Hajheidari M, Haller J, Hinzmann A, Jabusch HR, Kasieczka G, Klanner R, Korcari W, Kramer T, Kutzner V, Lange J, Lobanov A, Matthies C, Mehta A, Moureaux L, Mrowietz M, Nigamova A, Nissan Y, Paasch A, Pena Rodriguez KJ, Rieger M, Rieger O, Schleper P, Schröder M, Schwandt J, Stadie H, Steinbrück G, Tews A, Wolf M, Bechtel J, Brommer S, Burkart M, Butz E, Caspart R, Chwalek T, Dierlamm A, Droll A, Faltermann N, Giffels M, Gosewisch JO, Gottmann A, Hartmann F, Horzela M, Husemann U, Keicher P, Klute M, Koppenhöfer R, Maier S, Mitra S, Müller T, Neukum M, Quast G, Rabbertz K, Rauser J, Savoiu D, Schnepf M, Seith D, Shvetsov I, Simonis HJ, Trevisani N, Ulrich R, van der Linden J, Von Cube RF, Wassmer M, Wieland S, Wolf R, Wozniewski S, Wunsch S, Anagnostou G, Assiouras P, Daskalakis G, Kyriakis A, Stakia A, Diamantopoulou M, Karasavvas D, Kontaxakis P, Manousakis-Katsikakis A, Panagiotou A, Papavergou I, Saoulidou N, Theofilatos K, Tziaferi E, Vellidis K, Vourliotis E, Zisopoulos I, Bakas G, Chatzistavrou T, Kousouris K, Papakrivopoulos I, Tsipolitis G, Zacharopoulou A, Adamidis K, Bestintzanos I, Evangelou I, Foudas C, Gianneios P, Kamtsikis C, Katsoulis P, Kokkas P, Kosmoglou Kioseoglou PG, Manthos N, Papadopoulos I, Strologas J, Csanád M, Farkas K, Gadallah MMA, Lökös S, Major P, Mandal K, Pásztor G, Rádl AJ, Surányi O, Veres GI, Bartók M, Bencze G, Hajdu C, Horvath D, Sikler F, Veszpremi V, Beni N, Czellar S, Karancsi J, Molnar J, Szillasi Z, Teyssier D, Raics P, Ujvari B, Csorgo T, Nemes F, Novak T, Babbar J, Bansal S, Beri SB, Bhatnagar V, Chaudhary G, Chauhan S, Dhingra N, Gupta R, Kaur A, Kaur A, Kaur H, Kaur M, Kumar S, Kumari P, Meena M, Sandeep K, Sheokand T, Singh JB, Singla A, Virdi AK, Ahmed A, Bhardwaj A, Choudhary BC, Gola M, Kumar A, Naimuddin M, Priyanka P, Ranjan K, Saumya S, Shah A, Baradia S, Barman S, Bhattacharya S, Bhowmik D, Dutta S, Dutta S, Gomber B, Maity M, Palit P, Rout PK, Saha G, Sahu B, Sarkar S, Behera PK, Behera SC, Kalbhor P, Komaragiri JR, Kumar D, Muhammad A, Panwar L, Pradhan R, Pujahari PR, Sharma A, Sikdar AK, Tiwari PC, Verma S, Naskar K, Aziz T, Das I, Dugad S, Kumar M, Mohanty GB, Suryadevara P, Banerjee S, Chudasama R, Guchait M, Karmakar S, Kumar S, Majumder G, Mazumdar K, Mukherjee S, Thachayath A, Bahinipati S, Das AK, Kar C, Mal P, Mishra T, Muraleedharan Nair Bindhu VK, Nayak A, Saha P, Swain SK, Vats D, Alpana A, Dube S, Kansal B, Laha A, Pandey S, Rastogi A, Sharma S, Bakhshiansohi H, Khazaie E, Zeinali M, Chenarani S, Etesami SM, Khakzad M, Mohammadi Najafabadi M, Grunewald M, Abbrescia M, Aly R, Aruta C, Colaleo A, Creanza D, De Filippis N, De Palma M, Di Florio A, Elmetenawee W, Errico F, Fiore L, Iaselli G, Ince M, Maggi G, Maggi M, Margjeka I, Mastrapasqua V, My S, Nuzzo S, Pellecchia A, Pompili A, Pugliese G, Radogna R, Ramos D, Ranieri A, Selvaggi G, Silvestris L, Simone FM, Sözbilir Ü, Stamerra A, Venditti R, Verwilligen P, Abbiendi G, Battilana C, Bonacorsi D, Borgonovi L, Brigliadori L, Campanini R, Capiluppi P, Castro A, Cavallo FR, Cuffiani M, Dallavalle GM, Diotalevi T, Fabbri F, Fanfani A, Giacomelli P, Giommi L, Grandi C, Guiducci L, Lo Meo S, Lunerti L, Marcellini S, Masetti G, Navarria FL, Perrotta A, Primavera F, Rossi AM, Rovelli T, Siroli GP, Costa S, Di Mattia A, Potenza R, Tricomi A, Tuve C, Barbagli G, Camaiani B, Cassese A, Ceccarelli R, Ciulli V, Civinini C, D'Alessandro R, Focardi E, Latino G, Lenzi P, Lizzo M, Meschini M, Paoletti S, Seidita R, Sguazzoni G, Viliani L, Benussi L, Bianco S, Meola S, Piccolo D, Bozzo M, Chatagnon P, Ferro F, Mulargia R, Robutti E, Tosi S, Benaglia A, Boldrini G, Brivio F, Cetorelli F, De Guio F, Dinardo ME, Dini P, Gennai S, Ghezzi A, Govoni P, Guzzi L, Lucchini MT, Malberti M, Malvezzi S, Massironi A, Menasce D, Moroni L, Paganoni M, Pedrini D, Pinolini BS, Ragazzi S, Redaelli N, Tabarelli de Fatis T, Zuolo D, Buontempo S, Carnevali F, Cavallo N, De Iorio A, Fabozzi F, Iorio AOM, Lista L, Paolucci P, Rossi B, Sciacca C, Azzi P, Bacchetta N, Benettoni M, Bisello D, Bortignon P, Bragagnolo A, Carlin R, Checchia P, Dorigo T, Gasparini F, Gasparini U, Grosso G, Layer L, Lusiani E, Margoni M, Meneguzzo AT, Pazzini J, Ronchese P, Rossin R, Strong G, Tosi M, Yarar H, Zanetti M, Zotto P, Zucchetta A, Zumerle G, Abu Zeid S, Aimè C, Braghieri A, Calzaferri S, Fiorina D, Montagna P, Re V, Riccardi C, Salvini P, Vai I, Vitulo P, Asenov P, Bilei GM, Ciangottini D, Fanò L, Magherini M, Mantovani G, Mariani V, Menichelli M, Moscatelli F, Piccinelli A, Presilla M, Rossi A, Santocchia A, Spiga D, Tedeschi T, Azzurri P, Bagliesi G, Bertacchi V, Bhattacharya R, Bianchini L, Boccali T, Bossini E, Bruschini D, Castaldi R, Ciocci MA, D'Amante V, Dell'Orso R, Di Domenico MR, Donato S, Giassi A, Ligabue F, Mandorli G, Matos Figueiredo D, Messineo A, Musich M, Palla F, Parolia S, Ramirez-Sanchez G, Rizzi A, Rolandi G, Roy Chowdhury S, Sarkar T, Scribano A, Shafiei N, Spagnolo P, Tenchini R, Tonelli G, Turini N, Venturi A, Verdini PG, Barria P, Campana M, Cavallari F, Del Re D, Di Marco E, Diemoz M, Longo E, Meridiani P, Organtini G, Pandolfi F, Paramatti R, Quaranta C, Rahatlou S, Rovelli C, Santanastasio F, Soffi L, Tramontano R, Amapane N, Arcidiacono R, Argiro S, Arneodo M, Bartosik N, Bellan R, Bellora A, Biino C, Cartiglia N, Costa M, Covarelli R, Demaria N, Grippo M, Kiani B, Legger F, Mariotti C, Maselli S, Mecca A, Migliore E, Monteil E, Monteno M, Obertino MM, Ortona G, Pacher L, Pastrone N, Pelliccioni M, Ruspa M, Shchelina K, Siviero F, Sola V, Solano A, Soldi D, Staiano A, Tornago M, Trocino D, Umoret G, Vagnerini A, Belforte S, Candelise V, Casarsa M, Cossutti F, Da Rold A, Della Ricca G, Sorrentino G, Dogra S, Huh C, Kim B, Kim DH, Kim GN, Kim J, Lee J, Lee SW, Moon CS, Oh YD, Pak SI, Ryu MS, Sekmen S, Yang YC, Kim H, Moon DH, Asilar E, Kim TJ, Park J, Choi S, Han S, Hong B, Lee K, Lee KS, Lim J, Park J, Park SK, Yoo J, Goh J, Kim HS, Kim Y, Lee S, Almond J, Bhyun JH, Choi J, Jeon S, Jun W, Kim J, Kim J, Kim JS, Ko S, Kwon H, Lee H, Lee J, Lee S, Oh BH, Oh M, Oh SB, Seo H, Yang UK, Yoon I, Jang W, Kang DY, Kang Y, Kim D, Kim S, Ko B, Lee JSH, Lee Y, Merlin JA, Park IC, Roh Y, Song D, Watson IJ, Yang S, Ha S, Yoo HD, Choi M, Kim MR, Lee H, Lee Y, Lee Y, Yu I, Beyrouthy T, Maghrbi Y, Dreimanis K, Gaile A, Potrebko A, Seidel M, Torims T, Veckalns V, Ambrozas M, Carvalho Antunes De Oliveira A, Juodagalvis A, Rinkevicius A, Tamulaitis G, Bin Norjoharuddeen N, Hoh SY, Yusuff I, Zolkapli Z, Benitez JF, Castaneda Hernandez A, Encinas Acosta HA, Gallegos Maríñez LG, León Coello M, Murillo Quijada JA, Sehrawat A, Valencia Palomo L, Ayala G, Castilla-Valdez H, Heredia-De La Cruz I, Lopez-Fernandez R, Mondragon Herrera CA, Perez Navarro DA, Sánchez Hernández A, Oropeza Barrera C, Vazquez Valencia F, Pedraza I, Salazar Ibarguen HA, Uribe Estrada C, Bubanja I, Mijuskovic J, Raicevic N, Ahmad A, Asghar MI, Awais A, Awan MIM, Gul M, Hoorani HR, Khan WA, Shoaib M, Waqas M, Avati V, Grzanka L, Malawski M, Bialkowska H, Bluj M, Boimska B, Górski M, Kazana M, Szleper M, Zalewski P, Bunkowski K, Doroba K, Kalinowski A, Konecki M, Krolikowski J, Araujo M, Bargassa P, Bastos D, Boletti A, Faccioli P, Gallinaro M, Hollar J, Leonardo N, Niknejad T, Pisano M, Seixas J, Varela J, Adzic P, Dordevic M, Milenovic P, Milosevic J, Aguilar-Benitez M, Alcaraz Maestre J, Álvarez Fernández A, Barrio Luna M, Bedoya CF, Carrillo Montoya CA, Cepeda M, Cerrada M, Colino N, De La Cruz B, Delgado Peris A, Fernández Del Val D, Fernández Ramos JP, Flix J, Fouz MC, Gonzalez Lopez O, Goy Lopez S, Hernandez JM, Josa MI, León Holgado J, Moran D, Perez Dengra C, Pérez-Calero Yzquierdo A, Puerta Pelayo J, Redondo I, Redondo Ferrero DD, Romero L, Sánchez Navas S, Sastre J, Urda Gómez L, Vazquez Escobar J, Willmott C, de Trocóniz JF, Alvarez Gonzalez B, Cuevas J, Fernandez Menendez J, Folgueras S, Gonzalez Caballero I, González Fernández JR, Palencia Cortezon E, Ramón Álvarez C, Rodríguez Bouza V, Soto Rodríguez A, Trapote A, Vico Villalba C, Brochero Cifuentes JA, Cabrillo IJ, Calderon A, Duarte Campderros J, Fernandez M, Fernandez Madrazo C, García Alonso A, Gomez G, Lasaosa García C, Martinez Rivero C, Martinez Ruiz Del Arbol P, Matorras F, Matorras Cuevas P, Piedra Gomez J, Prieels C, Ruiz-Jimeno A, Scodellaro L, Vila I, Vizan Garcia JM, Jayananda MK, Kailasapathy B, Sonnadara DUJ, Wickramarathna DDC, Dharmaratna WGD, Liyanage K, Perera N, Wickramage N, Abbaneo D, Alimena J, Auffray E, Auzinger G, Baechler J, Baillon P, Barney D, Bendavid J, Bianco M, Bilin B, Bocci A, Brondolin E, Caillol C, Camporesi T, Cerminara G, Chernyavskaya N, Chhibra SS, Choudhury S, Cipriani M, Cristella L, d'Enterria D, Dabrowski A, David A, De Roeck A, Defranchis MM, Deile M, Dobson M, Dünser M, Dupont N, Elliott-Peisert A, Fallavollita F, Florent A, Forthomme L, Franzoni G, Funk W, Ghosh S, Giani S, Gigi D, Gill K, Glege F, Gouskos L, Govorkova E, Haranko M, Hegeman J, Innocente V, James T, Janot P, Kaspar J, Kieseler J, Kratochwil N, Laurila S, Lecoq P, Leutgeb E, Lintuluoto A, Lourenço C, Maier B, Malgeri L, Mannelli M, Marini AC, Meijers F, Mersi S, Meschi E, Moortgat F, Mulders M, Orfanelli S, Orsini L, Pantaleo F, Perez E, Peruzzi M, Petrilli A, Petrucciani G, Pfeiffer A, Pierini M, Piparo D, Pitt M, Qu H, Quast T, Rabady D, Racz A, Reales Gutiérrez G, Rovere M, Sakulin H, Salfeld-Nebgen J, Scarfi S, Selvaggi M, Sharma A, Silva P, Sphicas P, Stahl Leiton AG, Summers S, Tatar K, Tavolaro VR, Treille D, Tropea P, Tsirou A, Wanczyk J, Wozniak KA, Zeuner WD, Caminada L, Ebrahimi A, Erdmann W, Horisberger R, Ingram Q, Kaestli HC, Kotlinski D, Lange C, Missiroli M, Noehte L, Rohe T, Aarrestad TK, Androsov K, Backhaus M, Berger P, Calandri A, Datta K, De Cosa A, Dissertori G, Dittmar M, Donegà M, Eble F, Galli M, Gedia K, Glessgen F, Gómez Espinosa TA, Grab C, Hits D, Lustermann W, Lyon AM, Manzoni RA, Marchese L, Martin Perez C, Mascellani A, Meinhard MT, Nessi-Tedaldi F, Niedziela J, Pauss F, Perovic V, Pigazzini S, Ratti MG, Reichmann M, Reissel C, Reitenspiess T, Ristic B, Riti F, Ruini D, Sanz Becerra DA, Steggemann J, Valsecchi D, Wallny R, Amsler C, Bärtschi P, Botta C, Brzhechko D, Canelli MF, Cormier K, De Wit A, Del Burgo R, Heikkilä JK, Huwiler M, Jin W, Jofrehei A, Kilminster B, Leontsinis S, Liechti SP, Macchiolo A, Meiring P, Mikuni VM, Molinatti U, Neutelings I, Reimers A, Robmann P, Sanchez Cruz S, Schweiger K, Senger M, Takahashi Y, Adloff C, Kuo CM, Lin W, Yu SS, Ceard L, Chao Y, Chen KF, Chen PS, Cheng H, Hou WS, Khurana R, Li YY, Lu RS, Paganis E, Psallidas A, Steen A, Wu HY, Yazgan E, Yu PR, Asawatangtrakuldee C, Srimanobhas N, Agyel D, Boran F, Demiroglu ZS, Dolek F, Dumanoglu I, Eskut E, Guler Y, Gurpinar Guler E, Isik C, Kara O, Kayis Topaksu A, Kiminsu U, Onengut G, Ozdemir K, Polatoz A, Simsek AE, Tali B, Tok UG, Turkcapar S, Uslan E, Zorbakir IS, Karapinar G, Ocalan K, Yalvac M, Akgun B, Atakisi IO, Gülmez E, Kaya M, Kaya O, Özçelik Ö, Tekten S, Cakir A, Cankocak K, Komurcu Y, Sen S, Aydilek O, Cerci S, Hacisahinoglu B, Hos I, Isildak B, Kaynak B, Ozkorucuklu S, Simsek C, Sunar Cerci D, Grynyov B, Levchuk L, Anthony D, Bhal E, Brooke JJ, Bundock A, Clement E, Cussans D, Flacher H, Glowacki M, Goldstein J, Heath GP, Heath HF, Kreczko L, Krikler B, Paramesvaran S, Seif El Nasr-Storey S, Smith VJ, Stylianou N, Walkingshaw Pass K, White R, Ball AH, Bell KW, Belyaev A, Brew C, Brown RM, Cockerill DJA, Cooke C, Ellis KV, Harder K, Harper S, Holmberg ML, Linacre J, Manolopoulos K, Newbold DM, Olaiya E, Petyt D, Reis T, Salvi G, Schuh T, Shepherd-Themistocleous CH, Tomalin IR, Williams T, Bainbridge R, Bloch P, Bonomally S, Borg J, Breeze S, Brown CE, Buchmuller O, Cacchio V, Cepaitis V, Chahal GS, Colling D, Dancu JS, Dauncey P, Davies G, Davies J, Della Negra M, Fayer S, Fedi G, Hall G, Hassanshahi MH, Howard A, Iles G, Langford J, Lyons L, Magnan AM, Malik S, Martelli A, Mieskolainen M, Monk DG, Nash J, Pesaresi M, Radburn-Smith BC, Raymond DM, Richards A, Rose A, Scott E, Seez C, Shtipliyski A, Shukla R, Tapper A, Uchida K, Uttley GP, Vage LH, Virdee T, Vojinovic M, Wardle N, Webb SN, Winterbottom D, Coldham K, Cole JE, Khan A, Kyberd P, Reid ID, Abdullin S, Brinkerhoff A, Caraway B, Dittmann J, Hatakeyama K, Kanuganti AR, McMaster B, Saunders M, Sawant S, Sutantawibul C, Wilson J, Bartek R, Dominguez A, Uniyal R, Vargas Hernandez AM, Buccilli A, Cooper SI, Di Croce D, Gleyzer SV, Henderson C, Perez CU, Rumerio P, West C, Akpinar A, Albert A, Arcaro D, Cosby C, Demiragli Z, Erice C, Fontanesi E, Gastler D, May S, Rohlf J, Salyer K, Sperka D, Spitzbart D, Suarez I, Tsatsos A, Yuan S, Benelli G, Burkle B, Coubez X, Cutts D, Hadley M, Heintz U, Hogan JM, Kwon T, Landsberg G, Lau KT, Li D, Luo J, Narain M, Pervan N, Sagir S, Simpson F, Usai E, Wong WY, Yan X, Yu D, Zhang W, Bonilla J, Brainerd C, Breedon R, Calderon De La Barca Sanchez M, Chertok M, Conway J, Cox PT, Erbacher R, Haza G, Jensen F, Kukral O, Mocellin G, Mulhearn M, Pellett D, Regnery B, Taylor D, Yao Y, Zhang F, Bachtis M, Cousins R, Datta A, Hamilton D, Hauser J, Ignatenko M, Iqbal MA, Lam T, Manca E, Nash WA, Regnard S, Saltzberg D, Stone B, Valuev V, Chen Y, Clare R, Gary JW, Gordon M, Hanson G, Karapostoli G, Long OR, Manganelli N, Si W, Wimpenny S, Branson JG, Chang P, Cittolin S, Cooperstein S, Diaz D, Duarte J, Gerosa R, Giannini L, Guiang J, Kansal R, Krutelyov V, Lee R, Letts J, Masciovecchio M, Mokhtar F, Pieri M, Sathia Narayanan BV, Sharma V, Tadel M, Würthwein F, Xiang Y, Yagil A, Amin N, Campagnari C, Citron M, Collura G, Dorsett A, Dutta V, Incandela J, Kilpatrick M, Kim J, Li AJ, Masterson P, Mei H, Oshiro M, Quinnan M, Richman J, Sarica U, Schmitz R, Setti F, Sheplock J, Siddireddy P, Stuart D, Wang S, Bornheim A, Cerri O, Dutta I, Lawhorn JM, Lu N, Mao J, Newman HB, Nguyen TQ, Spiropulu M, Vlimant JR, Wang C, Xie S, Zhu RY, Alison J, An S, Andrews MB, Bryant P, Ferguson T, Harilal A, Liu C, Mudholkar T, Murthy S, Paulini M, Roberts A, Sanchez A, Terrill W, Cumalat JP, Ford WT, Hassani A, Karathanasis G, MacDonald E, Marini F, Patel R, Perloff A, Savard C, Schonbeck N, Stenson K, Ulmer KA, Wagner SR, Zipper N, Alexander J, Bright-Thonney S, Chen X, Cranshaw DJ, Fan J, Fan X, Gadkari D, Hogan S, Monroy J, Patterson JR, Quach D, Reichert J, Reid M, Ryd A, Thom J, Wittich P, Zou R, Albrow M, Alyari M, Apollinari G, Apresyan A, Bauerdick LAT, Berry D, Berryhill J, Bhat PC, Burkett K, Butler JN, Canepa A, Cerati GB, Cheung HWK, Chlebana F, Di Petrillo KF, Dickinson J, Elvira VD, Feng Y, Freeman J, Gandrakota A, Gecse Z, Gray L, Green D, Grünendahl S, Gutsche O, Harris RM, Heller R, Herwig TC, Hirschauer J, Horyn L, Jayatilaka B, Jindariani S, Johnson M, Joshi U, Klijnsma T, Klima B, Kwok KHM, Lammel S, Lincoln D, Lipton R, Liu T, Madrid C, Maeshima K, Mantilla C, Mason D, McBride P, Merkel P, Mrenna S, Nahn S, Ngadiuba J, Noonan D, Papadimitriou V, Pastika N, Pedro K, Pena C, Ravera F, Reinsvold Hall A, Ristori L, Sexton-Kennedy E, Smith N, Soha A, Spiegel L, Strait J, Taylor L, Tkaczyk S, Tran NV, Uplegger L, Vaandering EW, Weber HA, Zoi I, Avery P, Bourilkov D, Cadamuro L, Cherepanov V, Field RD, Guerrero D, Kim M, Koenig E, Konigsberg J, Korytov A, Lo KH, Matchev K, Menendez N, Mitselmakher G, Muthirakalayil Madhu A, Rawal N, Rosenzweig D, Rosenzweig S, Shi K, Wang J, Wu Z, Adams T, Askew A, Habibullah R, Hagopian V, Kolberg T, Martinez G, Prosper H, Schiber C, Viazlo O, Yohay R, Zhang J, Baarmand MM, Butalla S, Elkafrawy T, Hohlmann M, Kumar Verma R, Rahmani M, Yumiceva F, Adams MR, Becerril Gonzalez H, Cavanaugh R, Dittmer S, Evdokimov O, Gerber CE, Hofman DJ, Lemos DS, Merrit AH, Mills C, Oh G, Roy T, Rudrabhatla S, Tonjes MB, Varelas N, Wang X, Ye Z, Yoo J, Alhusseini M, Dilsiz K, Emediato L, Gandrajula RP, Karaman G, Köseyan OK, Merlo JP, Mestvirishvili A, Nachtman J, Neogi O, Ogul H, Onel Y, Penzo A, Snyder C, Tiras E, Amram O, Blumenfeld B, Corcodilos L, Davis J, Gritsan AV, Kang L, Kyriacou S, Maksimovic P, Roskes J, Sekhar S, Swartz M, Vámi TÁ, Abreu A, Alcerro Alcerro LF, Anguiano J, Baringer P, Bean A, Flowers Z, Isidori T, Khalil S, King J, Krintiras G, Lazarovits M, Le Mahieu C, Lindsey C, Marquez J, Minafra N, Murray M, Nickel M, Rogan C, Royon C, Salvatico R, Sanders S, Smith C, Wang Q, Williams J, Wilson G, Allmond B, Duric S, Gujju Gurunadha R, Ivanov A, Kaadze K, Kim D, Maravin Y, Mitchell T, Modak A, Nam K, Natoli J, Roy D, Rebassoo F, Wright D, Adams E, Baden A, Baron O, Belloni A, Bethani A, Eno SC, Hadley NJ, Jabeen S, Kellogg RG, Koeth T, Lai Y, Lascio S, Mignerey AC, Nabili S, Palmer C, Papageorgakis C, Wang L, Wong K, Abercrombie D, Busza W, Cali IA, Chen Y, D'Alfonso M, Eysermans J, Freer C, Gomez-Ceballos G, Goncharov M, Harris P, Hu M, Kovalskyi D, Krupa J, Lee YJ, Long K, Mironov C, Paus C, Rankin D, Roland C, Roland G, Shi Z, Stephans GSF, Wang J, Wang Z, Wyslouch B, Chatterjee RM, Crossman B, Evans A, Hiltbrand J, Jain S, Joshi BM, Kapsiak C, Krohn M, Kubota Y, Mans J, Revering M, Rusack R, Saradhy R, Schroeder N, Strobbe N, Wadud MA, Cremaldi LM, Bloom K, Bryson M, Claes DR, Fangmeier C, Finco L, Golf F, Joo C, Kravchenko I, Reed I, Siado JE, Snow GR, Tabb W, Wightman A, Yan F, Zecchinelli AG, Agarwal G, Bandyopadhyay H, Hay L, Iashvili I, Kharchilava A, McLean C, Morris M, Nguyen D, Pekkanen J, Rappoccio S, Williams A, Alverson G, Barberis E, Haddad Y, Han Y, Krishna A, Li J, Lidrych J, Madigan G, Marzocchi B, Morse DM, Nguyen V, Orimoto T, Parker A, Skinnari L, Tishelman-Charny A, Wamorkar T, Wang B, Wisecarver A, Wood D, Bhattacharya S, Bueghly J, Chen Z, Gilbert A, Hahn KA, Liu Y, Odell N, Schmitt MH, Velasco M, Band R, Bucci R, Castells S, Cremonesi M, Das A, Goldouzian R, Hildreth M, Hurtado Anampa K, Jessop C, Lannon K, Lawrence J, Loukas N, Lutton L, Mariano J, Marinelli N, Mcalister I, McCauley T, Mcgrady C, Mohrman K, Moore C, Musienko Y, Nelson H, Ruchti R, Townsend A, Wayne M, Yockey H, Zarucki M, Zygala L, Bylsma B, Carrigan M, Durkin LS, Francis B, Hill C, Lesauvage A, Nunez Ornelas M, Wei K, Winer BL, Yates BR, Addesa FM, Das P, Dezoort G, Elmer P, Frankenthal A, Greenberg B, Haubrich N, Higginbotham S, Kalogeropoulos A, Kopp G, Kwan S, Lange D, Marlow D, Mei K, Ojalvo I, Olsen J, Stickland D, Tully C, Malik S, Norberg S, Bakshi AS, Barnes VE, Chawla R, Das S, Gutay L, Jones M, Jung AW, Kondratyev D, Koshy AM, Liu M, Negro G, Neumeister N, Paspalaki G, Piperov S, Purohit A, Schulte JF, Stojanovic M, Thieman J, Wang F, Xiao R, Xie W, Dolen J, Parashar N, Acosta D, Baty A, Carnahan T, Decaro M, Dildick S, Ecklund KM, Fernández Manteca PJ, Freed S, Gardner P, Geurts FJM, Kumar A, Li W, Padley BP, Redjimi R, Rotter J, Shi W, Yang S, Yigitbasi E, Zhang L, Zhang Y, Zuo X, Bodek A, de Barbaro P, Demina R, Dulemba JL, Fallon C, Ferbel T, Galanti M, Garcia-Bellido A, Hindrichs O, Khukhunaishvili A, Ranken E, Taus R, Van Onsem GP, Goulianos K, Chiarito B, Chou JP, Gershtein Y, Halkiadakis E, Hart A, Heindl M, Jaroslawski D, Karacheban O, Laflotte I, Lath A, Montalvo R, Nash K, Osherson M, Salur S, Schnetzer S, Somalwar S, Stone R, Thayil SA, Thomas S, Wang H, Acharya H, Delannoy AG, Fiorendi S, Holmes T, Nibigira E, Spanier S, Bouhali O, Dalchenko M, Delgado A, Eusebi R, Gilmore J, Huang T, Kamon T, Kim H, Luo S, Malhotra S, Mueller R, Overton D, Rathjens D, Safonov A, Akchurin N, Damgov J, Hegde V, Lamichhane K, Lee SW, Mengke T, Muthumuni S, Peltola T, Volobouev I, Wang Z, Whitbeck A, Appelt E, Greene S, Gurrola A, Johns W, Melo A, Romeo F, Sheldon P, Tuo S, Velkovska J, Viinikainen J, Cardwell B, Cox B, Cummings G, Hakala J, Hirosky R, Joyce M, Ledovskoy A, Li A, Neu C, Perez Lara CE, Tannenwald B, Karchin PE, Poudyal N, Banerjee S, Black K, Bose T, Dasu S, De Bruyn I, Everaerts P, Galloni C, He H, Herndon M, Herve A, Koraka CK, Lanaro A, Loeliger A, Loveless R, Madhusudanan Sreekala J, Mallampalli A, Mohammadi A, Mondal S, Parida G, Pinna D, Savin A, Shang V, Sharma V, Smith WH, Teague D, Tsoi HF, Vetens W, Afanasiev S, Andreev V, Andreev Y, Aushev T, Azarkin M, Babaev A, Belyaev A, Blinov V, Boos E, Borshch V, Budkouski D, Bunichev V, Bychkova O, Chekhovsky V, Chistov R, Danilov M, Dermenev A, Dimova T, Dremin I, Dubinin M, Dudko L, Epshteyn V, Ershov A, Gavrilov G, Gavrilov V, Gninenko S, Golovtcov V, Golubev N, Golutvin I, Gorbunov I, Ivanchenko V, Ivanov Y, Kachanov V, Kardapoltsev L, Karjavine V, Karneyeu A, Kim V, Kirakosyan M, Kirpichnikov D, Kirsanov M, Klyukhin V, Kodolova O, Konstantinov D, Korenkov V, Kozyrev A, Krasnikov N, Kuznetsova E, Lanev A, Levchenko P, Litomin A, Lychkovskaya N, Makarenko V, Malakhov A, Matveev V, Murzin V, Nikitenko A, Obraztsov S, Okhotnikov V, Ovtin I, Palichik V, Parygin P, Perelygin V, Perfilov M, Petrushanko S, Pivovarov G, Polikarpov S, Popov V, Radchenko O, Savina M, Savrin V, Selivanova D, Shalaev V, Shmatov S, Shulha S, Skovpen Y, Slabospitskii S, Smirnov V, Sosnov D, Stepennov A, Sulimov V, Tcherniaev E, Terkulov A, Teryaev O, Tlisova I, Toms M, Toropin A, Uvarov L, Uzunian A, Vlasov E, Vorobyev A, Voytishin N, Yuldashev BS, Zarubin A, Zhizhin I, Zhokin A. Search for Exotic Higgs Boson Decays H→AA→4γ with Events Containing Two Merged Diphotons in Proton-Proton Collisions at sqrt[s]=13 TeV. PHYSICAL REVIEW LETTERS 2023; 131:101801. [PMID: 37739361 DOI: 10.1103/physrevlett.131.101801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 01/19/2023] [Indexed: 09/24/2023]
Abstract
We present the first direct search for exotic Higgs boson decays H→AA, A→γγ in events with two photonlike objects. The hypothetical particle A is a low-mass spin-0 particle decaying promptly to a merged diphoton reconstructed as a single photonlike object. We analyze the data collected by the CMS experiment at sqrt[s]=13 TeV corresponding to an integrated luminosity of 136 fb^{-1}. No excess above the estimated background is found. We set upper limits on the branching fraction B(H→AA→4γ) of (0.9-3.3)×10^{-3} at 95% confidence level for masses of A in the range 0.1-1.2 GeV.
Collapse
|
198
|
Luo T, Sun XR, Zou H, Zhao CQ, Li J. [Diagnosis of mucolipidosis type Ⅱ suggested by placental pathology: report of a case]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2023; 52:946-948. [PMID: 37670628 DOI: 10.3760/cma.j.cn112151-20221208-01031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/07/2023]
|
199
|
Yang L, Li J, Wang J. Mediastinal cavernous hemangioma with concurrent primary lung adenocarcinoma. Pulmonology 2023; 29:446-447. [PMID: 36717293 DOI: 10.1016/j.pulmoe.2022.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 12/05/2022] [Accepted: 12/07/2022] [Indexed: 01/30/2023] Open
|
200
|
Tumasyan A, Adam W, Andrejkovic JW, Bergauer T, Chatterjee S, Damanakis K, Dragicevic M, Escalante Del Valle A, Hussain PS, Jeitler M, Krammer N, Lechner L, Liko D, Mikulec I, Paulitsch P, Pitters FM, Schieck J, Schöfbeck R, Schwarz D, Templ S, Waltenberger W, Wulz CE, Darwish MR, Janssen T, Kello T, Rejeb Sfar H, Van Mechelen P, Bols ES, D'Hondt J, De Moor A, Delcourt M, El Faham H, Lowette S, Moortgat S, Morton A, Müller D, Sahasransu AR, Tavernier S, Van Doninck W, Vannerom D, Clerbaux B, De Lentdecker G, Favart L, Hohov D, Jaramillo J, Lee K, Mahdavikhorrami M, Makarenko I, Malara A, Paredes S, Pétré L, Postiau N, Starling E, Thomas L, Vanden Bemden M, Vander Velde C, Vanlaer P, Dobur D, Knolle J, Lambrecht L, Mestdach G, Niedziela M, Rendón C, Roskas C, Samalan A, Skovpen K, Tytgat M, Van Den Bossche N, Vermassen B, Wezenbeek L, Benecke A, Bruno G, Bury F, Caputo C, David P, Delaere C, Donertas IS, Giammanco A, Jaffel K, Jain S, Lemaitre V, Mondal K, Prisciandaro J, Taliercio A, Tran TT, Vischia P, Wertz S, Alves GA, Coelho E, Hensel C, Moraes A, Rebello Teles P, Aldá Júnior WL, Alves Gallo Pereira M, Barroso Ferreira Filho M, Brandao Malbouisson H, Carvalho W, Chinellato J, Da Costa EM, Da Silveira GG, De Jesus Damiao D, Dos Santos Sousa V, Fonseca De Souza S, Martins J, Mora Herrera C, Mota Amarilo K, Mundim L, Nogima H, Santoro A, Silva Do Amaral SM, Sznajder A, Thiel M, Torres Da Silva De Araujo F, Vilela Pereira A, Bernardes CA, Calligaris L, Tomei TRFP, Gregores EM, Mercadante PG, Novaes SF, Padula SS, Aleksandrov A, Antchev G, Hadjiiska R, Iaydjiev P, Misheva M, Rodozov M, Shopova M, Sultanov G, Dimitrov A, Ivanov T, Litov L, Pavlov B, Petkov P, Petrov A, Shumka E, Cheng T, Javaid T, Mittal M, Yuan L, Ahmad M, Bauer G, Hu Z, Lezki S, Yi K, Chen GM, Chen HS, Chen M, Iemmi F, Jiang CH, Kapoor A, Liao H, Liu ZA, Milosevic V, Monti F, Sharma R, Tao J, Thomas-Wilsker J, Wang J, Zhang H, Zhao J, Agapitos A, An Y, Ban Y, Chen C, Levin A, Li C, Li Q, Lyu X, Mao Y, Qian SJ, Sun X, Wang D, Xiao J, Yang H, Li J, Lu M, You Z, Gao X, Leggat D, Okawa H, Zhang Y, Lin Z, Lu C, Xiao M, Avila C, Barbosa Trujillo DA, Cabrera A, Florez C, Fraga J, Mejia Guisao J, Ramirez F, Rodriguez M, Ruiz Alvarez JD, Giljanovic D, Godinovic N, Lelas D, Puljak I, Antunovic Z, Kovac M, Sculac T, Brigljevic V, Chitroda BK, Ferencek D, Majumder D, Roguljic M, Starodumov A, Susa T, Attikis A, Christoforou K, Kole G, Kolosova M, Konstantinou S, Mousa J, Nicolaou C, Ptochos F, Razis PA, Rykaczewski H, Saka H, Finger M, Finger M, Kveton A, Ayala E, Carrera Jarrin E, Assran Y, Elgammal S, Mahmoud MA, Mohammed Y, Bhowmik S, Dewanjee RK, Ehataht K, Kadastik M, Lange T, Nandan S, Nielsen C, Pata J, Raidal M, Tani L, Veelken C, Eerola P, Kirschenmann H, Osterberg K, Voutilainen M, Bharthuar S, Brücken E, Garcia F, Havukainen J, Kim MS, Kinnunen R, Lampén T, Lassila-Perini K, Lehti S, Lindén T, Lotti M, Martikainen L, Myllymäki M, Ott J, Rantanen MM, Siikonen H, Tuominen E, Tuominiemi J, Luukka P, Petrow H, Tuuva T, Amendola C, Besancon M, Couderc F, Dejardin M, Denegri D, Faure JL, Ferri F, Ganjour S, Gras P, Hamel de Monchenault G, Jarry P, Lohezic V, Malcles J, Rander J, Rosowsky A, Sahin MÖ, Savoy-Navarro A, Simkina P, Titov M, Baldenegro Barrera C, Beaudette F, Buchot Perraguin A, Busson P, Cappati A, Charlot C, Damas F, Davignon O, Diab B, Falmagne G, Fontana Santos Alves BA, Ghosh S, Granier de Cassagnac R, Hakimi A, Harikrishnan B, Liu G, Motta J, Nguyen M, Ochando C, Portales L, Rembser J, Salerno R, Sarkar U, Sauvan JB, Sirois Y, Tarabini A, Vernazza E, Zabi A, Zghiche A, Agram JL, Andrea J, Apparu D, Bloch D, Bourgatte G, Brom JM, Chabert EC, Collard C, Darej D, Goerlach U, Grimault C, Le Bihan AC, Van Hove P, Beauceron S, Bernet C, Blancon B, Boudoul G, Carle A, Chanon N, Choi J, Contardo D, Depasse P, Dozen C, El Mamouni H, Fay J, Gascon S, Gouzevitch M, Grenier G, Ille B, Laktineh IB, Lethuillier M, Mirabito L, Perries S, Sordini V, Torterotot L, Vander Donckt M, Verdier P, Viret S, Adamov G, Lomidze I, Tsamalaidze Z, Botta V, Feld L, Klein K, Lipinski M, Meuser D, Pauls A, Röwert N, Teroerde M, Diekmann S, Dodonova A, Eich N, Eliseev D, Erdmann M, Fackeldey P, Fasanella D, Fischer B, Hebbeker T, Hoepfner K, Ivone F, Lee MY, Mastrolorenzo L, Merschmeyer M, Meyer A, Mondal S, Mukherjee S, Noll D, Novak A, Nowotny F, Pozdnyakov A, Rath Y, Redjeb W, Reithler H, Schmidt A, Schuler SC, Sharma A, Vigilante L, Wiedenbeck S, Zaleski S, Dziwok C, Flügge G, Haj Ahmad W, Hlushchenko O, Kress T, Nowack A, Pooth O, Stahl A, Ziemons T, Zotz A, Aarup Petersen H, Aldaya Martin M, Asmuss P, Baxter S, Bayatmakou M, Behnke O, Bermúdez Martínez A, Bhattacharya S, Bin Anuar AA, Blekman F, Borras K, Brunner D, Campbell A, Cardini A, Cheng C, Colombina F, Consuegra Rodríguez S, Correia Silva G, De Silva M, Didukh L, Eckerlin G, Eckstein D, Estevez Banos LI, Filatov O, Gallo E, Geiser A, Giraldi A, Greau G, Grohsjean A, Guglielmi V, Guthoff M, Jafari A, Jomhari NZ, Kaech B, Kasem A, Kasemann M, Kaveh H, Kleinwort C, Kogler R, Komm M, Krücker D, Lange W, Leyva Pernia D, Lipka K, Lohmann W, Mankel R, Melzer-Pellmann IA, Mendizabal Morentin M, Metwally J, Meyer AB, Milella G, Mormile M, Mussgiller A, Nürnberg A, Otarid Y, Pérez Adán D, Raspereza A, Ribeiro Lopes B, Rübenach J, Saggio A, Saibel A, Savitskyi M, Scham M, Scheurer V, Schnake S, Schütze P, Schwanenberger C, Shchedrolosiev M, Sosa Ricardo RE, Stafford D, Tonon N, Van De Klundert M, Vazzoler F, Ventura Barroso A, Walsh R, Walter D, Wang Q, Wen Y, Wichmann K, Wiens L, Wissing C, Wuchterl S, Yang Y, Zimermmane Castro Santos A, Aggleton R, Albrecht A, Albrecht S, Antonello M, Bein S, Benato L, Bonanomi M, Connor P, De Leo K, Eich M, El Morabit K, Feindt F, Fröhlich A, Garbers C, Garutti E, Hajheidari M, Haller J, Hinzmann A, Jabusch HR, Kasieczka G, Klanner R, Korcari W, Kramer T, Kutzner V, Lange J, Lobanov A, Matthies C, Mehta A, Moureaux L, Mrowietz M, Nigamova A, Nissan Y, Paasch A, Pena Rodriguez KJ, Rieger M, Rieger O, Schleper P, Schröder M, Schwandt J, Stadie H, Steinbrück G, Tews A, Wolf M, Bechtel J, Brommer S, Burkart M, Butz E, Caspart R, Chwalek T, Dierlamm A, Droll A, Faltermann N, Giffels M, Gosewisch JO, Gottmann A, Hartmann F, Horzela M, Husemann U, Keicher P, Klute M, Koppenhöfer R, Maier S, Mitra S, Müller T, Neukum M, Quast G, Rabbertz K, Rauser J, Savoiu D, Schnepf M, Seith D, Shvetsov I, Simonis HJ, Trevisani N, Ulrich R, van der Linden J, Von Cube RF, Wassmer M, Weber M, Wieland S, Wolf R, Wozniewski S, Wunsch S, Anagnostou G, Assiouras P, Daskalakis G, Kyriakis A, Stakia A, Diamantopoulou M, Karasavvas D, Kontaxakis P, Manousakis-Katsikakis A, Panagiotou A, Papavergou I, Saoulidou N, Theofilatos K, Tziaferi E, Vellidis K, Vourliotis E, Zisopoulos I, Bakas G, Chatzistavrou T, Kousouris K, Papakrivopoulos I, Tsipolitis G, Zacharopoulou A, Adamidis K, Bestintzanos I, Evangelou I, Foudas C, Gianneios P, Kamtsikis C, Katsoulis P, Kokkas P, Kosmoglou Kioseoglou PG, Manthos N, Papadopoulos I, Strologas J, Csanád M, Farkas K, Gadallah MMA, Komjáti C, Lökös S, Major P, Mandal K, Pásztor G, Rádl AJ, Surányi O, Veres GI, Bartók M, Bencze G, Hajdu C, Horvath D, Sikler F, Veszpremi V, Beni N, Czellar S, Karancsi J, Molnar J, Szillasi Z, Teyssier D, Raics P, Ujvari B, Csorgo T, Nemes F, Novak T, Babbar J, Bansal S, Beri SB, Bhatnagar V, Chaudhary G, Chauhan S, Dhingra N, Gupta R, Kaur A, Kaur A, Kaur H, Kaur M, Kumar S, Kumari P, Meena M, Sandeep K, Sheokand T, Singh JB, Singla A, Virdi AK, Ahmed A, Bhardwaj A, Choudhary BC, Gola M, Keshri S, Kumar A, Naimuddin M, Priyanka P, Ranjan K, Saumya S, Shah A, Baradia S, Barman S, Bhattacharya S, Bhowmik D, Dutta S, Dutta S, Gomber B, Maity M, Palit P, Rout PK, Saha G, Sahu B, Sarkar S, Behera PK, Behera SC, Kalbhor P, Komaragiri JR, Kumar D, Muhammad A, Panwar L, Pradhan R, Pujahari PR, Sharma A, Sikdar AK, Tiwari PC, Verma S, Naskar K, Aziz T, Das I, Dugad S, Kumar M, Mohanty GB, Suryadevara P, Banerjee S, Chudasama R, Guchait M, Karmakar S, Kumar S, Majumder G, Mazumdar K, Mukherjee S, Thachayath A, Bahinipati S, Das AK, Kar C, Mal P, Mishra T, Muraleedharan Nair Bindhu VK, Nayak A, Saha P, Sur N, Swain SK, Vats D, Alpana A, Dube S, Kansal B, Laha A, Pandey S, Rastogi A, Sharma S, Bakhshiansohi H, Khazaie E, Zeinali M, Chenarani S, Etesami SM, Khakzad M, Mohammadi Najafabadi M, Grunewald M, Abbrescia M, Aly R, Aruta C, Colaleo A, Creanza D, De Filippis N, De Palma M, Di Florio A, Elmetenawee W, Errico F, Fiore L, Iaselli G, Ince M, Maggi G, Maggi M, Margjeka I, Mastrapasqua V, My S, Nuzzo S, Pellecchia A, Pompili A, Pugliese G, Radogna R, Ramos D, Ranieri A, Selvaggi G, Silvestris L, Simone FM, Sözbilir Ü, Stamerra A, Venditti R, Verwilligen P, Abbiendi G, Battilana C, Bonacorsi D, Borgonovi L, Brigliadori L, Campanini R, Capiluppi P, Castro A, Cavallo FR, Cuffiani M, Dallavalle GM, Diotalevi T, Fabbri F, Fanfani A, Giacomelli P, Giommi L, Grandi C, Guiducci L, Lo Meo S, Lunerti L, Marcellini S, Masetti G, Navarria FL, Perrotta A, Primavera F, Rossi AM, Rovelli T, Siroli GP, Costa S, Di Mattia A, Potenza R, Tricomi A, Tuve C, Barbagli G, Camaiani B, Cassese A, Ceccarelli R, Ciulli V, Civinini C, D'Alessandro R, Focardi E, Latino G, Lenzi P, Lizzo M, Meschini M, Paoletti S, Seidita R, Sguazzoni G, Viliani L, Benussi L, Bianco S, Meola S, Piccolo D, Bozzo M, Ferro F, Mulargia R, Robutti E, Tosi S, Benaglia A, Boldrini G, Brivio F, Cetorelli F, De Guio F, Dinardo ME, Dini P, Gennai S, Ghezzi A, Govoni P, Guzzi L, Lucchini MT, Malberti M, Malvezzi S, Massironi A, Menasce D, Moroni L, Paganoni M, Pedrini D, Pinolini BS, Ragazzi S, Redaelli N, Tabarelli de Fatis T, Zuolo D, Buontempo S, Carnevali F, Cavallo N, De Iorio A, Fabozzi F, Iorio AOM, Lista L, Paolucci P, Rossi B, Sciacca C, Azzi P, Bacchetta N, Bortignon P, Bragagnolo A, Carlin R, Checchia P, Gasparini U, Grosso G, Layer L, Lusiani E, Margoni M, Meneguzzo AT, Passaseo M, Pazzini J, Ronchese P, Rossin R, Sgaravatto M, Simonetto F, Strong G, Tosi M, Ventura S, Yarar H, Zanetti M, Zotto P, Zucchetta A, Zumerle G, Abu Zeid S, Aimè C, Braghieri A, Calzaferri S, Fiorina D, Montagna P, Re V, Riccardi C, Salvini P, Vai I, Vitulo P, Asenov P, Bilei GM, Ciangottini D, Fanò L, Magherini M, Mantovani G, Mariani V, Menichelli M, Moscatelli F, Piccinelli A, Presilla M, Rossi A, Santocchia A, Spiga D, Tedeschi T, Azzurri P, Bagliesi G, Bertacchi V, Bhattacharya R, Bianchini L, Boccali T, Bossini E, Bruschini D, Castaldi R, Ciocci MA, D'Amante V, Dell'Orso R, Di Domenico MR, Donato S, Giassi A, Ligabue F, Manca E, Mandorli G, Matos Figueiredo D, Messineo A, Musich M, Palla F, Parolia S, Ramirez-Sanchez G, Rizzi A, Rolandi G, Roy Chowdhury S, Sarkar T, Scribano A, Shafiei N, Spagnolo P, Tenchini R, Tonelli G, Turini N, Venturi A, Verdini PG, Barria P, Campana M, Cavallari F, Del Re D, Di Marco E, Diemoz M, Longo E, Meridiani P, Organtini G, Pandolfi F, Paramatti R, Quaranta C, Rahatlou S, Rovelli C, Santanastasio F, Soffi L, Tramontano R, Amapane N, Arcidiacono R, Argiro S, Arneodo M, Bartosik N, Bellan R, Bellora A, Berenguer Antequera J, Biino C, Cartiglia N, Costa M, Covarelli R, Demaria N, Grippo M, Kiani B, Legger F, Mariotti C, Maselli S, Mecca A, Migliore E, Monteil E, Monteno M, Obertino MM, Ortona G, Pacher L, Pastrone N, Pelliccioni M, Ruspa M, Shchelina K, Siviero F, Sola V, Solano A, Soldi D, Staiano A, Tornago M, Trocino D, Umoret G, Vagnerini A, Belforte S, Candelise V, Casarsa M, Cossutti F, Da Rold A, Della Ricca G, Sorrentino G, Dogra S, Huh C, Kim B, Kim DH, Kim GN, Kim J, Lee J, Lee SW, Moon CS, Oh YD, Pak SI, Ryu MS, Sekmen S, Yang YC, Kim H, Moon DH, Asilar E, Kim TJ, Park J, Cho S, Choi S, Han S, Hong B, Lee K, Lee KS, Lim J, Park J, Park SK, Yoo J, Goh J, Kim HS, Kim Y, Lee S, Almond J, Bhyun JH, Choi J, Jeon S, Jun W, Kim J, Kim J, Kim JS, Ko S, Kwon H, Lee H, Lee J, Lee S, Oh BH, Oh M, Oh SB, Seo H, Yang UK, Yoon I, Jang W, Kang DY, Kang Y, Kim D, Kim S, Ko B, Lee JSH, Lee Y, Merlin JA, Park IC, Roh Y, Song D, Watson IJ, Yang S, Ha S, Yoo HD, Choi M, Kim MR, Lee H, Lee Y, Lee Y, Yu I, Beyrouthy T, Maghrbi Y, Dreimanis K, Gaile A, Potrebko A, Torims T, Veckalns V, Ambrozas M, Carvalho Antunes De Oliveira A, Juodagalvis A, Rinkevicius A, Tamulaitis G, Bin Norjoharuddeen N, Hoh SY, Yusuff I, Zolkapli Z, Benitez JF, Castaneda Hernandez A, Encinas Acosta HA, Gallegos Maríñez LG, León Coello M, Murillo Quijada JA, Sehrawat A, Valencia Palomo L, Ayala G, Castilla-Valdez H, Heredia-De La Cruz I, Lopez-Fernandez R, Mondragon Herrera CA, Perez Navarro DA, Sánchez Hernández A, Oropeza Barrera C, Vazquez Valencia F, Pedraza I, Salazar Ibarguen HA, Uribe Estrada C, Bubanja I, Mijuskovic J, Raicevic N, Ahmad A, Asghar MI, Awais A, Awan MIM, Gul M, Hoorani HR, Khan WA, Shoaib M, Waqas M, Avati V, Grzanka L, Malawski M, Bialkowska H, Bluj M, Boimska B, Górski M, Kazana M, Szleper M, Zalewski P, Bunkowski K, Doroba K, Kalinowski A, Konecki M, Krolikowski J, Araujo M, Bargassa P, Bastos D, Boletti A, Faccioli P, Gallinaro M, Hollar J, Leonardo N, Niknejad T, Pisano M, Seixas J, Toldaiev O, Varela J, Adzic P, Dordevic M, Milenovic P, Milosevic J, Aguilar-Benitez M, Alcaraz Maestre J, Álvarez Fernández A, Barrio Luna M, Bedoya CF, Carrillo Montoya CA, Cepeda M, Cerrada M, Colino N, De La Cruz B, Delgado Peris A, Fernández Del Val D, Fernández Ramos JP, Flix J, Fouz MC, Gonzalez Lopez O, Goy Lopez S, Hernandez JM, Josa MI, León Holgado J, Moran D, Perez Dengra C, Pérez-Calero Yzquierdo A, Puerta Pelayo J, Redondo I, Redondo Ferrero DD, Romero L, Sánchez Navas S, Sastre J, Urda Gómez L, Vazquez Escobar J, Willmott C, de Trocóniz JF, Alvarez Gonzalez B, Cuevas J, Fernandez Menendez J, Folgueras S, Gonzalez Caballero I, González Fernández JR, Palencia Cortezon E, Ramón Álvarez C, Rodríguez Bouza V, Soto Rodríguez A, Trapote A, Vico Villalba C, Brochero Cifuentes JA, Cabrillo IJ, Calderon A, Duarte Campderros J, Fernandez M, Fernandez Madrazo C, García Alonso A, Gomez G, Lasaosa García C, Martinez Rivero C, Martinez Ruiz Del Arbol P, Matorras F, Matorras Cuevas P, Piedra Gomez J, Prieels C, Ruiz-Jimeno A, Scodellaro L, Vila I, Vizan Garcia JM, Jayananda MK, Kailasapathy B, Sonnadara DUJ, Wickramarathna DDC, Dharmaratna WGD, Liyanage K, Perera N, Wickramage N, Abbaneo D, Alimena J, Auffray E, Auzinger G, Baechler J, Baillon P, Barney D, Bendavid J, Bianco M, Bilin B, Bocci A, Brondolin E, Caillol C, Camporesi T, Cerminara G, Chernyavskaya N, Chhibra SS, Choudhury S, Cipriani M, Cristella L, d'Enterria D, Dabrowski A, David A, De Roeck A, Defranchis MM, Deile M, Dobson M, Dünser M, Dupont N, Elliott-Peisert A, Fallavollita F, Florent A, Forthomme L, Franzoni G, Funk W, Ghosh S, Giani S, Gigi D, Gill K, Glege F, Gouskos L, Govorkova E, Haranko M, Hegeman J, Innocente V, James T, Janot P, Kaspar J, Kieseler J, Kratochwil N, Laurila S, Lecoq P, Leutgeb E, Lintuluoto A, Lourenço C, Maier B, Malgeri L, Mannelli M, Marini AC, Meijers F, Mersi S, Meschi E, Moortgat F, Mulders M, Orfanelli S, Orsini L, Pantaleo F, Perez E, Peruzzi M, Petrilli A, Petrucciani G, Pfeiffer A, Pierini M, Piparo D, Pitt M, Qu H, Quast T, Rabady D, Racz A, Reales Gutiérrez G, Rovere M, Sakulin H, Salfeld-Nebgen J, Scarfi S, Selvaggi M, Sharma A, Silva P, Sphicas P, Stahl Leiton AG, Summers S, Tatar K, Tavolaro VR, Treille D, Tropea P, Tsirou A, Wanczyk J, Wozniak KA, Zeuner WD, Caminada L, Ebrahimi A, Erdmann W, Horisberger R, Ingram Q, Kaestli HC, Kotlinski D, Lange C, Missiroli M, Noehte L, Rohe T, Aarrestad TK, Androsov K, Backhaus M, Berger P, Calandri A, Datta K, De Cosa A, Dissertori G, Dittmar M, Donegà M, Eble F, Galli M, Gedia K, Glessgen F, Gómez Espinosa TA, Grab C, Hits D, Lustermann W, Lyon AM, Manzoni RA, Marchese L, Martin Perez C, Mascellani A, Meinhard MT, Nessi-Tedaldi F, Niedziela J, Pauss F, Perovic V, Pigazzini S, Ratti MG, Reichmann M, Reissel C, Reitenspiess T, Ristic B, Riti F, Ruini D, Sanz Becerra DA, Steggemann J, Valsecchi D, Wallny R, Amsler C, Bärtschi P, Botta C, Brzhechko D, Canelli MF, Cormier K, De Wit A, Del Burgo R, Heikkilä JK, Huwiler M, Jin W, Jofrehei A, Kilminster B, Leontsinis S, Liechti SP, Macchiolo A, Meiring P, Mikuni VM, Molinatti U, Neutelings I, Reimers A, Robmann P, Sanchez Cruz S, Schweiger K, Senger M, Takahashi Y, Adloff C, Kuo CM, Lin W, Yu SS, Ceard L, Chao Y, Chen KF, Chen PS, Cheng H, Hou WS, Li YY, Lu RS, Paganis E, Psallidas A, Steen A, Wu HY, Yazgan E, Yu PR, Asawatangtrakuldee C, Srimanobhas N, Agyel D, Boran F, Demiroglu ZS, Dolek F, Dumanoglu I, Eskut E, Guler Y, Gurpinar Guler E, Isik C, Kara O, Kayis Topaksu A, Kiminsu U, Onengut G, Ozdemir K, Polatoz A, Simsek AE, Tali B, Tok UG, Turkcapar S, Uslan E, Zorbakir IS, Karapinar G, Ocalan K, Yalvac M, Akgun B, Atakisi IO, Gülmez E, Kaya M, Kaya O, Özçelik Ö, Tekten S, Cakir A, Cankocak K, Komurcu Y, Sen S, Aydilek O, Cerci S, Hacisahinoglu B, Hos I, Isildak B, Kaynak B, Ozkorucuklu S, Simsek C, Sunar Cerci D, Grynyov B, Levchuk L, Anthony D, Bhal E, Brooke JJ, Bundock A, Clement E, Cussans D, Flacher H, Glowacki M, Goldstein J, Heath GP, Heath HF, Kreczko L, Krikler B, Paramesvaran S, Seif El Nasr-Storey S, Smith VJ, Stylianou N, Walkingshaw Pass K, White R, Ball AH, Bell KW, Belyaev A, Brew C, Brown RM, Cockerill DJA, Cooke C, Ellis KV, Harder K, Harper S, Holmberg ML, Linacre J, Manolopoulos K, Newbold DM, Olaiya E, Petyt D, Reis T, Salvi G, Schuh T, Shepherd-Themistocleous CH, Tomalin IR, Williams T, Bainbridge R, Bloch P, Bonomally S, Borg J, Breeze S, Brown CE, Buchmuller O, Cacchio V, Cepaitis V, Chahal GS, Colling D, Dancu JS, Dauncey P, Davies G, Davies J, Della Negra M, Fayer S, Fedi G, Hall G, Hassanshahi MH, Howard A, Iles G, Langford J, Lyons L, Magnan AM, Malik S, Martelli A, Mieskolainen M, Monk DG, Nash J, Pesaresi M, Radburn-Smith BC, Raymond DM, Richards A, Rose A, Scott E, Seez C, Shtipliyski A, Shukla R, Tapper A, Uchida K, Uttley GP, Vage LH, Virdee T, Vojinovic M, Wardle N, Webb SN, Winterbottom D, Coldham K, Cole JE, Khan A, Kyberd P, Reid ID, Abdullin S, Brinkerhoff A, Caraway B, Dittmann J, Hatakeyama K, Kanuganti AR, McMaster B, Saunders M, Sawant S, Sutantawibul C, Wilson J, Bartek R, Dominguez A, Uniyal R, Vargas Hernandez AM, Buccilli A, Cooper SI, Di Croce D, Gleyzer SV, Henderson C, Perez CU, Rumerio P, West C, Akpinar A, Albert A, Arcaro D, Cosby C, Demiragli Z, Erice C, Fontanesi E, Gastler D, May S, Rohlf J, Salyer K, Sperka D, Spitzbart D, Suarez I, Tsatsos A, Yuan S, Benelli G, Burkle B, Coubez X, Cutts D, Hadley M, Heintz U, Hogan JM, Kwon T, Landsberg G, Lau KT, Li D, Luo J, Narain M, Pervan N, Sagir S, Simpson F, Usai E, Wong WY, Yan X, Yu D, Zhang W, Bonilla J, Brainerd C, Breedon R, Calderon De La Barca Sanchez M, Chertok M, Conway J, Cox PT, Erbacher R, Haza G, Jensen F, Kukral O, Mocellin G, Mulhearn M, Pellett D, Regnery B, Taylor D, Yao Y, Zhang F, Bachtis M, Cousins R, Datta A, Hamilton D, Hauser J, Ignatenko M, Iqbal MA, Lam T, Nash WA, Regnard S, Saltzberg D, Stone B, Valuev V, Chen Y, Clare R, Gary JW, Gordon M, Hanson G, Karapostoli G, Long OR, Manganelli N, Si W, Wimpenny S, Branson JG, Chang P, Cittolin S, Cooperstein S, Diaz D, Duarte J, Gerosa R, Giannini L, Guiang J, Kansal R, Krutelyov V, Lee R, Letts J, Masciovecchio M, Mokhtar F, Pieri M, Sathia Narayanan BV, Sharma V, Tadel M, Würthwein F, Xiang Y, Yagil A, Amin N, Campagnari C, Citron M, Collura G, Dorsett A, Dutta V, Incandela J, Kilpatrick M, Kim J, Li AJ, Marsh B, Masterson P, Mei H, Oshiro M, Quinnan M, Richman J, Sarica U, Schmitz R, Setti F, Sheplock J, Siddireddy P, Stuart D, Wang S, Bornheim A, Cerri O, Dutta I, Lawhorn JM, Lu N, Mao J, Newman HB, Nguyen TQ, Spiropulu M, Vlimant JR, Wang C, Xie S, Zhu RY, Alison J, An S, Andrews MB, Bryant P, Ferguson T, Harilal A, Liu C, Mudholkar T, Murthy S, Paulini M, Roberts A, Sanchez A, Terrill W, Cumalat JP, Ford WT, Hassani A, Karathanasis G, MacDonald E, Marini F, Patel R, Perloff A, Savard C, Schonbeck N, Stenson K, Ulmer KA, Wagner SR, Zipper N, Alexander J, Bright-Thonney S, Chen X, Cranshaw DJ, Fan J, Fan X, Gadkari D, Hogan S, Monroy J, Patterson JR, Quach D, Reichert J, Reid M, Ryd A, Thom J, Wittich P, Zou R, Albrow M, Alyari M, Apollinari G, Apresyan A, Bauerdick LAT, Berry D, Berryhill J, Bhat PC, Burkett K, Butler JN, Canepa A, Cerati GB, Cheung HWK, Chlebana F, Di Petrillo KF, Dickinson J, Elvira VD, Feng Y, Freeman J, Gandrakota A, Gecse Z, Gray L, Green D, Grünendahl S, Gutsche O, Harris RM, Heller R, Herwig TC, Hirschauer J, Horyn L, Jayatilaka B, Jindariani S, Johnson M, Joshi U, Klijnsma T, Klima B, Kwok KHM, Lammel S, Lincoln D, Lipton R, Liu T, Madrid C, Maeshima K, Mantilla C, Mason D, McBride P, Merkel P, Mrenna S, Nahn S, Ngadiuba J, Noonan D, Papadimitriou V, Pastika N, Pedro K, Pena C, Ravera F, Reinsvold Hall A, Ristori L, Sexton-Kennedy E, Smith N, Soha A, Spiegel L, Strait J, Taylor L, Tkaczyk S, Tran NV, Uplegger L, Vaandering EW, Weber HA, Zoi I, Avery P, Bourilkov D, Cadamuro L, Cherepanov V, Field RD, Guerrero D, Kim M, Koenig E, Konigsberg J, Korytov A, Lo KH, Matchev K, Menendez N, Mitselmakher G, Muthirakalayil Madhu A, Rawal N, Rosenzweig D, Rosenzweig S, Shi K, Wang J, Wu Z, Adams T, Askew A, Habibullah R, Hagopian V, Khurana R, Kolberg T, Martinez G, Prosper H, Schiber C, Viazlo O, Yohay R, Zhang J, Baarmand MM, Butalla S, Elkafrawy T, Hohlmann M, Kumar Verma R, Rahmani M, Yumiceva F, Adams MR, Becerril Gonzalez H, Cavanaugh R, Dittmer S, Evdokimov O, Gerber CE, Hofman DJ, Lemos DS, Merrit AH, Mills C, Oh G, Roy T, Rudrabhatla S, Tonjes MB, Varelas N, Wang X, Ye Z, Yoo J, Alhusseini M, Dilsiz K, Emediato L, Gandrajula RP, Karaman G, Köseyan OK, Merlo JP, Mestvirishvili A, Nachtman J, Neogi O, Ogul H, Onel Y, Penzo A, Snyder C, Tiras E, Amram O, Blumenfeld B, Corcodilos L, Davis J, Gritsan AV, Kang L, Kyriacou S, Maksimovic P, Roskes J, Sekhar S, Swartz M, Vámi TÁ, Abreu A, Alcerro Alcerro LF, Anguiano J, Baringer P, Bean A, Flowers Z, Isidori T, Khalil S, King J, Krintiras G, Lazarovits M, Le Mahieu C, Lindsey C, Marquez J, Minafra N, Murray M, Nickel M, Rogan C, Royon C, Salvatico R, Sanders S, Schmitz E, Smith C, Wang Q, Williams J, Wilson G, Allmond B, Duric S, Gujju Gurunadha R, Ivanov A, Kaadze K, Kim D, Maravin Y, Mitchell T, Modak A, Nam K, Natoli J, Roy D, Rebassoo F, Wright D, Adams E, Baden A, Baron O, Belloni A, Bethani A, Eno SC, Hadley NJ, Jabeen S, Kellogg RG, Koeth T, Lai Y, Lascio S, Mignerey AC, Nabili S, Palmer C, Papageorgakis C, Seidel M, Wang L, Wong K, Abercrombie D, Bi R, Busza W, Cali IA, Chen Y, D'Alfonso M, Eysermans J, Freer C, Gomez-Ceballos G, Goncharov M, Harris P, Hu M, Kovalskyi D, Krupa J, Lee YJ, Long K, Mironov C, Paus C, Rankin D, Roland C, Roland G, Shi Z, Stephans GSF, Wang J, Wang Z, Wyslouch B, Chatterjee RM, Crossman B, Evans A, Hiltbrand J, Jain S, Joshi BM, Kapsiak C, Krohn M, Kubota Y, Mans J, Revering M, Rusack R, Saradhy R, Schroeder N, Strobbe N, Wadud MA, Cremaldi LM, Bloom K, Bryson M, Claes DR, Fangmeier C, Finco L, Golf F, Joo C, Kravchenko I, Reed I, Siado JE, Snow GR, Tabb W, Wightman A, Yan F, Zecchinelli AG, Agarwal G, Bandyopadhyay H, Hay L, Iashvili I, Kharchilava A, McLean C, Morris M, Nguyen D, Pekkanen J, Rappoccio S, Williams A, Alverson G, Barberis E, Haddad Y, Han Y, Krishna A, Li J, Lidrych J, Madigan G, Marzocchi B, Morse DM, Nguyen V, Orimoto T, Parker A, Skinnari L, Tishelman-Charny A, Wamorkar T, Wang B, Wisecarver A, Wood D, Bhattacharya S, Bueghly J, Chen Z, Gilbert A, Gunter T, Hahn KA, Liu Y, Odell N, Schmitt MH, Velasco M, Band R, Bucci R, Castells S, Cremonesi M, Das A, Goldouzian R, Hildreth M, Hurtado Anampa K, Jessop C, Lannon K, Lawrence J, Loukas N, Lutton L, Mariano J, Marinelli N, Mcalister I, McCauley T, Mcgrady C, Mohrman K, Moore C, Musienko Y, Nelson H, Ruchti R, Townsend A, Wayne M, Yockey H, Zarucki M, Zygala L, Bylsma B, Carrigan M, Durkin LS, Francis B, Hill C, Lesauvage A, Nunez Ornelas M, Wei K, Winer BL, Yates BR, Addesa FM, Bonham B, Das P, Dezoort G, Elmer P, Frankenthal A, Greenberg B, Haubrich N, Higginbotham S, Kalogeropoulos A, Kopp G, Kwan S, Lange D, Marlow D, Mei K, Ojalvo I, Olsen J, Stickland D, Tully C, Malik S, Norberg S, Bakshi AS, Barnes VE, Chawla R, Das S, Gutay L, Jones M, Jung AW, Kondratyev D, Koshy AM, Liu M, Negro G, Neumeister N, Paspalaki G, Piperov S, Purohit A, Schulte JF, Stojanovic M, Thieman J, Wang F, Xiao R, Xie W, Dolen J, Parashar N, Acosta D, Baty A, Carnahan T, Decaro M, Dildick S, Ecklund KM, Fernández Manteca PJ, Freed S, Gardner P, Geurts FJM, Kumar A, Li W, Padley BP, Redjimi R, Rotter J, Shi W, Yang S, Yigitbasi E, Zhang L, Zhang Y, Zuo X, Bodek A, de Barbaro P, Demina R, Dulemba JL, Fallon C, Ferbel T, Galanti M, Garcia-Bellido A, Hindrichs O, Khukhunaishvili A, Ranken E, Taus R, Van Onsem GP, Goulianos K, Chiarito B, Chou JP, Gershtein Y, Halkiadakis E, Hart A, Heindl M, Jaroslawski D, Karacheban O, Laflotte I, Lath A, Montalvo R, Nash K, Osherson M, Salur S, Schnetzer S, Somalwar S, Stone R, Thayil SA, Thomas S, Wang H, Acharya H, Delannoy AG, Fiorendi S, Holmes T, Nibigira E, Spanier S, Bouhali O, Dalchenko M, Delgado A, Eusebi R, Gilmore J, Huang T, Kamon T, Kim H, Luo S, Malhotra S, Mueller R, Overton D, Rathjens D, Safonov A, Akchurin N, Damgov J, Hegde V, Lamichhane K, Lee SW, Mengke T, Muthumuni S, Peltola T, Volobouev I, Wang Z, Whitbeck A, Appelt E, Greene S, Gurrola A, Johns W, Melo A, Romeo F, Sheldon P, Tuo S, Velkovska J, Viinikainen J, Cardwell B, Cox B, Cummings G, Hakala J, Hirosky R, Joyce M, Ledovskoy A, Li A, Neu C, Perez Lara CE, Tannenwald B, Karchin PE, Poudyal N, Banerjee S, Black K, Bose T, Dasu S, De Bruyn I, Everaerts P, Galloni C, He H, Herndon M, Herve A, Koraka CK, Lanaro A, Loeliger A, Loveless R, Madhusudanan Sreekala J, Mallampalli A, Mohammadi A, Mondal S, Parida G, Pinna D, Savin A, Shang V, Sharma V, Smith WH, Teague D, Tsoi HF, Vetens W, Afanasiev S, Andreev V, Andreev Y, Aushev T, Azarkin M, Babaev A, Belyaev A, Blinov V, Boos E, Borshch V, Budkouski D, Bunichev V, Chekhovsky V, Chistov R, Danilov M, Dermenev A, Dimova T, Dremin I, Dubinin M, Dudko L, Epshteyn V, Ershov A, Gavrilov G, Gavrilov V, Gninenko S, Golovtcov V, Golubev N, Golutvin I, Gorbunov I, Ivanchenko V, Ivanov Y, Kachanov V, Kardapoltsev L, Karjavine V, Karneyeu A, Kim V, Kirakosyan M, Kirpichnikov D, Kirsanov M, Klyukhin V, Kodolova O, Konstantinov D, Korenkov V, Kozyrev A, Krasnikov N, Kuznetsova E, Lanev A, Levchenko P, Litomin A, Lukina O, Lychkovskaya N, Makarenko V, Malakhov A, Matveev V, Murzin V, Nikitenko A, Obraztsov S, Okhotnikov V, Oskin A, Ovtin I, Palichik V, Parygin P, Perelygin V, Pivovarov G, Polikarpov S, Popov V, Radchenko O, Savina M, Savrin V, Selivanova D, Shalaev V, Shmatov S, Shulha S, Skovpen Y, Slabospitskii S, Smirnov V, Snigirev A, Sosnov D, Stepennov A, Sulimov V, Tcherniaev E, Terkulov A, Teryaev O, Tlisova I, Toms M, Toropin A, Uvarov L, Uzunian A, Vlasov E, Vorobyev A, Voytishin N, Yuldashev BS, Zarubin A, Zhizhin I, Zhokin A. Observation of Same-Sign WW Production from Double Parton Scattering in Proton-Proton Collisions at sqrt[s]=13 TeV. PHYSICAL REVIEW LETTERS 2023; 131:091803. [PMID: 37721845 DOI: 10.1103/physrevlett.131.091803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Accepted: 08/18/2022] [Indexed: 09/20/2023]
Abstract
The first observation of the production of W^{±}W^{±} bosons from double parton scattering processes using same-sign electron-muon and dimuon events in proton-proton collisions is reported. The data sample corresponds to an integrated luminosity of 138 fb^{-1} recorded at a center-of-mass energy of 13 TeV using the CMS detector at the CERN LHC. Multivariate discriminants are used to distinguish the signal process from the main backgrounds. A binned maximum likelihood fit is performed to extract the signal cross section. The measured cross section for production of same-sign W bosons decaying leptonically is 80.7±11.2(stat) _{-8.6}^{+9.5}(syst)±12.1(model) fb, whereas the measured fiducial cross section is 6.28±0.81(stat)±0.69(syst)±0.37(model) fb. The observed significance of the signal is 6.2 standard deviations above the background-only hypothesis.
Collapse
|